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Abstract 
Non-communicable diseases are the second leading cause of death in South Africa. In South African 
Black individuals, risk factors for cardiovascular disease, such as hypertension, obesity and type 2 
diabetes mellitus, are common. These individual risk factors for cardiovascular disease 
(dyslipidaemia, hypertension, obesity and type 2 diabetes) are the focus of the present study in the 
Black isiXhosa-speaking population of Cape Town.  
Previous studies, in European and North American populations, have identified single nucleotide 
polymorphisms (SNPs) in various genes to be associated with non-communicable diseases that are 
risk factors for cardiovascular disease. However, few studies have been conducted in sub-Saharan 
Africa and even fewer have been conducted in South Africa.  
Identifying genes that contribute to the development of cardiovascular disease may help to 
understand its pathophysiology, identify individuals at higher risk and novel targets may aid 
preventative and treatment strategies.  
The aim of this study was to determine if selected genetic markers in genes encoding the 
angiotensin-converting enzyme (ACE), angiotensinogen (AGT), angiotensin II type I receptor 
(AT1R), transcription factor 7-like 2 (TCF7L2), fat-mass and obesity associated (FTO), melanocortin 
4 receptor (MC4R) and tumour necrosis factor-alpha (TNFα) are associated with cardiovascular 
disease risk in South African Black individuals.  
Of the 1 116 samples available for this study, DNA was extracted from 936 samples. SNPs in each 
of these genes were selected based on previous findings of association with disease in other African 
populations. Genotypes were analysed under additive, dominant and recessive association models 
using the R Statistical Package, snpassoc. 
The I/I genotype of rs4646994 of ACE was associated with blood pressure (p=0.014) and LDL-C 
(p=0.038) under a recessive inheritance model, while the D/D genotypes was associated with obesity 
and waist circumference under additive (p=0.047 and p=0.044, respectively) and dominant 
(p=0.04351 and p=0.04437, respectively) inheritance models. rs17782313 of MC4R was nominally 
associated with type 2 diabetes mellitus under dominant (T/C and C/C genotypes) (p=0.054) and 
recessive (T/T genotype) (p=0.075) inheritance models; and rs229616 (A/A genotype) was nominally 
associated with HDL-C (p=0.059) and rs1297034 was nominally associated with type 2 diabetes 
mellitus (p=0.075) under recessive inheritance models. Suggestive evidence of association with 
disease was observed for many of the genes, but further studies are needed to confirm this.  
Genetic associations with obesity and type 2 diabetes mellitus, risk factors for cardiovascular 
disease, observed in other African, as well as European and American populations, were replicated 
in this study. Novel associations with disease in South Africa and sub-Saharan Africa are reported 
and cross-phenotype associations were observed. This study suggests that these genes are 
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potentially causal in disease predisposition and progression in the South African Black population, 
where the prevalence of these diseases is high. This study suggests that this is an important 
population to study and further studies are warranted.  
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Opsomming 
Nie oordraagbare siekte is die tweede hoofoorsaak van dood in Suid Afrika. In Suid Afrikanse Swart 
mense, risiko faktore vir hart siekte, soos hoë bloeddruk, vetsug en suiker siekte, is algemeen. 
Metaboliese sindroom beskryf die groepering van hierdie risiko faktore, wat ŉ individu plaas met 
hoër risiko vir hart siekte.  
Voorige studies, in Europa en Amerika, het enkel nukleotied polimorfismes (ENP) in verskeie gene 
geidentifiseer wat verband hou met nie oordraagbare siektes, wat risiko faktore is vir hart siekte. 
Maar min studies is in sub-Sahariese Afrika gedoen, en nog minder in Suid Afrika.  
Die identifikasie van gene wat bydra tot die ontwikeling van hart siekte mag dalk help om die 
patofisiologie te verstaan, en om hoë risiko individu te identifiseer. Nuwe genetiese teikens mag ook 
dalk voorkomende en behandelings strategieë help.  
Die doel van hierdie study was dus om te bepaal of spesfieke genetiese teikens (die 
angiotensienomskekling ensiem (ACE), angiotensinogen (AGT), angiotnsien II tipe I reseptor 
(AT1R), transkripsiefator 7, 2-agtige (TCF7L2), vetmassa en vetsugverwante (FTO), melanocortine 
4 reseptor (MC4R) en tumor nekrose factor-alfa (TNFα) gene) is verband met hart siekte risiko in 
Suid Afrikanse Swart mense.  
Uit 1 116 monsters beskikbaar vir die study, DNS van 936 monsters was onttrek. ENP gekies in elk 
van die gene was gebasseer op voorige vindings van verbanding met siekte in Afrika lande. 
Genotipes was ontleed onder toevoeging, dominante en ressesiewe assosiasie modelle met die R 
statistike paket, snpassoc.  
Die I/I genotype van rs4646994 van ACE was met hoë bloeddruk (p=0.014) en LDL-C (p=0.038) 
geassosieer onder ŉ resessiewe model, terwyl die D/D genotype met vetsug en middellyf omtrek 
onder toevoeging (p=0.047 en p=0.044, onderskeidelik) en dominante (p=0.044 en p=0.044, 
onderskeidelik) modelle geassosieer was. Rs17782313 van MC4R was nominal geassosieer met 
suiker siekte geassosieer onder dominante (T/C en C/C genotype) (p=0.054) en resessiewe (T/T 
genotype) (p=0.075) modelle; rs229616 (A/A genotype) was nominaal geassosieer met HDL-C 
(p=0.059) en rs1297034 was nominaal geassosieer met suiker siekte (p=0.075) onder toevoeging 
modelle. Aanduidende bewyse vie assosiasie met hart siekte risiko faktore was waargeneem vir baie 
van die gene, maar meer studies is nodig om dit te bevestig.  
Genetiese assosiasies met vetsug en suiker siekte, risiko faktore vir hart siekte, waargeneem in 
ander Afrika, sowel as Europese en Noord Amerikanse mense, was herhaal in dié study. Nuwe 
assosiasies met siekte in Suid Afrika is berig en kruis-fenotipe assosiasies waargeneem. Dié study 
dui daarop dat hierdie gene moontlik oorsaaklik in die vatbaarheid en vordering van siekte is in Suid 
Afrikanse Swart mense, waar die voorkoms van hierdie siektes hoog is. Dié study dui ook daarop 
dat die Swart mense van Suid Afrika belangrik is om te studeer en meer studies geregverdig is.  
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1. Introduction 
Non-communicable diseases (NCDs) are non-transmittable diseases that occur mainly due to 
lifestyle choices. For the past 30 years, NCDs have been recognised as a major cause of death and 
disability (Nojilana et al., 2016). The four most prevalent NCDs are cardiovascular disease (CVD), 
type 2 diabetes mellitus (T2DM), cancer and chronic respiratory disease (WHO, 2008). At the 2011 
United Nations high-level meeting on NCD disease burden, NCDs were recognised as a growing 
threat to human health (Parry et al., 2011), reiterating the emphasis the World Health Organization 
(WHO) put on NCDs as a neglected global health issue (WHO, 2005).  
Some NCDs, such as hypertension, T2DM and stroke, are risk factors for CVD, and in the Black 
population of South Africa (SA), these CVD risk factors are the most frequently found morbidities 
and mortalities associated with chronic diseases, such as hypothyroidism, cancer and renal disease 
(Dalal et al., 2011; Tibazarwa et al., 2009; Alberts et al., 2005; Akinboboye et al., 2003).   
Risk factors for CVD and its associated diseases include unmodifiable risk factors, 
modifiable/lifestyle risk factors, environment risk factors and physiological intermediate risk factors 
(Figure 1.1) (Tekola-Ayele et al., 2013; Mayosi et al., 2009; Mollentze, 2003).  
 
Figure 1.1 Interactions between genes and environment in the pathophysiology of CVD (Adapted 
from Tekola-Ayele et al., 2013). 
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By 2030, death due to NCDs is estimated to increase from 28.0% in 2004 to 46.0% in sub-Saharan 
Africa (SSA), with the highest death rates observed in the Democratic Republic of Congo, Ethiopia, 
Nigeria and SA (Dalal et al., 2011). The rising trend of NCDs in SA is evident. In 2003, infectious 
diseases accounted for 28.0% of life years lost in SA, while death due to NCDs accounted for 25.0% 
(Steyn et al., 2003). By 2004, death due to NCDs in SA had increased to 28.0% (Mayosi et al., 2009, 
WHO, 2008), of which 12.0% was due to CVD, cancers, respiratory disease and T2DM, and 6.0% 
was due to neuropsychiatric disorders including bipolar depression, dementia, epilepsy and 
schizophrenia (WHO, 2008). In 2010, 594 710 deaths, a 3.85% increase from 2009, were reported 
in SA. Of those, NCDs accounted for 38.9% (Nojilana et al., 2016). Forty-four percent of the latter 
was due to CVD (of which 17.5% was due to stroke), 18.0% due to cancers, 9.3% due to chronic 
respiratory diseases and 8.0% due to T2DM (Nojilana et al., 2016). The age-standardised death 
rates in SA, per 100 000 population, has been reported as 287, 114, 58 and 52 for CVD, cancers, 
chronic respiratory disease and T2DM, respectively (Nojilana et al., 2016). The SA Coloured as well 
as the Indian populations, and Black populations have been found to have NCD mortality rates at 
1.4-fold and 1.3-fold higher than in the SA Caucasian population (Nojilana et al., 2016).  
Globally, low- and middle-income countries have the highest proportion of NCD burden (Nojilana et 
al., 2016). In the low-income countries of SSA, particularly in the Democratic Republic of Congo, 
Ethiopia, Nigeria and SA, death due to NCDs far exceeds that of higher income countries (Dalal et 
al., 2011; Mayosi et al., 2009; Lopez et al., 2006). Specifically, SA’s NCD burden was 2-3 times 
higher than in developed countries (WHO, 2008; WHO, 2005). However, by 2017, death due to 
NCDs in SA was 2-3 times higher than in developing countries, while that of developed countries 
surpassed SA (WHO, 2017). In the 1990s, population-based surveys in the Black population of SA 
revealed a high prevalence of hypertension (14.0-33.0%) and T2DM (4.8-6.0%), as well as smoking 
(13.0-33.0%), which is a known risk factor for many NCDs, but other risk factors were not examined 
in these surveys (Mollentze et al., 1995; Steyn et al., 1991). Surveys of the same population, 
conducted in the early 2000s, confirmed the high prevalence of hypertension and T2DM observed 
in the 1990s, and also reported a high prevalence of overweight and obesity, especially in females, 
with more than 50.0% of the female population being overweight or obese (Thorogood et al., 2007; 
Alberts et al., 2005). A later study of age-standardised mortality rates in Khayelitsha, Cape Town, 
found that 856.4 deaths per 100 000 were due to NCDs, compared to 450-500 deaths per 100 000 
in wealthier districts of Cape Town (Groenewald et al., 2008).  
Since the early 2000s, marked declines in the age-standardised death rates due to NCDs in SA 
Coloured (de Wit et al., 2010) and Indian individuals have been observed; however, only slight 
declines were observed in SA Black and Caucasian individuals (Nojilana et al., 2016). Age-
standardised death rates, due to CVD and T2DM, in particular, were reduced in SA Coloured and 
Indian individuals, while there was an increase of death rates due to CVD and T2DM in SA Black 
individuals (Nojilana et al., 2016). High mortality rates of cardiomyopathy, hypertensive heart 
Stellenbosch University  https://scholar.sun.ac.za
4 
 
disease, stroke and T2DM have been reported in SA Black individuals, who are currently undergoing 
a CVD epidemic. These increased rates may lead to high rates of ischaemic heart disease (IHD) 
and renal disease, as is observed in SA individuals of Indian descent (Nojilana et al., 2016). 
As previously mentioned, death due to NCDs in the adult SA population is second only to infectious 
diseases (human immunodeficiency virus (HIV), malaria and tuberculosis (TB)) (Mayosi et al., 2009). 
However, in SA, it is predicted that, by 2020, death due to NCDs will exceed that of infectious 
diseases (Murray & Lopez, 1997), and it will continue to increase if measures are not put in place to 
overcome the burden of NCDs (Mayosi et al., 2009; Abegunde et al., 2007). In 2013, because NCD 
burden in SA is predicted to rise, the SA National Department of Health (NDoH) set out national 
goals and targets for the prevention and control of NCDs (NDoH, 2013). Table 1.1 compares the SA 
NDoH goals and targets to that of the WHO’s global target for 2025.  
Table 1.1 Goals and targets for the prevention and control of NCDs in South Africa, by 2020, as 
set out by the NDoH and globally, by 2025, as set out by WHO. 
NDoH NCD prevention and control: 2020 SA 
goals and targets  
WHO NCD prevention and control: 2025 
global goals and targets (66TH World Health 
Assembly) 
Relative premature mortality (<60 years): reduce by 
25% 
NCD premature mortality reduce by 25% (all 4 major 
NCDs) 
Tobacco use: reduce by 20% Behavioural risk factors 
   Tobacco use: reduce by 30% (aged >15years) 
   Alcohol use: reduce by 10% 
   Salt/sodium intake: reduce by 30% 
Alcohol consumption (per capita): reduce by 20% 
Salt intake (mean population): <5g per day 
Percentage overweight/obese: reduce by 10% Biological risk factors 
  Prevent rise in diabetes and obesity 
  Prevalence of raised BP: reduce by 25% 
Prevalence of raised BP: reduce by 20% (via lifestyle 
and medication) 
Physical activity: increase by 10% (150min 
moderate-intensity per week) 
Behavioural risk factors 
   Physical activity: increase by 10% 
Females with STDs: screened for cervical cancer 
every 5years. 
Healthy females: 3 screens in a lifetime (and 
as per policy for females who are HIV-
positive) 
 
National systems response 
   Drug therapy and counselling to prevent heart 
   attack and stroke: 50% eligible candidates 
   receive care (eligibility: >40years with 10year 
   CVD risk <30%). 
   Treatment of major NCDs: 80% availability of  
    affordable basic technologies and essential 
    medicines in public and private facilities 
    
 
Asthma, diabetes and hypertension control: increase 
by 30% in sentinel sites 
Mental disorders (screening and treatment): 
increase by 30% (by 2030) 
NDoH – National Department of Health; WHO – World Health Organization; SA – South Africa; NCD – Non-communicable 
disease; g – grams; BP – Blood pressure; STD – Sexually transmitted disease; HIV – Human immunodeficiency virus 
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This rapid, predicted increase in NCD burden is thought to be largely due to the rapid urbanization 
and accompanying demographic and epidemiological transitions (Motala et al., 2011). Such 
transitions are characterised by a quadruple burden of disease: communicable (transmittable); non-
communicable (non-transmittable); perinatal and maternal; and injury related diseases/disorders 
(Mayosi et al., 2009). 
1.1 Metabolic syndrome (MetS) 
In 1988 the term “Syndrome X” was coined by Reaven (1988) to describe a clustering of metabolic 
abnormalities, with insulin action as the underlying cause. Syndrome X was later termed metabolic 
syndrome (MetS) (Alberti et al., 2006). Metabolic syndrome is often related to the four major NCDs 
(cardiovascular disease, cancer, chronic respiratory disease and T2DM), as MetS is a cluster of risk 
factors found together more often than by chance alone that place an individual at higher risk for the 
development of CVD and T2DM (O’Neill & O’Driscoll, 2015; Emmanuela et al., 2012; Motala et al., 
2011; Sookoian & Pirola, 2011; Gallagher et al., 2010; Ntyintyane et al., 2009; Ntyintyane et al., 
2006; Aizawa et al., 2006; Eckel et al., 2005).  
Metabolic syndrome is related to increased risk of morbidity and mortality (Ntyintyane et al., 2006), 
with insulin resistance (IR), a common thread among all risk factors for CVD, proposed as a linking 
factor to disease (Motala et al., 2011; Gallagher et al., 2010; Boura-Halfon & Zick, 2009; Eckel et al., 
2005; Grundy et al., 2005; Smith & LeRoith, 2004; Hu et al., 2004; Stephens et al., 1997; Hotamisligil 
et al., 1994; Reaven, 1988).  
Metabolic syndrome is accompanied by sustained inflammation (Ntyintyane et al., 2009; Boura-
Halfon & Zick, 2009; Grundy et al., 2005; Hu et al., 2004; Stephens et al., 1997; Hotamisligil et al., 
1994); the fundamental, unifying pathogenic mediator of CVD, T2DM and obesity (Lontchi-Yimagou 
et al., 2013). The low-grade, persistent presence of inflammation, due to obesity, may be correlated 
with the development of CVD and T2DM (Medzhitov, 2008; Hotamisligil, 2006). Risk factors for, and 
the diagnosis of MetS, as defined by the International Diabetes Federation’s (IDF) Joint Interim 
Statement (JIS), and subsequently CVD and its associated risk factors include abdominal obesity 
(presenting as an increased waist circumference (WC)); raised triglycerides (>1.7mmol/l (150mg/dl)) 
and reduced high-density lipoprotein cholesterol (HDL-C) (males: <1.03mmol/l (40mg/dl); females: 
<1.29mmol/l (50mg/dl)), referred to as dyslipidaemia; hypertension (systolic BP: >130mmHg; 
diastolic BP: >85mmHg), often present with obesity and/or IR; and elevated fasting glucose 
(>5.6mmol/l (100mg/dl)) (Alberti et al., 2009; Kooner et al., 2008; Ntyintyane et al., 2006; Vague, 
1956). To be diagnosed with MetS, three of the above mentioned five risk factors need to be present 
in an individual (Alberti et al., 2009).  
Various definitions exist for MetS (Table 1.2), but for the purpose of this study, the JIS criteria will be 
used for diagnosis. 
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Table 1.2 Various definitions of the metabolic syndrome.  
 
AACE – American Association of Clinical Endocrinology; EGIR – European Group for study on Insulin Resistance; IDF – 
International Diabetes Federation; JIS – Joint Interim Statement;  NCEP ATPiii – National Cholesterol Education Program 
Adult Treatment Panel III; WHO – World Health Organization 
1.2 Cardiovascular disease (CVD) 
Cardiovascular disease (CVD) refers to disorders of the heart and its blood vessels. Cardiovascular 
diseases are divided into 2 groups: acute CVDs, such as heart attack and stroke, and chronic CVDs 
such as cerebrovascular disease, congenital heart disease, coronary heart disease (CHD), deep 
vein thrombosis and pulmonary embolism, peripheral arterial disease and rheumatic heart disease 
(WHO, 2014; Motawi et al., 2011). Heart disease/failure due to non-ischaemic causes of 
hypertension, idiopathic cardiomyopathy (enlarged chambers or decreased muscle contractions) 
and rheumatic heart disease (damage to the valves) are the most common reasons for admission to 
hospital in the SA Black population, while ischaemic heart diseases account for 10% of 
hospitalization due to heart diseases/failure (Mayosi et al., 2009) 
In general, CVD patients report a higher frequency of hypertension, family history of CVD, smoking 
habits, T2DM and increased waist-to-hip ratios (Abd El-Aziz et al., 2012; Mayosi et al., 2009). These 
patients also have increased levels of low-density lipoprotein cholesterol (LDL-C), total cholesterol 
(TC) and triglycerides, while their HDL-C levels are decreased (Abd El-Aziz et al., 2012). All these 
factors are independently associated with CVD (Abd El-Aziz et al., 2012). In SSA, heart failure has 
been found to occur at a younger age and results in a higher rate of hospitalised mortality than in 
American and European countries (Carlson et al., 2017). The impact on CVD of its risk factors, such 
as BP and T2DM, differs dramatically between the sexes (Um et al., 2003). 
1.2.1 Epidemiology of cardiovascular disease in Africa 
Three quarters of the world’s annual deaths due to CVD occurs in low- and middle-income countries 
(WHO, 2014). After HIV/AIDS, CVD is the leading cause of death in SA (Msemburi et al., 2014), 
responsible for 1 in 6 deaths (Stats SA, 2015). This figure is greater than the deaths for all forms of 
NCEP ATPiii WHO IDF EGIR AACE JIS
Obesity
Increased WC                        
Males: >102cm                                       
Females: >88cm
Increased waist-to-hip ratio      
Males: >0.09                                         
Females: >0.82                               
or BMI >30kg/m2
Increased WC                        
Males: >90cm                                       
Females: >80cm
Increased WC                        
Males: >94cm                                       
Females: >80cm
Increased WC                        
Males: >94cm                                       
Females: >80cm
Triglycerides
Elevated plasma triglycerides 
>1.69mmol/l
Elevated plasma triglycerides 
>2mmol/l
Elevated plasma triglycerides 
>1.69mmol/l
Elevated plasma triglycerides 
>1.7mmol/l                          
Treatment
Elevated plasma triglycerides 
>1.7mmol/l
Elevated plasma triglycerides 
>1.7mmol/l
Glucose
Impaired fasting glucose                 
>6.1mmol/l
Glucose intolerance, IGT, T2DM Impaired fasting glucose                 
>5.6mmol/l
Impaired fasting glucose                 
>6.1mmol/l
Impaired fasting glucose                 
>6.1-6.9mmol/l                                                           
2h glucose tolerance                                
7.8-11.mmol/l
Impaired fasting glucose                 
>5.6mmol/l
Hypertension
Elevated BP                                     
>130/85mmHg 
antihypertensive medication
Elevated BP                                     
>140/90mmHg 
Elevated BP                                     
>130/85mmHg 
antihypertensive medication
Elevated BP                                     
>140/90mmHg 
antihypertensive medication
Elevated BP                                     
>130/85mmHg  
Elevated BP                                     
>130/85mmHg  
HDL-C
Low plasma HDL-C                    
Males: <1.04mmol/l             
Females: <1.29mmol/l
Low plasma HDL-C                    
Males: <0.9mmol/l             
Females: <1.0mmol/l
Low plasma HDL-C                    
Males: <1.04mmol/l             
Females: <1.29mmol/l
Low plasma HDL-C                    
<1.0 mmol/l                              
Treatment
Low plasma HDL-C                    
Males: <1.04mmol/l             
Females: <1.29mmol/l
Low plasma HDL-C                    
Males: <1.0mmol/l             
Females: <1.3mmol/l
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cancer combined (Msemburi et al., 2014). Per hour in SA, 5 people have a heart attack, 10 people 
suffer a stroke (HSFSA, 2016), and 215 people die per day from CVD (Stats SA, 2015). In 2013, 
nearly 1 million deaths in SSA (512 269 females and 445 445 males), an 81% increase from 1990 
(Mensah et al., 2015), was due to CVD, equating to 11.3% of all deaths and 38% of NCD-related 
deaths reported in SSA (Keates et al., 2017; Mensah et al., 2015).  
Cardiovascular disease is a polygenic disease that is influenced by many risk factors (Figure 1.1) 
(Abd El-Aziz et al., 2012; Motawi et al., 2011; Shaker et al., 2009; Abbate et al., 2008). Until the early 
2000s (Motala et al., 2011; Mensah, 2008; Sliwa et al., 2008; Ntyintyane et al., 2006; Joubert et al., 
2000; Walker & Sareli, 1997; Seedat et al., 1977; Mollentze et al., 1995), coronary artery disease 
(CAD) was believed to be rare in Black Africans (Mayosi et al., 2009; Ntyintyane et al., 2006; Steyn 
et al., 2005; Akinboboye et al., 2003; Ntyintyane et al., 2006; Muna, 1993). However, evidence now 
suggests that CAD is increasing in this population (Ntyintyane et al., 2009).  
1.2.1.1 CVD in South Africa 
In the 1990s, nearly 70 black patients were hospitalised at the Chris Hani Baragwanath Hospital in 
Soweto for CVD, and this number increased to 85 in 2002 and 150 in 2006 (Ntyintyane et al., 2006). 
In 1940, only a single death of a total of 352 autopsies that were performed on Black African adults 
was as a result of myocardial infarction and three decades later, CHD was still rare among Black 
individuals living in Durban and Johannesburg (Mensah, 2008). In 1990, CHD was the most common 
form of death due to diseases of the circulatory system in SA Caucasian and Asian individuals (165.3 
and 101.2 per 100 000, respectively), but was rare in SA Coloured (55.1 per 100 000) and Black (5.3 
per 100 000) individuals (Central Stats Unit, 1990). Until 2010, CHD was still rare in SA Black 
individuals, accounting for only 10.0% of all heart disease patients that present at hospital (Mayosi 
et al., 2009; Sliwa et al., 2008; Mayosi et al., 2009) and is still rare in Black individuals from Nigeria 
and Uganda (Nkoke & Luchuo, 2016; Mensah, 2008). Ischaemic heart disease was estimated to be 
found in only 10.0% of SA Black patients diagnosed with heart disease in 2009 (Mayosi et al., 2009), 
and remains uncommon in the SA Black population (Churchill, 2013), representing the lowest IHD 
death rates worldwide (Mensah et al., 2015).  
In Soweto, the annual number of heart failure diagnosis is fast exceeding that of previously 
diagnosed cases (Sliwa et al., 2008), and more than 78.0% of the population within Soweto has at 
least one risk factor for CVD (Tibazarwa et al., 2009), as is observed in Black individuals all over SA 
(Motawi et al., 2011). A study found that in SA Black individuals living in Soweto, <1.0% of deaths 
was attributable to CAD, whereas in SA Caucasian individuals it was responsible for 5% of deaths 
(Joubert et al., 2000). This low trend was also observed in SA black stroke patients (Joubert et al., 
2000), where a meta-analysis of NCD studies in SSA found that the prevalence of stroke ranged 
between 0.07% and 0.3% (Dalal et al., 2011). In 1995 the incidence of stroke was reported to be 
1.01 per 1 000 in the urban Black population of Mangaung (Mollentze et al., 1995). However, reports 
are emerging that Africans are disproportionately affected by stroke at a younger age, with attacks 
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more severe and leading to accelerated end-organ damage (Moran et al., 2013; Dalal et al., 2011; 
Tibazarwa et al., 2009; Vorster, 2002), possibly due to hyperfibrinogenaemia, increased 
hypertension, obesity and tobacco use (Vorster, 2002).  
A study of 4 162 individuals, of which 1 359 were Black Africans, found that Black individuals were 
more frequently diagnosed with heart failure and less frequently diagnosed with CAD than other SA 
populations (Sliwa et al., 2008). This was also observed in an earlier study of Black individuals in the 
Cape Peninsula (Steyn et al., 1991). A survey of 10 000 individuals in 200 hospital across SA found 
that 76.0% had one or more risk factors for stroke, an acute form of CVD, and 40.0% had two or 
more risk factors (Connor et al., 2005). In 2008 and 2009 all forms of CVD were responsible for 
13.7% and 14.0%, respectively, of deaths in SA (Raal et al., 2013). 
1.2.1.2 CVD in sub-Saharan Africa 
From 1997 to 2009, deaths as a result of CAD in older individuals increased from 70 deaths per 
100 000 population to 87 deaths per 100 000 population in Tunisian males (>55 years), and from 28 
deaths per 100 000 population to 41 deaths per 100 000 population in Tunisian females (>65 years) 
(Keates et al., 2017). This is in stark contrast to Sudan, where by 2002, CAD-associated deaths 
were already reported at 205 deaths per 100 000 population (Keates et al., 2017). In Kenya between 
2005 and 2009, CVD was responsible for 13% of all deaths, while a retrospective analysis of hospital 
admissions in Ethiopia reported that CVD was responsible for 32% of all deaths in the years 1981-
1982, 1991-1992, 2001-2002 and 2011-2012 (Keates et al., 2017). 
Ischaemic heart disease is the eighth leading cause of death in SSA (Ebireri et al., 2016; Mensah, 
2008). The southern region of SSA (Botswana, Namibia, SA) has the highest CVD burden, while the 
Western region (including, but in no way limited, to Ghana, Mali, Nigeria and Togo) has the lowest 
(Moran et al., 2013). In 2005, 361 000 deaths as a result of IHD were reported in Africa, and this 
number is estimated to double by 2030 (Mensah, 2008). Surprisingly, fewer deaths as a result of 
IHD were reported for SSA in 2013 than in 2005 (258 939 vs. 361 000, respectively), but this was 
still an 87.0% increase since 1990 (Mensah et al., 2015). In 2010, stroke was the leading cause of 
death and disability in SSA (Moran et al., 2013). In 2013, 409 840 deaths, almost double that 
reported in 1990, as a result of stroke were reported in SSA, but overall stroke mortality has 
increased by 1.0% (Mensah et al., 2015). 
 IHD is rare in the SA Black population (10% of CVD patients in 2009) (Churchill, 2013; Mayosi et 
al., 2009) and is thought to be due to favourable serum lipid profiles (decreased serum cholesterol, 
but stable HDL-C) and low homocysteine values, which have been suggested to protect SA Black 
individuals against IHD (Mayosi et al., 2009; Lemogoum et al., 2003; Vorster, 2002). However, SA 
Black individuals may soon transition to IHD, as the presence of risk factors associated with CVD is 
widespread (Table 1.3), and this ethnic population is undergoing a CVD epidemic, with high mortality 
rates for cardiomyopathy, hypertensive heart disease, stroke and T2DM (Nojilana et al., 2016). 
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A low frequency of the methylene tetrahydrofolate reductase (MTHFR) 677C-T mutation, which 
impairs remethylation of homocysteine (20.0% in SA Black individuals versus 56.0% in SA 
Caucasian individuals), thus contributing to the low homocysteine values observed in the SA Black 
population group, was proposed as a protective mechanism against IHD in SA Black individuals in 
the THUSA study (Loktionov et al., 1999). Increased levels of homocysteine contribute to CVD by 
promoting atherosclerosis and thrombosis (Sengwayo et al., 2013). Atherosclerosis is achieved by 
damaging the inner lining of arteries while thrombosis is achieved through sustained collagen 
activation, endothelial dysfunction, impaired thrombolysis, and oxidative stress (increased 
production of hydrogen peroxide and oxidation of low-density lipoproteins) (Sengwayo et al., 2013). 
Homocysteine plays a role in the aetiology of T2DM by regulating glucose metabolism and insulin 
absorption, and is also thought to contribute to the development of essential hypertension by 
inducing arteriolar constriction and increasing sodium reabsorption thereby enhancing arterial 
stiffness (Sengwayo et al., 2013). Homocysteine also increases oxidative stress, a common 
abnormal physiological process between hypertension, obesity and T2DM (Sengwayo et al., 2013).  
Table 1.3 Population groups in South Africa: Prevalence and level of selected CVD risk factors 
(Adapted from Vorster et al., 2002) 
Population 
group in South 
Africa 
Gender 
Prevalence (%) Level 
Hypertension 
(BP ≥160/95 
mmHg) 
Obesity (BMI 
> 30kg/m) 
Dyslipidaemia 
(45-54 years) 
(mmol/l) 
Black 
Female 13.0 30.5 4.70 
Male 10.3 7.7 4.20 
Coloured 
Female 17.1 28.3 6.30 
Male 12.4 9.1 6.09 
Indian 
Female 9.3 20.2 5.86 
Male 9.9 8.7 6.28 
Caucasian 
Female 12.0 24.3 6.62 
Male 15.2 19.8 6.39 
All 
Female 13.2 29.4  
Male 11.0 9.1  
1.2.2 Genetics of cardiovascular disease  
The heritability of CVD and its associated risk factors has strongly and consistently been supported 
by genome-wide association studies (GWAS) and twin and/or family studies (Dehghan et al., 2016). 
Overall, only about 10.0% of the predicted heritable risk for CVD, specifically CHD, has been 
explained by GWAS (McPherson, 2014; Zeller et al., 2012). 
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A Swedish study that followed 10 500 twin pairs for 35 years estimated the heritability of fatal CAD 
at 57.0% and 38.0% for males and females, respectively (Zdrakovic et al., 2002). However, a study 
in an American cohort, over a 9 to 26-year follow-up period, showed that single nucleotide 
polymorphisms (SNPs) associated with incident CAD in Caucasian Americans was not associated 
with CAD in their Black counterparts (Franceschini et al., 2011). This was also observed in another 
study which found that SNPs associated with 28 different disease phenotypes in European 
populations had low replicative results in African-ancestry populations (Marigorta & Navarro, 2013). 
These studies suggest that even though there is evidence for the heritability of CAD, it is variable 
among different ethnic population groups. 
In 2007, three GWAS reported a locus on chromosome 9p21.3 to be associated with CAD and 
myocardial infarction (MI) risk (Helgadottir et al., 2007; McPherson et al., 2007; Samani et al., 2007). 
This finding was later replicated in a GWAS of 8 090 African Americans (AfAms) from 5 population-
based cohorts, which also replicated 16 other SNPs associated with CVD and its associated risk 
factors in Europeans (Lettre et al., 2011). Homozygosity of these SNPs in the region of 9p21 has 
been associated with a 30.0-40.0% increased risk of CAD and a 15.0-20.0% increased risk in 
heterozygotes (Cambien & Tiret, 2007). Since the first associations of the 9p21 region with CAD, it 
has also been hypothesized to be associated with other disease, such as aggressive periodontitis 
(Schaefer et al., 2009), aortic aneurysm (Helgadottir et al., 2008), glioma (Shete et al., 2009), 
ischaemic stroke (Gschwendtner et al., 2009), malignant melanoma (Bishop et al., 2009) and T2DM 
(Zeggini et al., 2007). 
A GWAS of 64 297 European individuals identified 3 loci significantly associated with CHD, of which 
rs6941513, close to the Quaking homolog (QKI) gene, was the strongest hit of all the  SNPs reported. 
However, this association was not replicated in 8 201 AfAms (Dehghan et al., 2016).  
No studies have thus far been conducted to determine the genetics of CVD in Africa. However, the 
renin-angiotensin-aldosterone system (RAAS) has been proposed as one of the major players in 
CVD progression and diagnosis, as well as in the risk phenotypes associated with CVD. And thus, 
the genes involved in the RAAS could be implicated in disease.   
1.2.2.1 The renin-angiotensin-aldosterone system 
A key mechanism of CVD initiation and progression is inflammation (Farrario & Strawn, 2006). The 
main effector in the renin-angiotensin-aldosterone system (RAAS) (Figure 1.2), angiotensin II (Ang 
II) (Munóz-Duranga et al., 2016; Farrario & Strawn, 2006), plays an important role in inflammatory 
diseases, especially atherogenesis and renal disease (Farrario & Strawn, 2006).  
The RAAS (Figure 1.2) has been proposed to be involved in atherosclerosis pathogenesis, the 
leading cause of death worldwide (Shaker et al., 2009), and CAD prognosis (Abd-El Aziz et al., 
2012). It is involved in many of the diseases that are risk factors for CVD (Munóz-Duranga et al., 
2016; Farrario & Strawn, 2006; Lovati et al., 2001). The RAAS is a crucial hormonal pathway that 
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controls haemodynamic stability by regulating blood pressure, cardiac and vascular trophic effects, 
extracellular fluid volume and sodium-potassium balance (Munóz-Duranga et al., 2016; Farrario & 
Strawn, 2006).  
 
 
Figure 1.2 The renin-angiotensin-aldosterone system (RAAS). Adapted from Encyclopaedia 
Brittanica.                                                                                                                                        
ACE – Angiotensin-converting enzyme; AGT – Angiotensinogen; AT1R – Angiotensin II type I receptor; NaCl – Sodium 
chloride; H2O – Water; K+ - Potassium; H+ - Hydrogen 
In response to dehydration, haemorrhage, low blood pressure in renal glomerulus arterioles or 
sodium deficiency, an inactive form of renin is released from the kidneys. Inactive renin is activated 
in the bloodstream by either proteolytic or non-proteolytic mechanisms. Angiotensinogen (AGT), 
released by the liver at the same time as renin being released from the kidneys, is cleaved by the 
active renin to form angiotensin I (Ang I), which is further cleaved by the angiotensin-converting 
enzyme (ACE), released from the lungs, into angiotensin II (Ang II) (Munóz-Duranga et al., 2016; 
Farrario & Strawn, 2006). The presence of AngII results in the increase of blood pressure until it 
returns to normal (120/80 mmHg) through four mechanisms: (a) by inducing arteriole 
vasoconstriction; (b) stimulation of the sympathetic nervous system; (c) renal action or (d) by 
stimulating the adrenal cortex, through the angiotensin II type I receptor (AT1R), to release 
aldosterone, another major effector of the RAAS. The latter stimulates the kidneys to increase salt 
(NaCl) and water (H2O) reabsorption as well as increasing the secretion of potassium (K+) and 
hydrogen (H+) into the urine (Munóz-Duranga et al., 2016) (Figure 1.2).  
Previously, genes encoding parts of the RAAS have been associated with CAD (Zitouni et al., 2018; 
Abd El-Aziz et al., 2012; Shaker et al., 2009). A study of Egyptian CAD patients and unaffected 
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controls found that the patient group (cases) showed a higher frequency of diabetes, family history 
of CAD, hypertension, increased waist-to-hip ratio and smoking, as well as  homozygosity of the D-
, T- and C-alleles of the angiotensin-converting enzyme (ACE), angiotensinogen (AGT) and 
angiotensin II type I receptor (AT1R) genes respectively, and the presence of these factors were 
shown to be associated with CAD in the patient group (cases) . The risk observed for CAD was 
increased by the presence of other risk factors such as diabetes, dyslipidaemia, hypertension, 
obesity and smoking (Abd El-Aziz et al., 2012).  Renin contributes to BP elevation, through the action 
of AngII (Gafane et al., 2016). Angiotensin II promotes vasoconstriction and promotes increased 
renin synthesis. Angiotensin II also has damaging effects on the vasculature by activating profibrotic 
and proinflammatory pathways (Gafane et al., 2016), as well as contributing to cardiac remodelling, 
plaque rupture and thrombosis (Burrel et al., 2013). Increased levels of AngII also affects cell growth, 
immune response, inflammation, neuromodulation and proliferation (Zarebska et al., 2013). The 
vasoconstrictive action and damaging effects of AngII can be overcome by the action of the 
angiotensin-converting enzyme 2 (ACE2) protein, a 805 amino acid long protein located on 
chromosome Xp22, that degrades AngII (Burrel et al., 2013). In failing hearts and atherosclerotic 
vessels, increased levels of ACE2 have been found, associating ACE2 with CHD and heart failure 
(Burrel et al., 2013). 
Genes involved in the RAAS (Figure 1.2), such as AGT, ACE and AT1R have been found to be 
involved in CVD in Africa and are discussed below (Table 1.4).  
Angiotensinogen (AGT) 
The gene encoding angiotensinogen (AGT), spans 12 kilobases on chromosome 1 (1q42-q43) and 
consists of 5 exons. It is a member of the serpin gene superfamily, which is important for 
cardiovascular remodelling, and regulating blood pressure (BP) and the body’s fluid and salt balance 
(Shaker et al., 2009) (Figure 1.2).  
The T allele of the rs699 SNP, located in exon 2 of AGT, results in a missense amino acid substitution 
(methionine to threonine) at residue 235 (M235T); the T allele of the rs4762 SNP, also located in 
exon 2 of AGT results in a missense amino acid substitution (threonine to methionine) at residue 
174 (T174M) (Zarebska et al., 2013).  
A study of Egyptian CAD patients found the T allele of rs699 to be significantly associated with CAD 
and positively correlated with BP (Shaker et al. 2009). Higher frequencies of the rs699 T allele and 
rs4762 T allele were observed in Tunisian CAD patients when compared to controls (Abboud et al., 
2010), this was also observed by both Abd El-Aziz et al. (2012) and Motawi et al. (2011) in Egyptian 
CAD patients. In association with dyslipidaemia, hypertension, smoking and T2DM, T homozygosity 
of these SNPs resulted  in a 2.7-fold increased risk of CAD development (Abd El-Aziz et al., 2012) 
(Table 1.4). 
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Angiotensin-converting enzyme (ACE) 
The gene encoding angiotensin-converting enzyme (ACE), is located on chromosome 17 (17q23.3) 
and is 21kb long with 26 exons (Baroudi et al., 2009). ACE is a member of the metallopeptidase 
protein family, responsible for cleaving the decapeptide angiotensin I (Ang I) to the octapeptide 
angiotensin II (Ang II) (Figure 1.2) (Baroudi et al., 2009). 
Alu repeats are short, interspersed elements (SINEs) that have recently amplified within the human 
genome and are believed to have an African origin (Batzer & Deininger, 2002). The deletion (D) of 
a 287bp Alu repeat at intron 16 of the ACE gene has been found to affect the activity of ACE 
intracellularly and in cardiovascular tissues (Abd El-Aziz et al., 2012), and has been associated 
with an increased risk of CAD associated with this allele (Abd El-Aziz et al., 2012). The D allele 
was also found to be more frequent in CAD patients than in controls in this population (Abd El-Aziz 
et al., 2012). However, in Tunisian CAD patients, a higher frequency of the insertion (I) allele was 
observed in CAD patients and I homozygosity placed an individual at higher risk for CAD (Abboud 
et al., 2010). In association with dyslipidaemia, hypertension, obesity, smoking and T2DM, D 
homozygosity of this SNP resulted  in a 2.8-fold increased risk of CAD development (Abd El-Aziz 
et al., 2012) (Table 1.4). 
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 Table 1.4 A summary of genes that have been found to be associated with CVD in Africa. 
 
ACE – Angiotensin converting enzyme; AGT – Angiotensinogen; AT1R – Angiotensin II type I receptor; AngI – Angiotensin I; AngII – Angiotensin II; CAD - Coronary artery disease; 
CHD – Coronary heart disease; Chr – Chromosome; I/D – Insertion/deletion; MI – Myocardial infarction; SSA – sub-Saharan Africa 
 
 
  
Cases Controls
Egyptians 70 60 Associated with CAD Shaker et al., 2009
Egyptians 230 119 Increased risk of CAD, more frequent in patients Abd El-Aziz et al., 2012
Egyptians 100 50 More frequent in CAD patients Motawi et al ., 2011
Tunisians 341 316 Associated with CAD (p=0.001) Abboud et al., 2010
rs4762             T Tunisians 341 316 Associated with CAD (p=0.026) Abboud et al., 2010
Egyptians 70 60 Associated with CAD Shaker et al., 2009
Egyptians 230 119 Increased risk of CAD, more frequent in patients Abd El-Aziz et al., 2012
Tunisians 341 316 No difference in frequency between cases and controls Abboud et al ., 2010
D Egyptians 230 119 Increased risk of CAD, more frequent in patients Abd El-Aziz et al., 2012
I Tunisians 341 316 I homozygosity as risk for CAD (p=0.02) Abboud et al., 2010
T
ReferenceGene name Gene function Chr. Location Chr coordinates (GRCh 38) (From - To) SNP
Risk 
allele
Population 
studied 
No. samples
Results
230702523 - 2307145901q42-q43Cardiovascular remodelling; blood pressure controlAngiotensinogen (AGT )
rs699              
Crs5186             148697871 - 1487430033q21-q25
Vasoconstriction through AngII; 
mediates major cardiovascular 
effects of AngII
rs4646994                   
(I/D)63477061 - 6349838017q23
Catalyzes conversion of AngI to 
the physiologically active AngII
Angiotensin converting enzyme 
(ACE )
Angiotensin II type I receptor 
(AT1R )
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Angiotensin II type I receptor (AT1R) 
The angiotensin II type I receptor (AT1R) gene, a 60 kilobase gene located on chromosome 3 (3q24) 
and consisting of 5 exons and 4 introns, is a member of the G-protein coupled receptor superfamily. 
It is responsible for vasoconstriction through its effector molecule, angiotensin II (AngII) (Figure 1.2), 
as well as cardiac and vessel hypertrophy (Kooffreh et al., 2013). 
The rs5186 SNP is an A to C substitution in AT1R that occurs at position 1166 (A1166C) in the 3’ 
untranslated region of the AT1R gene (Ghogomu et al., 2016; Mehri et al., 2011). The SNP has been 
found to be associated with CAD in Egyptians (Shaker et al., 2009) and this association was 
replicated by Abd El-Aziz et al. (2012) in a different sample from the same population. This SNP has 
been associated with an increased risk of diabetic nephropathy, heart disease and hypertension 
(Aung et al., 2017), and through an epistatic interaction with the ACE insertion/deletion (I/D) 
polymorphism (rs46464994), at intron 16, AT1R is correlated with CHD (Aung et al., 2017; Wang & 
Staessen, 2000). In Tunisians, there was no allele frequency difference observed between CAD 
cases and controls for the rs5186 C risk allele (Abboud et al., 2010), suggesting that in this population 
the variant may not be involved in CAD pathogenesis.. In association with dyslipidaemia, 
hypertension, smoking and T2DM, C homozygosity of this SNP results in a 2.8-fold increased risk of 
CAD development (Table 1.4) (Abd El-Aziz et al., 2012). 
1.2.3 Concluding remarks - CVD 
Cardiovascular disease is the second leading cause of death in SA with the main contributor being 
stroke, which is disproportionately high in the SA Black population. Black CVD patients have high 
rates of diseases that are risk factors for CVD, such as T2DM, obesity and hypertension. Genes 
encoded by the RAAS, involved in controlling BP and sodium reabsorption, have been associated 
with CVD and its associated diseases. However, very few studies have associated genes of the 
RAAS with CVD in Africa, suggesting that the causal variant has not been found yet or that these 
genes, which play a very small role in CVD risk, may act together to increase risk of disease.  
1.3 Type 2 diabetes mellitus (T2DM) 
Various forms of diabetes mellitus exist. Type 1 diabetes mellitus is an inherited form that exists as 
either type 1A (autoimmune) or type 1B (ketosis-prone type 2 diabetes), while T2DM is considered 
a disease of lifestyle, to which there is also a genetic component which may contribute to 
susceptibility, and accounts for 90.0% of all diabetes cases worldwide (Levitt, 2008; Kengne et al., 
2005). Gestational diabetes is a pregnancy specific form of diabetes that occurs in 2.0-10.0% of all 
pregnant females (Madubedube, 2015). Maturity onset diabetes of the young (MODY), a 
heterogeneous group of disorders, is inherited in an autosomal dominant mode and is characterised 
by familial hyperglycaemia (Madubedube, 2015). 
Type 2 diabetes mellitus is a multifactorial, multiorgan metabolic disease, which occurs as a result 
of an interaction between environmental and genetic factors, with acute and chronic complications 
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(Mato et al., 2016; Guewo-Fokeng et al., 2015; Ouedemi et al., 2009), and which is characterised by 
IR (Baroudi et al., 2009). The disease occurs due to hyperglycaemia, when insufficient insulin is 
produced by the pancreas or when the body is unable to successfully utilise the insulin produced. It 
may also be as a result of reduced insulin secretion, increased peripheral IR or increased hepatic 
glucose output (Mato et al., 2016; Madubedube, 2015; Guewo-Fokeng et al., 2015; Nanfa et al., 
2015; Turki et al., 2013a; Turki et al., 2012; Ouedemi et al., 2009), leading to impaired glucose 
tolerance (IGT) (Christensen et al., 2009). Disease occurrence is also modulated by age, dietary 
habits, lifestyle, obesity and physical activity (Ouedemi et al., 2009).  
The complex, multifactorial nature of T2DM and the interplay between diseases is evidenced by a 
systematic review which stated that 2 out of 3 diabetic patients will die as a result of cardiovascular 
complications, while approximately 30.0% of CVD treated individuals are diabetic (Kengne et al., 
2005). The authors also reported that 5-8% of T2DM patients may be affected by CHD, 15% of 
patients who previously had a stroke are diabetic and 4-28% of such patients have peripheral 
vascular disease (Kengne et al., 2005). In Black African T2DM individuals, 44.4% had coexisting 
hypertension and dyslipidaemia, 42.5% had coexisting obesity and dyslipidaemia, and 33.1% had 
coexisting hypertension and obesity (Isezou & Ezunu, 2005). 
The rising rates of T2DM worldwide are attributable to the increased presence of obesity, physical 
inactivity and urbanization (Ganu et al., 2016; Levitt, 2008). Obesity, the most modifiable risk factors 
of T2DM, has been found to be a major risk factor for T2DM onset (Adeniyi et al., 2015; Lontchi-
Yimagou et al., 2013; Bouhaha et al., 2010a), as the development of T2DM and CVD risk factors is 
likely linked to body fat percentage and distribution (Borné et al., 2014; Luo et al., 2013; Jennings et 
al., 2009; Meisinger et al., 2006). Approximately 80.0% of all T2DM patients worldwide are obese 
(Thevenod et al., 2008), while in SA, 87% of all T2DM in males and females is attributed to excess 
body fat (Goedecke et al., 2009). 
The development of T2DM is preceded by IR (Grundy et al., 2005). This notion is supported by the 
persistent presence of IR in T2DM patients (Savage et al., 2005). However, T2DM only develops if 
insufficient insulin is produced by the patients’ β-cells. Not  all IR patients develop T2DM, but all 
T2DM patients are IR (Savage et al., 2005). The IR observed in T2DM patients is as a result of 
increased activation of the inflammatory pathways, which is intensified by hyperglycaemia, another 
characteristic of T2DM, promoting the chronic complications of disease (Lontchi-Yimagou et al., 
2013). Black females in SA have been found to be more IR than their Caucasian counterparts 
(Goedecke et al., 2009). Disease progression of T2DM may lead to macrovascular (CVD and stroke) 
and microvascular (lower limb amputation, nephropathy leading to blindness, neuropathy, renal 
failure and retinopathy) complications (Thevenod et al., 2008; van Tilburg et al., 2001). Indeed, β-
cell dysfunction has been observed mostly in African T2DM patients (Oli et al., 2009; Kahn et al., 
2003; Jensen et al., 2002; Bell et al., 1996; Joffe et al., 1992).  
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1.3.1 Epidemiology of type 2 diabetes mellitus in Africa 
In 2013, 8.6% (522 600) of all deaths reported in Africa were diabetes-related (IDF, Diabetes Atlas, 
2013). The burden of T2DM is high in SSA and continues to rise, surpassing that of developed 
countries. By 2006, 10.8 million people in SSA were estimated to have diabetes by the IDF Atlas 
(Levitt, 2008) and by 2010 T2DM accounted for 6% of the total deaths that year (Mbanya et al.,  
2010).  
The prevalence of T2DM in SSA is estimated to increase by 109.6% to 41.5 million people in 2035, 
from 19.8 million in 2013 (Guewo-Fokeng et al., 2015), exceeding the 50% predicted worldwide 
increase (Roglic et al., 2005). In addition, the prevalence of IGT is expected to increase by 75.8% to 
47.3 million in 2030, from 26.9 million in 2010 (Mbanya et al., 2010). Early on in disease progression, 
levels of insulin are increased to compensate for the increased glucose levels. However, this 
increased level of insulin secretion is not able to manage the increased glucose levels accompanying 
disease progression for extended periods of time and thus a state of IR is reached (Wiegend et al., 
2005). The progression from normal glucose tolerance to IGT, and thus T2DM, is modulated by IR 
(Wiegend et al., 2005). Impaired glucose tolrance precedes T2DM and may thus be an indication of 
T2DM progression in high-risk individuals (Wiegend et al., 2005; Motala et al., 2005). It has also 
been found that individuals with IGT progress to T2DM 2-10-fold faster than individuals with normal 
glucose tolerance (Ferrannini et al., 2004). 
In 2014, the prevalence of T2DM in Africa (7.1%) was similar to that of the Americas (8.3%) and 
European countries (7.3%). However, death per 100 000 population was much higher in the African 
compared to the America and European countries (111.3 versus 72.6 and 55.7, respectively) due to 
poor disease management (WHO, 2016). 
 No clear gender distribution pattern of T2DM has been observed in any population (Tuei et al., 
2010). In SA (Cape Town), Sudan and Tanzania equal rates of T2DM have been reported in males 
and females. However, in urban Cameroon, Sudan and Tanzania T2DM is more common in males; 
while in rural Cameroon, Mali, Mauritania, SA (Durban) and Sudan, T2DM was more common in 
females (Tuei et al., 2010). 
1.3.1.1 T2DM in South Africa 
In the year 2000, nearly 1.5 million people were estimated to be diabetic in SA and T2DM accounted 
for 2.6% of the total deaths in that year, making it the tenth leading cause of death in SA (Bradshaw 
et al., 2007). There has been a steady increase in the prevalence of T2DM and IGT in SA (Table 
1.5). From 1990 to 1993 the prevalence of T2DM in SA increased by 2-3%, and continued to rise 
(Mayosi et al., 2009; Walker et al., 1997; Levitt et al., 1993) (Table 1.5). Between 1999 and 2006, 
T2DM prevalence increased by 38% in SA (Mayosi et al., 2009) and remains the second leading 
cause of death in the SA adult population (WHO, 2016; Mayosi et al., 2009) . 5In SA, Black 
individuals have the lowest prevalence of T2DM (Rheeder, 2006; Molleutze & Levitt, 2005) (Table 
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1.5). In 2003, the prevalence of T2DM in SA Xhosa- and Zulu-speaking individuals was reported at 
8% and 5.3%, respectively (Motala et al., 2003), and by 2006, the prevalence of T2DM in SA Blacks, 
as a whole, was reported at 6%, compard to Indians (13%), Coloureds (10.8%) and Caucasians 
(8.5%) (Molleutze & Levitt, 2005; Rheeder, 2006). However, with difficulty managing disease 
observed in Black SA T2DM patients (Gill et al., 2009; Westaway et al., 2005), this population is at 
increased risk of death due to T2DM (Gill et al., 2009). 
The high prevalence of IGT is indicative of a population at risk for the development of T2DM as 
nearly 70.0% of all individuals with IGT may progress to T2DM (Christensen et al., 2009; Motala, 
2002). A study in Cape Town found that IGT prevalence was 7.0% in 1969 and had increased to 
12.2% in 1993 (Table 1.5) (Motala, 2002), compared to the overall prevalence of IGT reported for 
SA in the same year (7%) (Levitt et al., 1993). However, it has been noted that in areas of high IGT 
prevalence there is usually a low prevalence of T2DM and vice versa (Motala et al., 2003). 
Impaired glucose tolerance has also been associated with having an overweight or obese body 
mass index (BMI) and an obese WC (Christensen et al., 2009). 
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Table 1.5 The epidemiology and rising trends of T2DM in South Africa. 
Prevalence Area/Town/Province Year Comments Reference 
T2DM 
0.6 – 3.6 SA 
1960 
- 
1980 
 McLarty et al., 1990 
2.9 Mamelodi, Pretoria 1973 
 
Levitt et al., 1993 
3.6 Gugulethu, Cape Town 
 
4.8 – 8 SA >1984  Motala et al., 2003 
2.2 – 3.6 SA <1985  Christensen et al., 2009; Levitt, 2008 
4.8 – 6 SA 1990 Population based survey Mayosi et al., 2009 
5.3 SA 1990s Blacks Walker et al., 1997 
8 SA 1993  
Christensen et al., 
2009; Levitt et al., 
1993 
4.2 Durban 1993 More females (5,2%) than males (2,3%) Omar et al., 1993 
4.8 QwaQwa 
1995 
 
Mollentze et al., 1995 
6 Mangaung  
2.45 Transkei 2001 Factory workers Erasmus et al., 2001a 
4.8 / 6 Orange Free State 
2003 
Semi-urban/Urban 
Motala et al., 2003 5.3 Durban Zulu 
8 Cape Town Xhosa 
13 
SA 
2005 
- 
2006 
Indians 
Molleutze & Levitt, 
2005; Rheeder, 2006 
10.8 Coloureds 
8.5 Caucasians 
6 Blacks 
4.5 SA 2008 Individuals >15 years WHO, 2008 
3.9 Ubombo 2008  Motala et al., 2008 
26 Bellville South, Cape Town 2012 
Coloureds; 28,7% in 
individuals <60 years Erasmus et al., 2012a 
IGT 
7 SA 1993  Levitt et al., 1993 
12.2 Cape Town 1969 -1993 
Increase from 7,0 in 
1963 Motala et al., 2012 
6.9 Durban 1993 More males (11,5%) than females (5,5%) Omar et al., 1993 
2.7 Transkei 2001 Factory workers Erasmus et al., 2001a 
4.8 KwaZulu Natal 2008 Similar between males and females Motala et al., 2008 
15.3 Bellville South, Cape Town 2012 Coloureds Erasmus et al., 2012b 
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1.3.1.2 T2DM in sub-Saharan Africa  
The earliest study to determine the prevalence of T2DM in SSA countries was conducted in Ghana 
in 1958 (Christensen et al., 2009) and approximately 20 years later, in 1980, the prevalence of 
T2DM was still below 1% (Table 1.6) (McLarty et al., 1990). By 1985 the prevalence of T2DM for 
most countries in SSA was still below 1%, with the exception of Côte D’Ivoire, Egypt and Northern 
Sudan (Table 1.6) and a clear rural-urban difference was starting to emerge. From the 1990s the 
prevalence of T2DM started increasing rapidly and will continue to do so, as suggested by the 
studies presented in Table 1.6. In 2011, the overall prevalence of T2DM in SSA was reported to 
range from 0-16% (Dalal et al., 2011). The estimated prevalence of T2DM in African populations 
increased from 3 million individuals in 1994 to 7.1 million individuals in 2000 (Tuei et al., 2010). 
Particular African countries have also reported high numbers of T2DM patients (SA, 6.5 million; 
Nigeria, 3.9 million; Ethiopia, 1.9 million and Tanzania, 1.7 million) (IDF, 2013). The prevalence of 
IGT is also increasing with an overall estimate of 9.1% for Africa in 2013 (Table 1.6) (IDF, 2013).  
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Table 1.6 The epidemiology and rising trends of T2DM in sub-Saharan Africa. 
Prevalence Country Year Comments Reference 
T2DM 
0.4 Ghana 1958 Urban Christensen et al., 2009 
<1 SSA 1960 – 
1980 
 
McLarty et al., 1990 
5.7 Côte D'Ivoire  
0.5 / 2.5 
Tanzania 1984 
Rural, Sukuma/Haya tribe 
Ahren et al., 1984 1.9 Urban, Mwanza Town 
<1 
SSA <1985 
Rural (Ethiopia, Ghana, 
Lesotho, Malawi, Uganda) Ahren et al., 1984; Levitt, 
2008 
0.6 – 1.2 Urban Africa 
5.7 Ivory Coast <1985  Levitt, 2008 
0 Togo 
>1984 
 
Motala et al., 2003 9.3 Egypt  
10.4 Northern Sudan  
0.3 Gambia 1990s  Christensen et al., 2009 
2 Nigeria 1990s  Cooper et al.,1997 
3.4 – 8.3 Northern Sudan 1990s  Elgabir et al., 1996 & 1998 
6.8 
Tanzania 1996 
Males, Increase from 3,3 
in 1980 
Motala, 2002 
4.8 Females, Increase from 0,9 in 1980 
6.3 Ghana 2002  Amoah et al., 2002 
6.1 Guinea 2008  Balde et al., 1997 
4 
West Africa 2008 
Urban 
Abubakari et al., 2008 
2.6 Rural 
4.2 Kenya 2009  Christensen et al., 2009 
10 Tunisia 2009  Baroudi et al., 2009 
14.3 Africa 2012  Crowther & Norris, 2012 
3.6 / 5.5 
Ghana 2016 
Rural males/females 
Agyemang et al., 2016 
10.3 / 9.2 Urban males/females 
0 – 16 SSA <2011 Meta-analysis Dalal et al., 2011 
15.4 Reunion Island 
2013 
 
IDF, 2013 
12.1 Seychelles  
10.7 Gabon  
9.7 Zimbabwe  
IGT 
2.9 – 7.9 Northern Sudan 1990s  Elgabir et al., 1996 & 1998 
1.8 Cameroon 
2003 
Urban 
Motala et al., 2003 
13.1 Egypt Rural 
13.4 Ghana 2008  Balde et al., 1997 
12 Kenya 2009  Christensen et al., 2009 
9.1 Africa 2013  IDF, 2013 
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1.3.2 Genetics of type 2 diabetes mellitus 
Although the aetiology of T2DM comprises a genetic component, genetic studies have thus far only 
explained ~15% of the heritability of T2DM (Groop & Pociot, 2014). The disease is believed to arise 
from the inheritance of a variety of susceptibility genes that exert a partial effect on T2DM 
development, and only when combined with specific risk factors is the disease expressed (Ouedemi 
et al., 2009; Freeman & Cox, 2006). Genes that confer risk of T2DM are called “diabetogenes” and 
have been found to encode proteins responsible for glucose metabolism, insulin activity and/or signal 
transduction for insulin action (Ouedemi et al., 2009). 
The risk of developing T2DM is greater on the offspring if the mother has T2DM (Groop & Pociot, 
2014), suggesting that DNA methylation and imprinting contribute to unique risk allele parent-of-
origin transmission (Kong et al., 2009). Offspring with either parent affected by T2DM have a 40% 
risk of disease development, whereas having two T2DM affected parents pushes the lifetime risk up 
to 70% (Ahlqvist et al., 2011; Poulson et al., 1999). Offspring of diabetic parents are also more likely 
to suffer from β-cell dysfunction and glucose intolerance (Sobngwi et al., 2002; Mbanya et al., 2000). 
In a study of Black SA T2DM individuals, family history, and specifically maternal T2DM, was found 
to play an important role in the heritability of T2DM, with 27.3% reporting a family history (Erasmus 
et al., 2001b). Of the 27.3% that reported a positive family history, 82.6% had one affected family 
member and 17.4% had two or more affected family members, 87.8% of which was a first-degree 
family member. Maternal diabetes was reported for 64.7% of the affected individuals, while paternal 
diabetes was reported for only 27% of the affected individuals (Erasmus et al., 2001b). Both maternal 
and paternal T2DM was reported for 6.6% of the affected individuals (Erasmus et al., 2001b). 
Rare monogenic forms of diabetes observed in families has made it evident that there is a genetic 
component to T2DM (Gottlied, 1980). Genetic predisposition to T2DM and abnormal glucose 
tolerance has been shown in twin studies, with heritability ranging from 26-77% (Poulsen et al., 1999; 
Carlsson et al., 2013) and 30-61%, respectively (Poulsen et al., 1999). This notion is strengthened 
by discordant rates of T2DM between mono- and dizygotic twins (Newman et al., 1987). Monozygotic 
twins have a higher concordance than dizygotic twins for both T2DM and abnormal glucose (50% 
vs. 37% and 43% vs. 37%, respectively) (Poulsen et al., 1999). It has also been shown that 18% of 
the genetic predisposition to T2DM is shared with the genetic predisposition to BMI (Carlsson et al., 
2013). The high prevalence of T2DM in certain ethnic groups and admixture modifications (Stern & 
O’Connel, 1999; Knowler et al., 1990; Zimmet et al., 1983) of individuals in the same areas allows 
us to investigate gene-environment interactions that may influence susceptibility to T2DM (Zimmet 
et al., 1983). Susceptibility loci identified in recently admixed populations give an indication of genes 
that may be present in the ancestry population.    
A meta-analysis of 13 Tunisian studies (4608 controls and 5080 cases) found that SNPs in the genes 
transcription factor 7-like 2 (TCF7L2), tumour necrosis factor α (TNFα) and ACE amongst others 
were associated with T2DM in Tunisians with OR ranging from 1.43 – 6.72 (Berhouma et al., 2012). 
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A meta-analysis of 60 African studies (14 302 controls and 20 464 cases) found associations 
between ACE, melanocortin 4 receptor (MC4R), TCF7L2 and TNFα amongst others and T2DM 
(Yako et al., 2016). A summary of all the genes discussed below that have been found to be involved 
in T2DM in Africa are presented in Table 1.7. 
1.3.2.1 Transcription factor 7-like 2 (TCF7L2) 
The transcription factor 7-like 2 (TCF7L2) gene is located on chromosome 10 (10q25.3) and consists 
of 19 exons that span across a 200kb-long DNA region. The protein encoded by TCF7L2 is a 
member of the T-cell specific family and encodes a high-mobility group box-containing transcription 
factor which is an effector in the Wnt signalling pathway. The Wnt signalling pathway has been 
shown to downregulate adipogenesis in adipocytes via TCF7L2 (Nguimmo-Metsadjio et al., 2017).  
The rs7903146 SNP of TCF7L2 is the most consistently replicated locus associated with T2DM in 
SSA populations (Table 1.7) (Adeyemo et al., 2015; Turki et al., 2013a; Berhouma et al., 2012), as 
well as in AfAms, Hispanics, Asians, American Indians (Florez et al., 2006), Danes and Icelandics 
(Helgason et al., 2007). 777The T allele of the rs7903146 SNP has consistently been described as 
the risk allele for T2DM in the Sudanese (Ibrahim et al., 2016) and Ghanaian (Danquah et al., 2013) 
populations, with individuals harbouring at least one T allele being at a 39% increased risk of 
developing T2DM (Table 1.7) (Danquah et al., 2013). These fidnings were supported by a meta-
analysis of 60 African studies (14 302 controls and 20 464 cases), which found that cases harbouring 
the TT genotype of the rs7903146 SNP in TCF7L2 had 40-45% greater odds of developing T2DM 
than those that were C homozygotes (Yako et al., 2016). A Tunisian study, comprising 884 cases 
and 513 controls, found that the T allele of rs7903146 increased T2DM susceptibility (OR=1.25, 
95%CI=1.06-1.47, p=0.006), with TT carriers having a 56% risk of T2DM susceptibility compared to 
CC carriers (Table 1.7) (Ezzidi et al., 2009). However, individual studies have reported contradictory 
findings. For example, in the Cameroonian population, the C allele (OR=16.56), and particularly the 
CT genotype, has been associated with increased risk of T2DM, while the TT genotype has been 
found to be protective against T2DM (OR=0.054) (Table 1.7) (Guewo-Fokeng et al., 2015; Ngwa et 
al., 2015). As observed in Cameroonians (Guewo-Fokeng et al., 2015; Ngwa et al., 2015), the C 
allele and CT genotype was also associated with T2DM in a SA Zulu population (Table 1.7) (Pirie et 
al., 2010), suggesting that the C allele is heterozygous dominant and is associated with disease in 
this population.   
In the SA Coloured population, the rs7903146 T allele (p=0.011) was more frequent in T2DM patients 
and the CT or TT genotypes (p=0.025) were significantly associated with T2DM (Yako et al., 2015a). 
Under an additive model, the rs7903146 SNP was nominally associated with an increased risk of 
T2DM (OR=1.43, 95%CI=1.00-2.04, p=0.053) (Table 1.7) (Yako et al., 2015a). A study in Lebanese 
and Tunisian Arabs found that TCF7L2 rs7903146 TT genotype was significantly associated with 
T2DM in both populations (OR 1.38, 95% CI 1.2-1.59, p<0001 and OR 1.36, 95%CI 1.18-1.86, 
p<0.001, respectively) 7 (Mtiraoui et al., 2012a). However, in another study of 331 Tunisian cases 
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and 403 Tunisian controls, rs7903146 was found to have no significant differences between the two 
groups (Kifagi et al., 2011). In Tunisians the TT genotype was associated with T2DM, but not obesity, 
which modulated the effect of this genotype (TT) on T2DM risk 7 (Bouhaha et al., 2010a). Thus, TT 
was only associated with T2DM in nonobese individuals. Under a dominant (OR=1.68, 95%CI=1.39-
2.03, p=9.57x10-8), recessive (OR=1.65, 95%CI=1.31-2.08, p=1.98x10-5) and log-additive (OR=1.47, 
95%CI=1.29-1.66, p=4.06x10-9) model, rs7903146 was significantly associated with T2DM in 
Moroccans (1 193 cases and 1 055 controls) (Table 1.7) (Cauchi et al., 2012). It was also associated 
with T2DM in Tunisians (1 446 cases and 943 controls) under a dominant (OR=1.32, 95%CI=1.06-
1.63, p=0.01) and log-additive (OR=1.39, 95%CI=1.04-1.37, p=0.01) model (Table 1.7) (Cauchi et 
al., 2012). The rs7903146 SNP is located in intron 4 of the TCF7L2 gene and although the 
functionality is still unclear, it is believed to affect insulin secretion (Danquah et al., 2016). 
Another study in Tunisian Arabs (900 cases and 875 controls) found several SNPs in intron 4 of the 
TCF7L2 gene, with unclear functional roles, to be associated with T2DM. The minor allele 
frequencies (MAF) of these SNPs were significantly higher in cases than in controls. These SNPs 
included rs4506565 (p=2.4x10-8), rs7903146 (p=1.2x10-6), rs12243326 (p=8.4x10-8) and rs12255372 
(p=1.1x10-5) 7 (Turki et al., 2013a). In a study of 566 SA Coloured individuals, neither rs7903146 or 
rs12255372 were associated with T2DM (Table 1.7) (Madubedube, 2015). The association of the 
TCF7L2 rs12255372 TT genotype with T2DM in Arab Africans replicated a case-control study in the 
SA Zulu population (178 cases and 200 controls) (OR 1.84, 95%CI 1.19-2.83, p=0.0035) (Pirie et 
al., 2010) and a replication study (621 cases and 448 controls) and meta-analysis in West African 
populations (Tong et al., 2009; Helgason et al., 2007). The association of rs12255372 was later 
replicated in two case-controls studies (60 cases and 60 controls each) in a Cameroonian population 
(OR 3.92, 95%CI 2.04-7.67, p<0.0001) (Nanfa et al., 2015; Ngwa et al., 2015) (Table 1.7). A study 
of 240 cases and 128 controls in Sudan found that the rs7903146 TT genotype (OR 1.69, 95%CI 
1.21-2.38, p=0.002) and rs12255372 TT genotype (OR 1.72, 95% CI 1.2-2.41, p=0.003) of TCF7L2 
were associated with T2DM (Ibrahim et al., 2016).  
1.3.2.2 Tumour necrosis factor-alpha (TNFα) 
The TNFα gene, a 3 kilobase gene located on chromosome 6 (6p21.33) and consisting of 4 exons, 
is a member of the tumour necrosis family type II transmembrane protein TNFα is a proinflammatory 
cytokine that is involved in the acute phase reaction in systemic inflammation (Berhouma et al., 
2012).  
The rs1800629 SNP in the TNFα gene is a functional G to A substitution at position 308 upstream 
from the transcription initiation site in the promoter (Bouhaha et al., 2010b). The AG or AA genotype 
of rs1800629 leads to the overexpression of TNFα, which plays a role in the transition of IR to T2DM 
and has also been reported in obese subjects (Bouhaha et al., 2010b). Increased levels of TNFα 
directly correlates with obesity grade by contributing to IR and thus potentially playing a role in T2DM 
etiology (Bouhaha et al., 2010b). Two separate meta-analyses of Tunisian studies, which included 
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20 464 and 5 080 cases, and 14 302 and 5 608 controls, respectively, associated SNP rs1800630 
in the TNFα gene with T2DM (Table 1.7) (Yako et al., 2016; Berhouma et al., 2012). However, this 
association was not seen in an earlier study in Tunisians 7 (Bouhaha et al., 2010b).  
The rs1800630 is a C to A substitution at position 386 in the promoter region of TNFα (Kallel et al., 
2013). The CA and AA genotypes were more frequent in the cases (35.5%) than controls (22.3%) 
(OR=1.91, 95%CI=1.31-2.80, p=0.001) 7 (Kallel et al., 2013), however no association analysis 
results have been reported. 
1.3.2.3 Angiotensin-converting enzyme (ACE) 
As discussed in section 1.2.2.3, the angiotensin-converting enzyme (ACE) is a metallopeptidase 
protein responsible for cleaving angiotensin I (Ang I) to angiotensin II (Ang II).  
In a meta-analysis of 13 Tunisian studies (5 080 cases and 4 608 controls), the deletion (D) of a 
287bp Alu repeat was associated with T2DM (Berhouma et al., 2012), in support of findings reported 
by other studies. In a study of 272 (172 cases and 100 controls) Arabs and Berbers from Tunisia, 
the DD genotype was associated with T2DM susceptibility (Baroudi et al., 2009). This finding was 
replicated in two other subsets of the same population, consisting of 115 cases and 116 controls 
(Mehri et al., 2010a), and 114 cases and 175 controls (Mehri et al., 2010b): D allele: OR=3.08, 
95%CI=2.09-4.51, p<0.0001 and OR=3.10, 95%CI=2.1-4.4, p<0.001, respectively; DD genotype: 
OR=4.93, 95%CI=2.71-8.97, p<0.0001 and OR=7.2, 95%CI==3.5-14.8, p<0.001, respectively 7, and 
is thought to act synergistically with the MTHFR C677T SNP (Mehri et al., 2010a). The ACE DD 
genotype, in conjunction with hypertension, was found to be the most significant T2DM contributor 
(Mehri et al., 2010b).  
However, in a study of 203 Egyptian cases and 311 Egyptian controls, the I allele was more frequent 
in cases than in controls (68.8% vs 52.5%) and the ID and II genotypes were significantly associated 
with increased T2DM susceptibility (OR=2.0, p=0.0007) 7 (Settin et al., 2015).  
1.3.2.4 Fat-mass and obesity associated (FTO) gene  
The FTO gene, a 457kb gene located on chromosome 16 (16q12.2) and consisting of 9 exons, is a 
member of the alphaketoglutarate-dependent hydrolase superfamily, is involved in DNA 
demethylation (Yang et al., 2017).  
The rs9939609 SNP results in a functional T to A substitution, controlling food intake and preference, 
in intron 1 of the FTO gene (Leoŕiska-Duniec et al., 2018). Individuals without this SNP manage to 
limit their food intake while those with this SNP have a greater appetite (Leoŕiska-Duniec et al., 
2018). In a study of participants of Zulu ethnicity (178 cases and 200 ethnically matched controls), 
the TT genotype of SNP rs9939609 had no association with T2DM (Table 1.7) (Pirie et al., 2010). 
The rs17817499 SNP was not associated with T2DM in North Africans, even after adjustment for 
BMI in a meta-analysis (Table 1.7) (Yang et al., 2017).  
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However, in SA Coloured individuals, under a log additive model, the minor allele (T) of the 
rs9941349 SNP of the FTO gene was associated with T2DM (OR=1.40, 95%CI=1.00-1.47, p=0.049) 
(Table 1.7) (Madubedube, 2015). Similar values were observed in the same population by Yako et 
al. (2015a) (Table 1.7). 
A study conducted in Moroccans (1 193 cases and 1 055 controls) found that the rs1421085 SNP of 
the FTO gene is significantly associated with T2DM in Moroccans under a dominant (OR=1.34, 
95%CI=1.03-1.49, p=0.02) and log-additive (OR=1.18, 95%CI=1.04-1.35, p=0.01) model (Table 
1.7), while under a recessive model it was only nominally associated with T2DM (p=0.07) (Cauchi et 
al., 2012). 
1.3.2.5 Melanocortin 4 receptor (MC4R) 
The MC4R gene, a 2 kilobase gene located on chromosome 18 (18q21.32) and consisting of 1 exon, 
is G-protein coupled receptor of the melanocortin receptor family, that regulates energy homeostasis 
and food intake (Logan et al., 2016). 
The rs17782313 SNP, a C to T substitution near MC4R with unknown function, was significantly 
associated with T2DM in Moroccans (1 193 cases and 1 055 controls) under a log-additive model 
(OR=1.18, 95%CI=1.00-1.39, p=0.05) (Table 1.7), while under a dominant and recessive model it 
was only nominally associated (p=0.10 and p=0.09, respectively) (Cauchi et al., 2012). In Tunisians 
(1 446 cases and 943 controls), the C genotype of this SNP was only nominally associated with 
T2DM under a dominant model (p=0.08) (Cauchi et al., 2012).  
A study 900 Tunisian cases and 748 Tunisian controls found that the T allele of the rs1942872 SNP 
3’ of MC4R was more frequent in cases than in controls and that it was  significantly associated with 
T2DM 7 (Turki et al., 2013b). 
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 Table 1.7 A summary of genes found to be associated with T2DM in Africa.
 
Cases Controls
Africans 20 464 14 302 TT genotype 40-45% higher odds of developing T2DM Yako et al., 2016
Sudanese 240 128 Associated (OR 1.69, 95% CI 1.21-2.38, p=0.002) Ibrahim et al., 2016
Tunisians 900 883 Associated Turki et al., 2014
Tunisians Associated Berhouma et al., 2012
Moroccans 1 193 1 055
Signicantly associated under a 
dominant, recessive and log-
additive model
Tunisians 1 446 943
Significantly associated under 
a dominant and log-additive 
model
Africans 1 035 740 Most significantly associated locus Adeyemo et al., 2015
SA Coloureds No association with T2DM or IR Madubedube, 2015
SA Coloureds
T allele more prevalent in 
cases than controls (32.2% vs 
24.2%). Nominal under 
additive model: OR 1.43, 95% 
CI 1.00 - 2.04, p=0.053
Yako et al., 2015b
SA Zulu 178 200 CT risk genotype Pirie et al., 2010
Cameroonians 37 / 60 37 / 60
C risk allele (OR 16.56), CT risk 
genotype (OR18.56), T allele 
protective
Guewo-Fokeng et al., 
2015; Ngwa et al., 
2015
rs12243326 C Tunisians 900 883 Gender-independent association Turki et al., 2014
Sudanese 240 128 Associated (OR 1.7, 95% CI 1.2-2.41, p=0.003) Ibrahim et al., 2016
West Africans 621 448 TT genotype associated Tong et al., 2009
Cameroonians 60 / 60 60 / 60 Associated (OR 3.92, 95% CI 2.04 - 7.67)
Nanfa et al., 2015; 
Ngwa et al., 2015
SA Zulu 178 200 Associated (OR 1.84, 95% CI 1.19 - 2.83, p=0.0035) Pirie et al., 2010
Tunisians 900 883 Gender-independent association Turki et al., 2014
SA Coloureds No association with T2DM or IR Madubedube, 2015
Tunisians Associated Yako et al., 2016
Tunisians Associated Berhouma et al., 2012
Angiotensin-converting 
enzyme (ACE ) Cleaves AngI to AngII 7q23.3 63477061 - 63498380 rs4646994 D Tunisians Associated Berhouma et al., 2012
Meta-analysis
Meta-analysis
Meta-analysis
rs12255372 T 
31575567 - 315783366p21.3Proinflammatory cytokineTumor necrosis fator alpha (TNFa ) Ars1800629
T
Meta-analysis
Cauchi et al., 2012
566
566
566
Gene name No. samples Results Reference
Transcrption factor 7-like 
2 (TCF7L2 ) 112950220 - 11316767810q25.3
Encodes effector for Wnt 
signalling pathway
rs7903146
C
Population 
studied
Risk 
alleleSNP
Chr coordinates (GRcH 38) 
(From - To)Chr. LocationGene function
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Unless specified, ethnicity of SA Blacks was not stated in the article. 
ACE – Angiotensin converting enzyme; AngI – Angiotensin I; AngII – Angiotensin II; Chr - Chromosome; FTO – Fat-mass and obesity associated; I/D – Insertion/deletion; OR – Odds 
ratio; SA – South Africa; SNP – Single nucleotide polymorphism; T2DM – Type 2 diabetes mellitus; TCF7L2 -Transcription factor 7-like 2; TNFα – Tumour necrosis factor alpha; 95% 
CI – 95% Confidence interval 
rs9939609 T SA Zulu 178 200 No significant association Pirie et al., 2010
rs17817499 A North Africans No association, even after adjustment for BMI Yang et al., 2017
SA Coloureds
Associated under a log-
additive model (OR 1.4, 95% CI 
1 - 1.96, p=0.049)
Madubedube, 2015
SA Coloureds
Nominal under log-additive 
model (OR 1.43, 95% CI 1 - 
1.96, p=0.052)
Yako et al., 2015b
rs1421085 C Moroccans 1 193 1 055
Significantly associated under 
dominant and log-additive 
models
Cauchi et al., 2012
Melanocortin 4 receptor 
(MC4R )
Energy homeostasis and 
food intake 18q21.32 60371110 - 60372775 rs17782313 C Moroccans 1 193 1 055
Significantly associated under 
a log-additive model; nominal 
under dominant and recessive 
models
Cauchi et al., 2012
Fat-mass and obesity 
associated (FTO )
rs9941349
Meta-analysis
T
566
566
53701692 - 5415851218q21.32Energy homeostasis and food intake
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1.3.3 Concluding remarks – T2DM 
Type 2 diabetes mellitus is the most common form of diabetes worldwide and can be in part due to 
obesity, a major contributor, and the accompanying IR and inflammation. Type 2 diabetes mellitus 
is often preceded by and/or accompanied by obesity, hypertension and dyslipidaemia. In SSA, 
TCF7L2 is the most consistently replicated gene associated with T2DM, more specifically the 
rs7903146 SNP. Based on studies reviewed here, TCF7L2 is a promising target for genetic studies 
in our populations. TCF7L2 is possibly the gene with the biggest effect on T2DM risk and other 
variants in other genes may have a very small influence on T2DM risk. Although FTO was not 
associated with T2DM in SA Zulus, association has been seen in SA Coloured individuals and it may 
be important in SA Xhosas. FTO has also been associated with obesity, the most modifiable risk 
factor of T2DM.  
1.4 Obesity 
Obesity is a chronic state of inflammation that results from a continuing imbalance between energy 
intake and expenditure (Mato et al., 2016; Ngwa et al., 2015; Joffe et al., 2010), characterised by 
increased body fat stores (Tuei et al., 2010). This energy imbalance affects feeding behaviours and 
time spent active (Mato et al., 2016; Ngwa et al., 2015), and often precedes other risk factors for 
CVD (Deedwania & Gupta, 2006; Despres & Lemieux, 2006). Other factors associated with obesity 
include aging, economic transition, genetics, globalization, industrialization, physical inactivity and 
urbanization (Adeyemo et al., 2015), as well as educational attainment, female gender  and tobacco 
use (Adeniyi et al., 2015). Currently, there are three measures of obesity used to assess health risk, 
namely BMI, WC and waist-to-hip ratio (Matsha et al., 2013). The gold standard of obesity 
measurement is BMI, where weight (in kg) is divided by the square root of the height (Adab et al., 
2018). However, BMI measurement has a low sensitivity, is unable to differentiate between lean and 
fat mass, provides no details of fat distribution or no clear insight into the correlation between total 
body fat and obesiy risk (Adab et al., 2018). Determining body fat distribution is essential as the 
distribution of fat around the abdomen/central body region is a major predictor of disease risk (Adab 
et al., 2018). Both WC and waist-to-hip ratios are measures of central obesity and are better at 
predicting cardiometabolic disease, mortality and visceral adiposity than BMI (Adab et al., 2018; 
Matsha et al., 2013); however, population-specific cut-points are lacking and generalized cut-points 
are not good predictors in African populations (Matsha et al., 2013; Crowther & Norris, 2012).    
Abdominal/visceral obesity is the distribution of fat around the central (stomach) region, while 
peripheral obesity is the distribution of fat in the lower body (Keswell et al., 2016). Visceral/abdominal 
obesity, measured by waist circumference, rather than generalised obesity which is measured by 
body mass index (BMI), is a risk factor for CVD and T2DM (Alberti et al., 2009; Yusuf et al., 2005; 
Ohlson et al., 1985). The distribution of body fat, rather than percent body fat, is also a risk factor for 
CVD and T2DM (Borné et al., 2014; Luo et al., 2013; Jennings et al., 2009; Meissinger et al., 2006), 
as the distribution of body fat is also a greater predictor of dyslipidaemia and IR than percent body 
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fat (Keswell et al., 2016). Abdominal obesity is more common in males and is associated with a 
higher risk of IHD, while peripheral obesity is more common in females and carries a lower risk of 
CVD (Sengwayo et al., 2013).  
Increase in body fat promotes the expression and secretion of inflammatory cytokines such as TNFα. 
Increased levels of TNFα during inflammation promote proinflammatory cytokine secretion 
(Gallagher et al., 2010; Wang & Trayhurn, 2006) and adipocyte apoptosis, which modifies adipose 
tissue mass in an effort to limit the development or extent of obesity (Joffe et al., 2010; Prins et al., 
1997). Tumour necrosis factor-α has also been found to promote IR (Hotamisligil et al., 1996), by 
inhibiting the insulin receptor substrate I pathway (Boura-Halfon & Zick, 2009; Stephens et al., 1997; 
Hotamisligil et al., 1996; Hotamisligil et al., 1994). Insulin resistance is important in the 
pathophysiology and control of T2DM and is associated with obesity, a risk factor for T2DM (Joffe et 
al., 2010; Ntyintyane et al., 2006). Insulin resistance and vascular resistance during obesity are 
mediated by dysfunctional endothelial and microvascular systems, present early on in obese 
subjects (Gallagher et al., 2010; Villela et al., 2009; Faloia et al., 2000). Reduced insulin sensitivity 
and higher levels of blood insulin concentrations, associated with increased weight, have been 
associated with obesity (Makuyana et al., 2004). Raised serum triacylglycerol and decreased levels 
of HDL-C have also been associated with increased levels of TNFα (Joffe et al., 2010). 
1.4.1 Epidemiology of obesity in Africa 
1.4.1.1 Obesity in South Africa 
In SA it has been found that obesity is extremely common in females (Keswell et al., 2016). Black 
females have been found to be more obese than their Caucasian counterparts, with more peripheral 
fat seen in Black females compared to central fat in Caucasian females (Keswell et al., 2016). Over 
a period of 15 years, from 1998 to 2013, the prevalence of overweight and obesity in SA males 
increased by 1.5% (from 29.0% in 1998 to 30.7% in 2013) and by 8% in SA females (from 56.0% in 
1998 to 64% in 2013) (Table 1.8) (Puoane et al., 2002; Shisana et al., 2013). However, no clear 
gender pattern is observed. In the Black, Coloured and Indian populations of SA, females were found 
to be more obese than males, while in the Caucasian population of SA, males have been found to 
be more obese than females (Table 1.8) (Shisana et al., 2013; Sengwayo et al., 2013). In the Heart 
of Soweto Study, obesity was found to be the most prevalent CVD risk factor, with more females 
than males affected (Adeniyi et al., 2015; Tibazarwa et al., 2009; Voster, 2002). In 2008, physical 
inactivity, a known factor in obesity onset and diagnosis, was reported in 46-56% of the SA 
population (NDoH, 2013), with overweight and obesity, partly as a result of physical inactivity, at 
58.5% and 71.8%, respectively (NDoH, 2013; Bradshaw et al., 2007). The 2008 WHO estimate of 
obesity was much lower than that of the NDoH (31.3% by WHO compared to 71.8% by the NDoH) 
(Table 1.8) (NDoH, 2013; WHO, 2008). 
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The prevalence of T2DM and hypertension in Black obese SA females has been found to be higher 
than in their Caucasian counterparts (7% vs 3.6% and 30% vs 15%, respectively), who are prone to 
CHD and hypercholesterolaemia (Schutte et al., 2008; Seedat, 1983). However, studies have 
suggested that within the obese population of SA, up to 40% may not be at a greater risk of 
developing CVD and T2DM, as they are metabolically normal (Stefan et al., 2008; Brochu et al., 
2001). 
Table 1.8 The epidemiology and rising trends of obesity in South Africa.  
Prevalence 
Area/Town 
/Province 
Year Comments Reference 
22.2 Transkei 2001 Factory workers 
Erasmus et al., 
2001b 
42.5 SA 2005 Blacks 
Isezou & Ezunu, 
2005 
58.5 
SA 2008 
Overweight NDoH, 2013; 
Bradshaw et al., 
2007 
71.8 Obese 
31.3 SA 2008 Overall WHO, 2008 
42 SA 2013 
Highest prevalence in SSA 
females 
Ajayi et al., 2016 
43 Soweto 2013 
More prevalent in Black females 
(55.0%) than males (23.0%) 
Adeniyi et al., 2015; 
Tibazarwa et al., 
2009; Vorster, 2002 
40 – 70 Soweto 2013 Obese BMI Logan et al., 2016 
30.7 
SA 2013 
Overweight/obese males, 
Increase from 29,0% in 1998 Puaone et al., 2012; 
Shisana et al., 2013 
64 
Overweight/obese females; 
Increase from 56,0 in 1998 
9.4 / 15.1 / 
7.6 / 26.5 
SA 2013 
Males; 
Black/Coloured/Indian/Caucasian 
Shisana et al., 2013 
39.9 / 34.9 / 
32.4 / 22.7 
Females; 
Black/Coloured/Indian/Caucasian 
25.9 – 54.3 
SA 2013 
Females Sengwayo et al., 
2013 3 – 20.4 Males 
60.2 Mthatha 2015  Adeniyi et al., 2015 
85 / 54 SA 2016 Overweight + Obese/Obese only Ajayi et al., 2016 
27 SA 2017 Overall Keates et al., 2017 
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1.4.1.2 Obesity in sub-Saharan Africa 
A meta-analysis of NCDs in SSA reported an overall prevalence of obesity ranging from 0.4-43% 
between all countries (Dalal et al., 2005) and in 2014, WHO estimated that in most African countries, 
less than 15.0% of the adult population is obese (Table 1.9) (Keates et al., 2017). As shown in Table 
1.9, obesity is rising in SSA and there is a clear rural-urban difference in the prevalence of obesity. 
Contrary to what is seen in other countries, in SSA countries, obesity is more prevalent in females 
(10-15%) than in males (4-5%) (Keates et al., 2017). In 1995, in 18 SSA countries, 1-7.1% of females 
were found to have an obese BMI, but this figure was greatly inflated in SA females (31%) (table 
1.9) (Levitt, 2008).  Overall for Africa, obesity prevalence was highest in females, ranging from 10.8% 
in Ethiopia to 34.7% in Ghana, compared to males (2.0% in Ethiopia, 12.2% in the Democratic 
Republic of Congo and 13.8% in Cameroon) (Table 18) (Peer et al., 2014a).  In 2013, females in SA 
had the highest prevalence of obesity (42.0%) while their counterparts in Ethiopia had the lowest 
(1.8%) (Table 1.9) (Ajayi et al., 2016). In males the highest prevalence was reported in Equatorial 
Guinea (25.0%) and the lowest in Uganda (1.8%) (Table 1.9) (Ajayi et al., 2016).  
Interestingly, the prevalence of obesity in Cameroon follows that seen in non-African countries. From 
1994 to 2003 the prevalence of an overweight BMI in rural Cameroon increased by 54% in females 
and 82% in males and that of abdominal obesity in urban Cameroon increased by 32% in females 
and 190.0% in males (Table 1.9) (Fezeu et al., 2008). By 2010, the prevalence of abdominal obesity 
in Cameroon was 67% in females and 18.0% in males (Table 1.9) (Tuei et al., 2010). Although the 
observed increase of obesity is greater in males, the overall prevalence of obesity in males remains 
lower than that observed in females. This could possibly be explained by the fact that  males 
generally do more physical work, but with the adoption of westernised diets and lifestyles, males are 
more at risk to gain weight than females, which have generally been more overweight than males 
due to traditional views of a bigger woman being healthy and more fertile.  
In 2012 the prevalence of obesity in Africa was 50.1% (Table 1.9) (Crowther & Norris, 2012). In 
Nigeria, SA, Tanzania, rural Uganda and urban Uganda the prevalence of overweight and obesity 
combined was 68%, 85%, 75%, 46% and 48%, while the prevalence of obesity alone was 31%, 54%, 
40%, 10% and 14%, respectively (Table 1.9) (Ajayi et al., 2016).  
In Africa it is estimated that 20-50% of the urban population is overweight or obese (Ajayi et al., 
2016), and the high prevalence of obesity seen in Egypt (29%) and SA (27%) is comparable to that 
of high-income countries (Keates et al., 2017). 
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Table 1.9 The epidemiology and rising trends of obesity in sub-Saharan Africa. 
Prevalence Country Year Comments Reference 
3.7 Tanzania 1984 9,1% of diabetic population obese Ahren et al., 1984 
1 – 7.1 SSA 1995 18 Countries; Females; Obese BMI; 31% in SA Levitt, 2008 
30 / 33 
Cameroon 1994 – 2003 
Overweight BMI; Males/Females 
Fezeu et al., 2008 
7 / 22 Obesity; Males/Females 
18 / 67 Obese BMI; Males/Females 
0.4 – 43 SSA 2005 Meta-analysis Dalal et al., 2005 
5.1 Guinea 2007  Balde et al., 2007 
39.8 / 15.8 
Kenya 2008 
Overweight; Urban/Rural 
Christensen et al., 2009 
15.5 / 5.1 Obese; Urban/Rural 
28.2 / 52.2 Benin 
2009 
Abdominal obesity; Rural/Urban 
Ntandou et al., 2009 18 / 32 Cotonou, Benin Obese/Abdominal obesity 
10.6 / 23.8 Ouidah, Benin Obese/Abdominal obesity 
67 / 18 Cameroon 2010 Abdominal obesity; Females/Males Tuei et al., 2010 
50.1 Africa 2012  Crowther & Norris, 2012 
1.8 Ethiopia 
2013 
Lowest prevalence in females 
Ajayi et al., 2016 25 
Equatorial 
Guinea Highest prevalence in males  
1.8 Uganda Lowest prevalence in males 
<15 SSA 2014 Overall Keates et al., 2017 
10.8 Ethiopia 
2014 
Females 
Peer et al., 2014a 
34.7 Ghana 
2 Ethiopia 
Males 12.2 
Democratic 
Republic of 
Congo 
13.8 Cameroon 
68 / 31 Nigeria 
2016 
Overweight + Obese / Obese 
only 
Ajayi et al., 2016 
75 / 40 Tanzania Overweight + Obese / Obese only 
46 / 10 
Uganda 
Rural; Overweight + Obese / 
Obese only 
48 / 14 Urban; Overweight + Obese / Obese only 
1.3 / 6.9 
Ghana 2016 
Males; Rural/Urban 
Agyemang et al., 2016 
8.3 / 33.9 Females; Rural/Urban 
20 / 50 Africa 2016 Urban; Overweight/Obese Ajayi et al., 2016 
29 Egypt 2017  Keates et al., 2017 
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1.4.2 Genetics of obesity 
Twin studies have noted a strong genetic component linked to BMI, with heritability estimates ranging 
from 55.0-87.0% (Min et al., 2013; Tarnoki et al., 2014a). In Nigeria, the heritability estimate is 
reported at only 36.0% (Kramer et al., 2005). However, the effects of genes predisposing an 
individual to obesity have been shown to be modified by physical inactivity, with dietary protein intake 
having no such effects (Silventoinen et al., 2009). Monogenic obesity is an autosomal form of obesity 
that is characterised by severe obesity without developmental delays (O’Rahilly, 2009; Coll et al., 
2004). It occurs as a result of increased appetite due to weakened satiety (Coll et al., 2004). The fat 
mass and obesity-associated gene (FTO) was the first locus identified by GWAS to harbour common 
variants associated with obesity predisposition (Ndiaye et al., 2011).  
A systematic review of 43 SSA studies, ranging between 85 and 2 332 participants, identified 300 
polymorphisms in 42 genes that were associated with obesity in Africa (Yako et al., 2015b). This 
included some of the genes in the current study such as ACE, FTO, and MC4R. Of the genes 
identified by Yako et al. (2015b), only SNPs in FTO and MC4R were previously validated by a 
genome-wide association study (GWAS) in Ghanaian, Nigerian and SA Black individuals (Yako et 
al., 2015b). A summary of all the genes discussed below that have been found to be involved in 
obesity and other factors of body mass in Africa are presented in Table 1.10. 
1.4.2.1 Fat-mass and obesity associated (FTO) gene 
Variants in the FTO gene (section 1.3.3.4) are the most consistently replicated variants for obesity 
in many populations (Lombard et al., 2012; Adeyemo et al., 2010; Hennig et al., 2009), with an effect 
size of 0.35 kg/m2 per susceptibility allele (Hennig et al., 2009); however, data is scarce in African 
populations (Adeyemo et al., 2010).  
The rs1121980 and rs7204609 SNPs, located in intron 1 of the FTO gene, were associated with 
obesity in 517 West Africans (Table 1.10) (Adeyemo et al., 2010). The rs7204609 SNP, as well as 
the SNPs rs17817288 and rs12447107 in intron 8 of the FTO gene, were also found to be associated 
with percentage body fat in West Africans, while rs16952624 showed no association (Table 1.10) 
(Adeyemo et al., 2010).  A study of 990 SA Black adolescents associated the minor allele (G) of 
rs17817449  with a 2.5% increased risk of BMI per susceptibility allele (Lombard et al., 2012) while 
it has been reported much lower in Europeans and Asians (1.53 and 1.32, respectively) (Jacobsson 
et al., 2012).  
Some of these SNPs, plus others of the FTO gene (rs17817288, rs17817449, rs7204609, 
rs3571812, rs9931494, rs1121980 and rs8050136) have been found to be significantly associated 
with obesity in Ghanaian, Nigerian and SA black individuals by GWAS (Yako et al., 2015a). An earlier 
study of 2 208 Gambian males and females, the first of its kind in Africa, observed no association 
between any SNPs in the FTO gene and obesity (Table 1.10) (Hennig et al., 2009). 
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1.4.2.2 Melanocortin 4 receptor (MC4R) 
So far 20 genetic variations, positioned in the leptin/melanocortin pathway, involved in the regulation 
of inflammation and whole-body energy homeostasis (Coll et al., 2004), have been identified to play 
a role in monogenic obesity (Lombard et al., 2012; O’Rahilly, 2009; Coll et al., 2004). The MC4R 
gene (section 1.2.3.5), is a G-protein coupled receptor of the melanocortin receptor family, that 
regulates energy homeostasis and food intake (Logan et al., 2016). 
A deficiency in MC4R, resulting in decreased cell surface receptor expression, decreased or absent 
ligand binding, incorrect protein folding and reduced signal transduction, is the most common form 
of monogenic obesity (Logan et al., 2016). The MC4R genetic variants responsible for monogenic 
obesity are found in only 0.05% of the population, with a prevalence between 0.5-1.0% in obese 
patients and accounting for 6.0% of severe cases of obesity that manifest during childhood (Logan 
et al., 2016). 
The rs17782313 SNP of MC4R, a C to T substitution with unknown function, was found to be 
associated with BMI in Black adolescents, particularly the T allele conferred a2.5% increased risk of 
an obese BMI (Table 1.10) (Lombard et al., 2012). In a study of 297 SA non-monogenic, obese 
subjects (63% Black Africans), 42 Black participants had 8 MC4R SNPs previously identified in a 
South African cohort to play a role in monogenic obesity. The most prevalent SNPs were rs229616 
(4%), rs121913560 (1.5%) and rs61741819 (1.2%) (Table 1.10). The remaining 5 MC4R variants 
were found in 1.18% of the total study population (Logan et al., 2016). This study also found that 
carrying any one of the 8 MC4R variants identified, leads to a 4.5-fold increased risk of developing 
monogenic obesity (Logan et al., 2016). The presence of any of these MC4R variants also resulted 
in an elevated prevalence of MetS amongst obese individuals (Logan et al., 2016). 
1.4.2.3 Angiotensinogen (AGT) 
The missense rs699 (threonine to methione) and rs4762 (methionine to threonine) SNPs of the 
angiotensinogen gene (section 1.2.2.2) was associated with increased BMI in 550 preeclamptic (PE) 
pregnant Tunisian females (Table 1.10) (Zitouni et al., 2018). In Nigerians and Zimbabweans, 
average BMI has been associated with circulating AGT levels, however no genetic association 
analyses were conducted to determine whether or not the AGT levels were influenced by the 
presence of DNA sequence variants (Cooper et al., 1998). 
1.4.2.4 Transcription factor 7-like 2 (TCF7L2) 
The TCF4 protein, encoded by TCF7L2, was shown to downregulate adipogenesis in adipocytes 
(section 1.2.3.2). No association with obesity was observed for the TCF7L2 rs12255372 (Ngwa et 
al., 2015) and rs7903146 (Nguimmo-Metsadjio et al., 2017) SNPs in Cameroon (Table 1.10). No 
other studies investigating the genetic association ofthese or any other SNPs in this gene with T2DM 
in African populations was found. 
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1.4.2.5 Angiotensin-converting enzyme (ACE) 
The rs4646994 I/D polymorphism of the ACE gene (section 1.2.2.3) has been found to be associated 
with the risk of obesity, with the differences in risk observed attributable to sex and racial influences 
(Kramer et al., 2005). Although a study conducted in 1 158 Black individuals from Ibadan, Nigeria 
and 1 080 AfAms, found no association between obesity and the rs4646994 I/D polymorphism, they 
did find that the ACE1-ACE5 (TACAT) haplotype in the promoter region of the gene was over-
transmitted from parents to their obese offspring (Table 1.10) (Kramer et al., 2005). A meta-analysis 
of 14 studies (3 371 cases and 4 490 controls) found that the D allele (p=0.026) and DD genotype 
(p=0.010) was significantly associated with the risk of overweight or obesity (Table 1.10) (Mao & 
Huang, 2015). In Ethiopian females, the DD genotype was associated with IR and high BMI, IR and 
WC, and IR and waist-to-height ratio (Table 1.10) (Motawi et al., 2016). 
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 Table 1.10 A summary of genes found to be associated with obesity and other measures of body fat distribution in Africa. 
 
Cases Controls
Ghanaians; 
Nigerians, SA 
blacks
Significantly associated Yako et al., 2015
West Africans Associated with percent body fat Adeyemo et al., 2010
Ghanaians; 
Nigerians, SA 
blacks
Significantly associated Yako et al., 2015
SA Blacks Assoicated with BMI, 2.5% increased risk per allele Lombard et al., 2012
Ghanaians; 
Nigerians, SA 
blacks
Significantly associated Yako et al., 2015
West Africans Associated with obesity and percent body fat Adeyemo et al., 2010
rs3571812 T
Ghanaians; 
Nigerians, SA 
blacks
Significantly associated Yako et al., 2015
rs9931494 G
Ghanaians; 
Nigerians, SA 
blacks
Significantly associated Yako et al., 2015
Ghanaians; 
Nigerians, SA 
blacks
Significantly associated Yako et al ., 2015
West Africans Associated Adeyemo et al., 2010
rs8050136 A
Ghanaians; 
Nigerians, SA 
blacks
Significantly associated Yako et al., 2015
rs12447107 G West Africans Associated with percent body fat Adeyemo et al., 2010
rs16952624 T West Africans No association with obesity or percent body fat Adeyemo et al., 2010
All SNPs above Gambians Does not influence measures of body mass Hennig et al., 20092 208
16q12.2 53701692 - 54158512
Grs17817288
517
517
Grs17817449
990
517
GWAS
GWAS
GWAS
GWAS
GWAS
GWAS
GWAS
rs7204690
517
ReferenceGene name Gene function Chr. Location Chr coordinates (GRCh 38) (From - To) SNP
Risk 
allele
Population 
studied 
No. samples
Results
Fat mass and obesity associated 
(FTO ) DNA demethylase
Ars1121980
517
T
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Table 1.10 Continued 
Unless specified, ethinicity of SA Blacks was not stated in the articles. 
AGT – Angiotensinogen; BMI – Body mass index; Chr – Chromosome; DNA – Deoxyribonucleic acid; FTO – Fat-mass and obesity associated; GWAS – Genome-wide association 
study; MC4R – Melanocortin 4 receptor; SA – South Africa;  TCF7L2 – Transcription factor 7-like 2; WC – waist circumference 
rs229616        G SA blacks 198 99 Highly prevalent in obese individuals Logan et al., 2016
rs121913560  G SA blacks 198 99 Highly prevalent in obese individuals Logan et al., 2016
rs61741819      G SA blacks 198 99 Highly prevalent in obese individuals Logan et al., 2016
rs17782313 T SA Blacks Assoicated with BMI, 2.5% increased risk per allele Lombard et al., 2012
rs699 T Tunisians 550 278 Associated with increased BMI in pregnant women Zitouni et al., 2018
rs4760 T Tunisians 500 278 Associated with increased BMI in pregnant women Zitouni et al., 2018
rs12255372 T Cameroonians 35 30 No association with obesity Ngwa et al., 2015
rs7903146 T Cameroonians 35 30 No association with obesity Nguimmo-Metsadjio et al., 2017
Nigerians, 
AfAms
TACAT (ACE1-ACE5) haplotype 
over-transmitted from parents 
to obese offspring
Kramer et al., 2005
Africans 3 371 4 490
D (p=0.026) and DD (p=0.010) 
associated with risk of 
overweight and obesity
Mao & Huang, 2015
Ethiopians
DD carriers: siginificant 
associations between IR and 
high BMI (OR=8.89, 95%CI=1.94-
40.71, p=0.004); IR and WC 
(OR=9.63, 95%CI=2.14-43.36, 
p=0.003); IR and waist:height 
(OR=6.86, 95%CI=1.25-37.61, 
p=0.034)
Motawi et al., 2016
Encodes effector for Wnt 
signalling pathway 10q25.3 112950220 - 113167678
Transcription factor 7-like 2 
(TCF7L2 )
60371110 - 6037277518q21.32
990
230702523 - 2307145901q42-q43Cardiovascular remodelling; blood pressure controlAngiotensinogen (AGT )
Melanocortin 4 receptor (MC4R ) Regulates energy homeostasis and food intake 
1 158/1 080
D
80
63477061 - 6349838017q23.3Cleaves AngI to AngIIAngiotensin-converting enzyme (ACE ) rs4646994
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1.4.3 Concluding remarks – obesity 
Obesity often precedes other diseases associated with CVD and is associated with IR and 
inflammation. Obesity, specifically peripheral obesity, is more common in Black females than in 
their Caucasian counterparts or in males, contrary to what is seen in other countries. The FTO 
gene is the most consistently replicated gene associated with obesity, although no specific SNP 
stands out in Africans as the causal variant. In other countries, the rs9939609 SNP stands out. 
Another top gene includes MC4R. The various SNPs within genes and between genes could 
potentially interact to increase obesity risk. 
1.5  Hypertension 
Hypertension is characterised by stiff arterial walls that increases resistance to blood flow, requiring 
the heart to beat with more force, increasing the pressure of the blood being pumped out of the heart 
(Sengwayo et al., 2013). Mechanical damage to the heart, kidneys and vascular system occurs as 
a result of the high pressure observed in hypertension (Munóz-Duranga et al., 2016) due to low 
plasma renin concentrations and increased cardiovascular response to stress (Gafane et al., 2016).  
Hypertension occurs as a result of sustained elevated BP (Reiter et al., 2016) and can present in 
different forms. Primary/essential hypertension is diagnosed in an individual when the cause of 
arterial hypertension is unknown, while secondary hypertension is preceded by abnormal 
physiological conditions that affect kidneys, heart or the endocrine system (Munóz-Duranga et al., 
2016). Additionally, hypertension can occur in preeclampsia, a multisystem pregnancy disorder 
(Zitouni et al., 2018; Aung et al., 2017). All forms of hypertension predispose an individual to many 
serious medical problems such as blindness, heart failure and stroke, renal failure, and ventricular 
arrhythmias (Rayner & Spence, 2017), and contributes to 75.0% of all heart attacks and strokes 
(Sengwayo et al., 2013). Hypertension is a widespread problem due to its severe associated 
complications and frequent underdiagnosis (Schutte et al., 2008).  
Essential hypertension and the associated salt-sensitive phenotype (Figure 1.3) appears polygenic 
in nature (Poch et al., 2001). A high dietary salt intake mediates BP response to the environment 
(Poch et al., 2001). This salt-sensitive phenotype is said to be heterogenous in nature as it is found 
in 50.0% of hypertensive patients (Poch et al., 2001). A genetic component to salt-sensitivity (Figure 
1.3) has also been established, as is exhibited by the familial history of hypertension, and familial 
resemblance of BP response to salt, found in normotensive and hypertensive individuals when 
compared to salt-resistant individuals (Poch et al., 2001). In addition, the genetic nature of essential 
hypertension was supported by the  sodium retention hypothesis which was proposed to explain the 
higher prevalence of hypertension in Africans, as hypertensive indigenous Africans appear to be 
more salt-sensitive (Figure 1.3), with reduced plasma renin levels (Rayner & Spence, 2017; Edina-
Melenge et al., 2017; Reiter et al., 2016; Weissberg et al., 1987), than their normotensive 
counterparts (Rayner & Spence, 2017; Weissberg et al., 1987). It is thought that the retention of 
sodium and water, especially in West Africans, was a survival adaptation due to limited access to 
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fluid and periods of drought in rural areas but may now predispose the more urban individuals to 
hypertension (Reiter et al., 2016).  
 
Figure 1.3 The mechanism of salt-sensitive hypertension (Adapted from Rayner & Spence, 2017). 
An individual is predisposed to essential hypertension by factors such as age, cigarette smoking, 
diet, ethnicity, hormones, physical inactivity, sex and stress. This mosaic basis of hypertension was 
proposed by Paige in 1960 (Frolich et al., 1991). Essential hypertension, as a result of environmental 
and genetic factors, is the most common disorder of aging and is the leading cause of CVD (Rayner 
& Spence, 2017; Poch et al., 2001), that results in a continual elevation in BP (Schutte et al., 2008). 
It is linked to IR and oxidative stress, promoting inflammatory pathways (Ceriello & Motz, 2004; Saad 
et al., 2004; Sowers & Frolick, 2004; Facchini et al., 2001; Griendling & Alexander, 1997), which are 
in turn associated with obesity and T2DM (Ceriello & Motz, 2004; Dandona et al., 2004; Sattar et al., 
2003). IR, oxidative stress and inflammation are known risk factors for CVD (Mayosi et al., 2009; 
Medzhitov, 2008; Hotamisligil, 2006; Farrario & Strawn, 2006; Mollentze, 2003), T2DM (Medzhitov, 
2008; Hotamisligil, 2006) and obesity (Stenlöf et al., 2006; Coll et al., 2004). The oxidative stress 
and inflammation induced by hypertension is responsible for end-organ damage, mainly as a result 
of fibrosis (Munóz-Duranga et al., 2016). Low renin hypertension is common in Black individuals, as 
they have been found to have suppressed RAAS (Figure 1.2) activity and a resultant low renin status, 
associated with a sustained increase in BP and end-organ damage (Gafane et al., 2016). 
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Hypertension is the most prevalent (Gafane et al., 2016; Munóz-Duranga et al., 2016) and most 
modifiable (Edinga-Melenge et al., 2017) risk factor for CVD and stroke (Munóz-Duranga et al., 
2016), but it is the leading cause of death due to CVD worldwide (Edinga-Melenge et al., 2017). In 
40.0–60.0% of T2DM patients, hypertension and T2DM coexist (Edinga-Melenge et al., 2017). 
Hypertension is 1.5–3 times more prevalent in T2DM patients compared to nondiabetic individuals 
(Edinga-Melenge et al., 2017). In Black children BP increases faster over time than in their 
Caucasian counterparts, resulting in increased prevalence of hypertension in Black adults (Bloem et 
al., 1995). 
The progression of renal failure to end-stage renal disease (ESRD) is driven by hypertension 
(Edinga-Melenge et al., 2017; Lovati et al., 2001). Both hypertension and ESRD are as a result of 
an excess production of AngII (Figure 1.2), which mediates vasoconstriction, and thereby 
hypertension, and the progression to renal disease (Lovati et al., 2001). 
1.5.1 Epidemiology of hypertension in Africa 
Insulin resistance and obesity are the leading causes of hypertension (Duvnjak et al., 2008; Sowers, 
2004). Hypertension contributes to 75% of all heart attacks and strokes (Sengwayo et al., 2013) and 
85% of MetS patients are hypertensive (Duvnjak et al., 2008; Sowers, 2004).  
1.5.1.1 Hypertension in South Africa 
Since 1998, the prevalence of hypertension in SA has increased (Table 1.11), being present in more 
than 40.0% of the population over 25 years (Yako et al., 2018; Reiter et al., 2016; Day et al., 2014). 
In the Black population of SA, hypertension has been found to be common, with prevalence 
estimates ranging between 9%-70% (Table 1.11) (Schutte et al., 2008; Cappucio et al., 2004; 
Vorster, 2002; Mollentze et al., 1995; Akinkugbe et al., 1985), with a high stroke mortality rate 2-fold 
higher in hypertensives than in their Caucasian counterparts (Schutte et al., 2008; Opie et al., 2005). 
Black individuals are also at increased risk of heart failure, peripheral vascular disease and renal 
failure due to hypertension (Seedat, 1999). This is believed to be as a result of the increased 
fibrinogen levels observed in Africans (Schutte et al., 2008). A study of Black SA females found that 
they had higher BP when compared to their Caucasian counterparts, with increased peripheral 
vascular disease with a link to IR (Schutte et al., 2008). 
,  
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Table 1.11 The epidemiology and rising trends of hypertension in South Africa. 
Prevalence Area/Town/Province Year Comments Reference 
9.4 SA 1982 Zulu Seedat, 1982 
25 
Durban 1983 
Urban Zulu 
Seedat, 1983 17.2 Caucasians 
14.2 Ethnic Indians 
29 QwaQwa 
1995 
 
Mollentze et al., 
1995 
30.3 Mangaung  
69.8 QwaQwa & Mangaung Stroke patients 
40 SA 1998 - 2018 Individuals >25 years 
Yako et al., 2018; 
Reiter et al., 2016; 
Day et al., 2014 
55 
SA 2005 
Overall 
Connor et al., 2003 
59 Blacks 
43 / 41 SA 2008 Males / Females NDoH, 2013 
42.2 SA 2008 Overall WHO, 2008 
33 Soweto 2009  Tibazarwa et al., 2009 
 
1.5.1.2 Hypertension in sub-Saharan Africa 
 In 6 low- and middle-income countries (China, Ghana, India, Mexico, Russian Federation and SA), 
the highest prevalence of hypertension (77.9%) was reported in people over the age of 50 years 
(Lloyd-Sherlock et al., 2014). By 2025, the prevalence of hypertension in SSA is estimated to 
increase from 80 million in 2000 to 150 million (Ghogomu et al., 2016). In the year 2000, hypertension 
in SSA was reported in approximately 12% of the SSA population (Table 1.12) and this number is 
projected to double by 2025 (Yako et al., 2018).  
Hypertension prevalence varies between rural and urban populations (Table 1.12). In West Africa 
the prevalence of hypertension in rural and urban populations was 16% and 20% (Table 1.12), 
respectively, and is believed to be due to the presence of obesity in these communities (Cooper & 
Rotimi, 1997; Seedat et al., 1982). 
In 1985 the hypertension prevalence in SSA was below that of either the West Indies or the United 
States of America (Akinkugbe, 1985), but an ever-rising increase of hypertension in SSA will result 
in the prevalence exceeding that of either country. 
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Table 1.12 The epidemiology and rising trends of hypertension in sub-Saharan Africa. 
Prevalence Country Year Comments Reference 
7 Lesotho 1976  Mokhobo et al., 1976 
4.1 – 11 Ghana 1977  Pobee et al., 1977 
5.9 Nigeria 1978  Oviasu et al., 1978 
16 / 20 West Africa 1982 - 1997 Rural/Urban 
Cooper & Rotimi, 1997; 
Seedat, 1982 
11 Cameroon 1998  Mbanya et al., 1998 
12 SSA 2000 Overall Yako et al., 2018 
54.3 Africa 2005 T2DM patients Isezou & Ezunu, 2005 
24.1 / 26.5 Benin 
2009 
Rural/Urban 
Ntandou et al., 2009 
23 Cotonou, Benin 
 
14.7 – 69.9 SSA 2014 Overall Ataklte et al., 2014 
 
1.5.2 Genetics of hypertension 
Many genes, with mild effects on BP, have been associated with hypertension (Butler, 2010), 
However, the underlying genetics are poorly understood (Edinga-Melenge et al., 2017; Tiffin et al., 
2010). The heritability of hypertension ranges between 30.0-60.0% (Tarnoki et al., 2014b), with 
inconsistent clinical presentations and drug response. However, approximately only 2.0% of the total 
variation in BP has been explained by the discovery of associated genetic loci, which have been 
broadly replicated with modest odd’s ratios (Levy et al., 2009; Newton-Cheh et al., 2009, Fox et al., 
2011; Johnson et al., 2011; Zeller et al., 2012).  
A genetic component is responsible for 50.0% of all hypertensive cases (Ghogomu et al., 2016; 
Butler, 2010; Jeanemaitre et al., 2007). Disease expression is believed to be modified by genetic 
factors as seen by the female predominance, reduced penetrance and variable expressivity of 
pulmonary arterial hypertension (Austin & Loyd, 2014). The RAAS (Figure 1.2) has been 
demonstrated to play a central role in BP response to a high-salt diet (Figure 1.3) (Poch et al., 2001; 
Svetkey et al., 2001), as well as in the genesis of arterial hypertension (Munóz-Duranga et al., 2016). 
A summary of all the genes discussed below that have been found to be involved in hypertension 
and other measures of BP in Africa are presented in Table 6. 
1.5.2.1 Angiotensinogen (AGT) 
Angiotensinogen, produced in the liver, is converted to AngI, the prohormone of AngII, by interaction 
with renin (Figure 1.2) (Bloem et al., 1995). Sodium retention and vascular resistance is increased 
by AngII, making it important for BP regulation (Bloem et al., 1995). 
Elevated levels of AGT in plasma, due to the rs699 (TT) SNP in this gene (section 1.2.2.2), leads to 
increases in both systolic and diastolic BP (Table 1.13) (Zitouni et al., 2018; Bloem et al., 1995). In 
Nigerians and Zimbabweans, hypertensive individuals were found to possess higher levels of 
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circulating AGT than normotensives (Cooper et al., 1998), but the genetic changes that may 
contribute to the increased levels of this protein were not investigated in this study. The T allele of 
rs699 has been reported to be the predominant allele in African American Black individuals (Bloem 
et al., 1995) and may thus contribute to the higher BP observed in SA Black individuals.  
The T-allele of the AGT rs699 variant has a frequency ranging from 40% in Caucasian individuals to 
90% in Nigerians (Barlassina et al., 2000; Wang & Staessen, 2000). The association of rs699 with 
hypertension is the most replicated association for hypertension in many populations (Barlassina et 
al., 2000; Wang & Staessen, 2000). This was also observed in a meta-analysis of individuals of West 
African descent, where the frequency of the T allele was 81% in individuals of West African descent 
and 42% in their Caucasian African counterparts (Reiter et al., 2016). Another meta-analysis of 
individuals of West African descent showed a strong tendency to increased risk for hypertension 
among individuals with the TT genotype, but this association was not observed in an earlier study of 
1 308 Nigerians (Table 1.13) (Kooffreh et al., 2013a). In Egyptian CAD patients, the TT genotype of 
rs699 was positively correlated with BP (Table 1.13) (Shaker et al., 2009), and may thus modulate 
the association with CVD (section 1.2.2.2).  In one SA study, the T allele of rs699 was found to be 
more common in Black Xhosa or Zulu soeaking PE and late-onset PE patients, and was associated 
with a 2-fold higher risk of PE development in hypertensive females (Table 1.13) (Aung et al., 2017). 
In a Tunisian Black cohort, the T allele was significantly higher in PE patients and associated with 
increased risk and severity of PE (Table 1.13) (Zitouni et al., 2018). The high prevalence of the rs699 
T allele in Black individuals, found to be associated with hypertension, may indicate a genetic cause 
for the high prevalence of hypertension observed in SA Black individuals (Tibazarwa et al., 2009; 
Ataklte et al., 2014) and could be a valuable gene variant to look at (Yako et al., 2018; Reiter et al., 
2016; Day et al., 2014; Schutte et al., 2008).  
The rs4762 SNP found in exon 2 of the AGT has been reported in a Ghanaian population, and 
associated with both higher SBP and higher DBP and may play a role in the high prevalence of 
hypertension observed in this Black population (Robinson & Williams, 2004), but this association 
was not replicated in an Algerian population (Table 1.13) (Amrani et al., 2015). Neither rs699 and 
rs4762 was found to be associated with hypertension in a Nigerian cohort (Table 1.13) (Rotimi et al., 
1997). 
33In a Tunisian cohort, the T allele of the rs4762 SNP was associated with an increased risk of 
developing PE (Table 1.13) (Zitouni et al., 2018). These findings were not observed in an earlier 
study of an SA Black, Zulu speaking cohort (Roberts et al., 2004). In a recent study, having either 
the rs699 and rs4762 risk alleles was also associated with increased BMI (Zitouni et al., 2018). 
1.5.2.2 Angiotensin-converting enzyme (ACE) 
The ACE protein, encoded by the ACE gene on chromosome 17 (section 1.2.2.3), cleaves Ang I to 
Ang II. Angiotensin II is involved in BP regulation, and variations in ACE levels may thus affect BP 
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(Lombard et al., 2012). The rs4343 (A262T) and rs4291 (A11860G) variants, located in exon 16 and 
the promoter region of rs4646994, have the strongest effect on circulating ACE levels, and were 
associated with systolic BP in a combined linkage and association study of 1343 individuals from 
332 Nigerian families (Zhu et al. 2001). The CAD haplotype, thought to be involved in regulating 
circulating ACE levels and covering approximately 9kb of the ACE gene, consisting of the variants 
rs4309 (C5467T), rs4331 (A9596G) and rs4646994 (I/D), was significantly associated with 
hypertension in a Nigerian cohort (Table 1.13) (Bouzekri et al., 2004).  
Although ACE levels are similar in Black and Caucasian individuals, ACE levels was inversely 
associated with diastolic BP in Black individuals, but positively associated with diastolic BP in 
Caucasian individuals, which may be indicative of possible underlying ethnic differences in BP 
regulation (He et al., 1999). No association was observed between the ACE rs4646994 I/D 
polymorphism and hypertension in Tunisians (388 cases and 425 controls) (Table 1.13) (Kabadou 
et al., 2013). 
1.5.2.3 Angiotensin II type I receptor (AT1R) 
The angiotensin II type I receptor (AT1R) (section 1.2.2.4) is involved in mediating the salt-
conserving and vasoconstrictive actions of the RAAS (Figure 1.2) (Ghogomu et al., 2016; Kooffreh 
et al., 2013b).  A computational analyses of candidate genes of hypertension in SA Black individuals 
ranked the rs5186 SNP of the AT1R gene (section 1.1.3.4), implicated in BP control and blood 
volume in the cardiovascular system, as the most plausible candidate gene for disease (Table 1.13) 
(Tiffin et al., 2010). However, in the same population, this SNP was found to have similar distributions 
in PE patients and normotensive pregnant controls (Table 1.13) (Aung et al., 2017), suggesting that 
this SNP may not be associated with increased BP in pregnant Black females from SA. No 
association was observed between the rs5186 SNP and hypertension in the Calabar and Uyo cities 
of Nigeria (Kooffreh et al., 2013b) and in a Cameroonian population from the South West region 
(Ghogomu et al., 2016), with similar genotype distributions between normotensive and hypertensive 
individuals (Table 1.13) (Ghogomu et al., 2016; Kooffreh et al., 2013b). 
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Table 1.13 A summary of genes associated with hypertension and other features of blood pressure in Africa. 
 
ACE – Angiotensin converting enzyme; AGT – Angiotensinogen; AngI – Angiotensin I; AngII – Angiotensin II; AT1R – Angiotensin II type I receptor; BMI – Body mass index; BP – Blood pressure; Chr – 
Chromosome; DBP – Diastolic blood pressure; PE – Pre-eclampsia; SA – South Africa; SBP – Systolic blood pressur
Cases Controls
SA black 357 246
Significantly higher in PE and 
late-onset PE than 
normotensives
Aung et al., 2017
Tunisians 544 278
Associated with increased PE 
risk and severity; T 
homozygosity positively 
associated with PE
Zitouni et al., 2018
Nigerians 138 116
No association with 
hypertension; possitively 
associated with concentration in 
males
Rotimi et al., 1997
West Africans; 
Nigerians
TT associated with increased risk 
in West Africans, but not in 
Nigerians
Kooffreh et al., 2013a
Egyptians 70 60 TT positively correlated with BP in CAD patients Shaker et al., 2009
Algeria 82 72 No association with BP Amrani et al., 2015
SA black 544 278 Associated with increased PE risk Zitouni et al., 2018
Ghanaians; 
Algerian 82 72
Higher SBP and DBP in 
Ghanaians, not in Algerians
Robinsson & Williams, 2004; 
Amrani et al., 2015
Nigerians 138 116 No association Rotimi et al., 1997
H1 haplotype (-
1074T/G, -532C/T, 
384A/G, 1164A/G, 
2186T/G), 
TTAAT Nigerians
Associated with increased 
serum angiotensinogen 
(p=0.042)
Fejerman et al., 2006
-255G/A; -44G/A A Mali (Dogon) No association between BMI and systolic or diastolic BP Taylor et al., 2013
C5467T, A9596G, 
I/D CAD Nigerians
Haplotype associated with 
hypertension (p=0.007) Bouzekri et al., 2004
A-262T; A11860G Nigerians Associated with systolic BP Zhu et al., 2001
rs4646994 D Tunisians 388 425 No association Kabadou et al., 2013
SA black Top ranked candidate gene for hypertension Tiffin et al., 2010
Nigerians; 
Cameroonians 612/32 612/50
No association with 
hypertension
Kooffreh et al., 2013b; 
Ghogomu et al., 2016
SA black 357 246 Similar distribution in PE and normotensives Aung et al., 2010
Computational 
analysis
1158
1343 people from 
332 families
ReferenceGene name Gene function Chr. Location Chr coordinates (GRCh 38) (From - To) SNP
Risk 
allele
Population 
studied 
No. samples
Results
199
Crs5186148697871 - 1487430033q21-q25
Vasoconstriction through AngII; 
mediates major cardiovascular 
effects of AngII
595 people from 
184 families
230702523 - 2307145901q42-q43Cardiovascular remodelling; blood pressure controlAngiotensinogen (AGT )
Trs699 
Trs4762          
Meta-analysis
63477061 - 6349838017q23Catalyzes conversion of AngI to the physiologically active AngII
Angiotensin converting enzyme 
(ACE )
Angiotensin II type I receptor 
(AT1R )
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1.5.3 Concluding remarks - hypertension 
Hypertension is the most common disorder of aging and is the leading cause of CVD. It is linked to 
obesity and T2DM by its accompanying IR and inflammation and is thus the most modifiable risk 
factor of CVD. Hypertension is very common in Black Africans. The RAAS is responsible for BP 
regulation, and AGT, the main regulator of the system has repeatedly been associated with 
hypertension and BP control in Black Africans and is a promising target for genetic studies of BP. 
Other genes of the RAAS have also been associated with hypertension and may interact with AGT 
to exert their effects.  
1.6 Dyslipidaemia 
Dyslipidaemia is characterised by increased TC, triglycerides and LDL-C, and decreased HDL-C 
levels (Ellman et al., 2015; Bentley et al., 2012; Brown et al., 2006). Dyslipidaemia is associated with 
increased CVD risk (Bentley & Rotimi, 2012; Kathiresan et al., 2008; Brown et al., 2006; Kotowski et 
al., 2006; Chien et al., 2005; Knoblauch et al., 2004; Lai et al., 2004). Dyslipidaemia is common in 
T2DM patients, predating glucose intolerance (Adeyemo et al., 2005) and is associated with obesity 
(Ellman et al., 2015). Higher cholesterol has been associated with increased atherogenesis (Karaye 
& Habib, 2014). Atherogenic dyslipidaemia is a combination of increased triglycerides and decreased 
HDL-C concentrations (Ntyintyane et al., 2006). 
Hypercholesterolaemia is diagnosed when TC is greater than 5 mmol/l (Karaye & Habib, 2014). 
Familial hypercholesterolaemia is an autosomal dominant disease that contributes to CHD mortality 
(Kotze & Theart, 2003), and in the 1970s, familial hypercholesterolaemia was found to have a high 
prevalence in SA (Seftel, 2003). In 2016 familial hypercholesterolaemia was still common (1 in 200 
to 1 in 500) and is said to be the most significant monogenic disorder of lipoprotein metabolism 
(Khine & Marais, 2016). If untreated, homozygous familial hypercholesterolaemia is associated with 
a 20-fold increased risk of CHD; and untreated heterozygous familial hypercholesterolaemia in males 
results in a 2-fold increased risk of a coronary event by 50 years, and a 0.3-fold increase in females 
(Khine & Marais, 2016).  
Postprandial lipaemia, a rise in triglycerides and triglyceride-rich lipoproteins after eating, is common 
in SA Black CAD patients (Ntyintyane et al., 2008). In addition to the increased triglyceride 
concentrations, a prolonged postprandial response is also observed in CAD patients (Ntyintyane et 
al., 2008). Postprandial lipaemia results in hypertriglyceridaemia with decreased HDL-C and 
increased LDL-C (Ntyintyane et al., 2008). Increased triglyceride concentrations after eating has also 
been associated with hypertension, MetS, obesity and T2DM (Ntyintyane et al., 2008). 
In urban Black populations in SA, mean serum cholesterol is twice as high as that found in traditional, 
rural populations (Walker et al., 1997). Total cholesterol, triglycerides and LDL-C serum levels have 
been positively associated with CHD, while HDL-C serum levels is negatively associated with CHD 
(Adeyemo et al., 2005). In T2DM patients, increased triglycerides and decreased HDL-C are the 
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most common lipid abnormalities observed (Makuyana et al., 2004). The degree of insulin production 
and IR, and thus progression to T2DM, has been found to be determined by the level of tissue 
triglycerides (Makuyana et al., 2004). The prevalence of dyslipidaemia in SA follows the trend seen 
for CVD in SA with SA Indian and Caucasian individuals having the highest prevalence, followed by 
Coloured individuals and generally uncommon in Black individuals (Mayosi et al., 2009; Seftel, 
2003). This is supported by the finding that in the absence of dyslipidaemia, CHD is rare in Black 
individuals, even though the prevalence of T2DM, hypertension and smoking is high (Seftel, 2003).  
1.6.1 Epidemiology of dyslipidaemia in Africa 
1.6.1.1 Dyslipidaemia in South Africa 
In Xhosa speaking Black females, it has been found that they have lower levels of TC, triglycerides, 
HDL-C and LDL-C compared to their Caucasian counterparts, and this could explain the lower rates 
of lipid related mortalities in the Black population (47 vs. 152 per 100 000, respectively) (Ellman et 
al., 2015). 
As shown in Table 1.14, the prevalence of dyslipidaemia is the lowest in the Black population of SA, 
when compared to Caucasian, Indian and Coloured individuals in SA. A survey conducted in 2005 
involving 10 000 individuals from 200 hospital across SA reported a dyslipidaemia prevalence of 
37.0% in Caucasian individuals, but only 5.0% in Black individuals (Connor et al., 2005). In the same 
year, a study in indigenous Nigerians found the prevalence to be 72.4% (Table 1.14) (Isezou & 
Ezunu, 2005). This vast difference in the prevalence of dyslipidaemia could be attributed to varying 
nutritional habits across these geographical locations. The overall prevalence of 
hypercholesterolaemia was reported at 47.6% in a subset of the SA adult population (Table 1.14) 
(Karaye & Habib, 2014) with the prevalence of hypercholesterolaemia lowest amongst adult SA 
Black individuals at 27.6%, followed by Coloured (80.7%), Asian and Indian (81.7%) and highest 
amongst Caucasian (89.2%) individuals (Table 1.14) (Karaye & Habib, 2014). This huge difference 
in the prevalence of hypercholesterolaemia across different populations in SA may be as a result of 
the adoption of a more westernised diet containing more fats in Caucasian, Coloured and Indian 
populations, whereas the Black population may still be following a traditional diet that contains more 
fibre. The lower prevalence of hypercholesterolaemia in SA Black individuals may be as a result of 
their favourable serum lipid profiles (increased serum cholesterol, but stable HDL-C) and low 
homocysteine, which has also been proposed to protect SA black individuals from IHD (Mayosi et 
al., 2009; Lemogoum et al., 2003; Vorster, 2002). 
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Table 1.14 The epidemiology and rising trends of dyslipidaemia in South Africa.  
Prevalence Area/Town/Province Year Comments Reference 
16.5 / 25.8 Cape Peninsula 1991 High-risk TC; Black males/Females Steyn et al., 1991 
12.5 QwaQwa 
1995 
High-risk 
hypercholesterolaemia 
Mollentze et al., 1995 
6 Mangaung 
34 QwaQwa Moderate-risk 
hypercholesterolaemia' 44.8 Mangaung 
37 
SA 2005 
Caucasians 
Connor et al., 2005 
5 Blacks 
72.4 SA 2005 Blacks Isezou & Ezunu, 2005 
31 / 37 SA 2008 Raised blood cholesterol; Males/Females Nojilana et al., 2016 
13 Soweto 2009 Total cholesterol Tibazarwa et al., 2009 
47.6 
SA 2014 
Hypercholesterolaemia; Overall 
Karaye & Habib, 2014 
27.6 Blacks 
80.7 Coloureds 
81.7 Asians & Indians 
89.2 Caucasians 
 
1.6.1.2 Dyslipidaemia in sub-Saharan Africa 
A meta-analysis of 16 studies of dyslipidaemia in SSA (Kenya, Nigeria, South Africa, Sudan), 
estimated a prevalence of 38.4% across all studies (Table 1.15) (Karaye & Habib, 2014). 
Dyslipidaemia prevalence was highest amongst IHD patients (49.6%), followed by stroke patients 
(26.5%) and heart failure patients (11.4%), with high cholesterol responsible for a big part of the 
burden (Karaye & Habib, 2014).  
Another meta-analysis in SSA reported a fairly low prevalence of hypercholesterolaemia in West 
African countries (Nigeria and Sierra Leone), while in North African countries (Egypt and Tunisia) it 
was much higher (Table 1.15) (Keates et al., 2017), similar to that reported for SA (47.6%) (Karaye 
& Habib, 2014). In all studies included in this meta-analysis, females had significantly higher values 
for total cholesterol, triglycerides, HDL-C, LDL-C and HDL-C/TC than males. This is thought to be 
due to a diet higher in fat and a less physically active lifestyle (Keates et al., 2017). Interestingly, in 
other studies, it has been found that females consistently have higher hypercholesterolaemia values, 
while low HDL-C and relatively high LDL-C and triglycerides levels are consistently reported in both 
males and females (Keates et al., 2017). 
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Table 1.15 The epidemiology and rising trends of dyslipidaemia in sub-Saharan Africa.  
Prevalence Country Year Comments Reference 
25.3 / 37.5 Benin 2009 Reduced HDL-C; Rural/Urban Ntandou et al., 2009 
38.4 SSA 2014 Meta-analysis Karay & Habib, 2014 
48 North Africa 
2017 
Egypt & Tunisia 
Keates et al., 2017 
20 - 30 East & Central Africa 
 
1.6.2 Genetics of dyslipidaemia 
A twin study investigating lipid profiles was the first of its kind to include AfAms and reported a 
heritability range of 69-92% (Iliadou et al., 2005), but genes involved in the pathogenesis has not 
been fully elucidated (Frikke-Schmidt et al., 2004). For all components of abnormal lipids, a 
combined heritability of 30-80% has been reported in Mexican-Americans (Adeyemo et al., 2005). 
However, the heritability of the individual measures of abnormal lipids differs. The heritability of total 
cholesterol, HDL-C and triglycerides has been reported at 8-72%, 21-79% and 19-72%, respectively 
(Elder et al., 2009).  
Of all the SNPs associated with dyslipidaemia by GWAS, two thirds have been successfully 
replicated in an array of populations. (Ndiaye et al., 2011). Most notably is 3 SNPs in the vicinity of 
the cholesteryl ester transfer protein (CETP) gene, which have been associated with high values of 
LDL-C, total cholesterol and triglycerides (Teslovich et al., 2010). Genes identified by GWAS 
involved in familial hypercholesterolaemia include the low-density lipoprotein receptor (LDLR), 
apolipoprotein B (APOB) and proprotein convertase subtilisin/kexin type 9 (PCSK9) (Zeller et al., 
2012) and many of the genes associated with blood lipid concentrations have also been associated 
with CAD risk (Teslovich et al., 2010). 
It is thought that the aggregation of numerous genetic loci, that on their own exert a small influence 
on lipoprotein levels, exert a significant effect on CVD risk (Kotze & Thiart, 2003). It is also thought 
that due to additive effects, low-penetrance CVD-associated genetic loci are pronounced in familial 
hypercholesterolaemia (Kotze & Thiart, 2003). 
Dyslipidaemia has not been studied to any great extent in African populations. However, studies of 
recent African-ancestry populations, i.e. AfAms, have identified genes that are likely to also be 
present in populations from the African continent. The apolipoprotein gene cluster (apolipoprotein 
A1 (APOA1)/apolipoprotein C3 (APOAC3)/apolipoprotein A4 (APOA44)/apolipoprotein A5 
(APOA5)), leptin (LEP) and leptin receptor (LEPR) have repeatedly been associated with 
dyslipidaemia (Chien et al., 2005; Frikke-Schmidt et al., 2004). Although genes involved in familial 
hypercholesterolaemia have been identified in other populations, this association has not been 
confirmed in African populations. Instead, a study conducted in a SA population reported an 
association of the TNFα with dyslipidaemia. (Joffe et al., 2011; Joffe et al., 2010). Evidence from this 
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study suggests that this may be an important gene to study in the pathogenesis of dyslipidaemia, 
and it has also been associated with T2DM. 
1.6.2.1 Tumour necrosis factor-alpha (TNFα) 
Tumour necrosis factor-alpha concentrations have been associated with obesity and increased IR 
(section 1.3).  Whole-body lipid metabolism is influenced by TNFα and raised concentrations thereof 
has been associated with increased levels of triglycerides and low levels of HDL-C (Joffe et al., 
2011).  
The rs1800629 SNP in the TNFα gene (section 1.3.3.2) is a functional G to A substitution at position 
308 upstream from the transcription initiation site in the promoter (Bouhaha et al., 2010b). The A 
allele has been associated with increased TNFα production. In SA Black females, the relationship 
between dietary fat intake (%E), risk of obesity and lipid concentrations was found to be modified by 
SNP rs1800629 (Joffe et al., 2010). In SA Caucasian females, total cholesterol was found to be 
acted upon by the interaction of the rs1800629 genotype and dietary fat intake (%E). In GG, carriers 
decreased TC levels were observed with increased %E; while in AG and AA carriers, increased %E 
was associated with increased TC (Joffe et al., 2011).  
1.6.3 Concluding remarks - dyslipidaemia 
Dyslipidaemia is found in T2DM patients, predating IGT, and is associated with obesity. However, 
overall dyslipidaemia in Black Africans is rare, with prevalence higher in females than in males. The 
LEP and LEPR genes have consistently been associated with dyslipidaemia in other countries, but 
no such studies have been performed in African populations. Thus, more studies regarding the 
genes involved in dyslipidaemia in African populations are needed.  
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1.7 Study rationale 
Identifying genes that contribute to the development of CVD and its associated risk factors, 
especially diabetes and hypertension, particularly in the isiXhosa-speaking Black population of South 
Africa may help to provide a better understanding of the pathways involved in their development. 
Identifying genes associated with disease may enable the early identification of individuals at high-
risk of CVD, as well as identify novel targets for pharmaceutical and preventative strategies. New 
therapeutic strategies may also be developed by the discovery of functional mutations that reduce 
disease risk.  
The focus of this study was on the genetic risk factors associated with CVD and its associated risk 
factors, particularly T2DM, hypertension, obesity and dyslipidaemia, in the isiXhosa-speaking Black 
population of Cape Town. Of particular interest are the single nucleotide polymorphisms (SNPs) 
found in the transcription factor 7-like 2 (TCF7L2); melanocortin 4 receptor (MC4R); angiotensinogen 
(AGT); angiotensin II type I receptor (AT1R); fat-mass and obesity associated (FTO) and tumour 
necrosis factor alpha (TNFα) genes, as they have previously been associated with the diseases that 
this study will focus on, both globally and in SSA. 
In particular, the SA Black population was chosen as very few studies investigating the genetic risk 
of CVD and its associated risk factors have been conducted in this population (Yako et al., 2016; 
Logan et al., 2016; Pillay et al.,2015; Tekola-Ayele et al., 2013; Pirie et al., 2010; Barlassina et al., 
2000). However, studies in other African countries, particularly Nigeria (Yako et al., 2016; Barlassina 
et al., 2000), Cameroon, Ghana (Yako et al., 2016; Jeck et al., 2004), and the predominantly Arab 
North African countries of Egypt (Abd El-Aziz et al., 2012; Shaker et al., 2009), Lebanon (Mtiraoui et 
al., 2012a) and Tunisia (Yako et al., 2016; Turki et al., 2014; Turki et al., 2013a; Turki et al., 2012; 
Berhouma et al., 2012; Mtiraoui et al., 2012a), have replicated some of the genetic findings of other 
countries, mainly the United States of America and Europe. Thus, not much is known about the 
genetic associations with CVD related diseases in the SA Black population. 
1.8 Aim and objectives  
1.8.1 Aim 
To determine if genetic variants selected from previous studies performed in sub-Saharan African 
populations are associated with CVD and its associated risk factors in Black South Africans 
participating in the Cardiovascular Risk in Black South Africans (CRIBSA) Study.  
1.8.2 Objectives 
1. To select genetic markers associated with disease in studies previously performed in African 
populations that could potentially be associated with cardiovascular disease, such as type 2 diabetes 
mellitus, obesity, hypertension, dyslipidaemia and MetS , in South African Black individuals. 
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2. To optimise the DNA extraction protocol using the Gentra PureGene blood kit and extract DNA 
from buffy coat samples. 
3. To optimise the PCR amplification protocol and genotype characterise samples by gel 
electrophoresis, and to test variants for association with CVD and its associated disease risk factors. 
4. To test variants for association with CVD and its associated disease risk factors (as mentioned in 
Objective 1) using relevant bioinformatic tools after KASP genotyping. 
Articles cited in this thesis were found using the following searches: “cardiovascular diseases in 
South Africa”; “metabolic syndrome in South Africa”; “hypertension in South Africa”; “obesity in South 
Africa”; “type 2 diabetes mellitus in South Africa”; “dyslipidaemia in South Africa”; “cardiovascular 
diseases in sub-Saharan Africa”; “metabolic syndrome in sub-Saharan Africa”; “hypertension in sub-
Saharan Africa”; “obesity in sub-Saharan Africa”; “type 2 diabetes mellitus in sub-Saharan Africa”; 
“dyslipidaemia in sub-Saharan Africa”; “cardiovascular diseases in Africa”; “metabolic syndrome in 
Africa”; “hypertension in Africa”; “obesity in Africa”; “type 2 diabetes mellitus in Africa”; “dyslipidaemia 
in Africa”; “genes involved in cardiovascular diseases”; “genes involved in metabolic syndrome”; 
“genes involved in hypertension”; “genes involved in obesity”; “genes involved in type 2 diabetes 
mellitus”; “genes involved in dyslipidaemia”; “genes involved in cardiovascular diseases in South 
Africa”; “genes involved in metabolic syndrome in South Africa”; “genes involved in hypertension in 
South Africa”; “genes involved in obesity in South Africa”; “genes involved in type 2 diabetes mellitus 
in South Africa”; “genes involved in dyslipidaemia in South Africa”; “genes involved in cardiovascular 
diseases in sub-Saharan Africa”; “genes involved in metabolic syndrome in sub-Saharan Africa”; 
“genes involved in hypertension in sub-Saharan Africa”; “genes involved in obesity in sub-Saharan 
Africa”; “genes involved in type 2 diabetes mellitus in sub-Saharan Africa”; “genes involved in 
dyslipidaemia in sub-Saharan Africa”; “genes involved in cardiovascular diseases in Africa”; “genes 
involved in metabolic syndrome in Africa”; “genes involved in hypertension in Africa”; “genes involved 
in obesity in Africa”; “genes involved in type 2 diabetes mellitus in Africa”; “genes involved in 
dyslipidaemia in Africa”; “genetics of cardiovascular diseases in South Africa”; “genetics of metabolic 
syndrome in South Africa”; “genetics of hypertension in South Africa”; “genetics of obesity in South 
Africa”; “genetics of type 2 diabetes mellitus in South Africa”; “genetics of dyslipidaemia in South 
Africa”; “genetics of cardiovascular diseases in sub-Saharan Africa”; “genetics of metabolic 
syndrome in sub-Saharan Africa”; “genetics of hypertension in sub-Saharan Africa”; “genetics of 
obesity in sub-Saharan Africa”; “genetics of type 2 diabetes mellitus in sub-Saharan Africa”; “genetics 
of dyslipidaemia in sub-Saharan Africa”; “genetics of cardiovascular diseases in Africa”; “genetics of 
metabolic syndrome in Africa”; “genetics of hypertension in Africa”; “genetics of obesity in Africa”; 
“genetics of type 2 diabetes mellitus in Africa”; “genetics of dyslipidaemia in Africa” 
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2. Methods and materials 
Sections 2.1 – 2.3 were completed before the commencement of this MSc project as part of the 
Cardiovascular Risk in Black South Africans (CRIBSA) Study (PI: Dr Nasheeta Peer). Section 2.4 
onwards were completed for this MSc thesis.  
2.1 Sample cohort and sampling procedure  
The CRIBSA sample cohort consists of 1 116 isiXhosa-speaking Black participants (n=1 116), 
between the ages of 25 and 74 years. Participants were recruited in 2008/09 from predominantly 
Black areas of Cape Town (Khayelitsha, Gugulethu, Crossroads, Nyanga and Langa). A three-stage 
cluster sampling, stratified by area and housing type, was included in the sampling procedure which 
has been described previously (Peer et al., 2014b; Peer et al., 2012). Participants were excluded if 
they were unable to give consent, on tuberculosis treatment or anti-retroviral therapy, bedridden, 
cancer patients who had received treatment within the last year prior to sampling, pregnant or 
lactating mothers, or were resident in Cape Town for less than 3 months. The 2001 census was used 
to calculate prespecified age and gender quotas, ensuring at least 50 participants in each gender 
category.  
2.2 Data collection 
Questionnaires regarding socio-demographic status such as gender, age, level of education, 
employment status, household type and number of occuoants, acces to electricity and water, 
household appliances and mode of transport and relevant medical history, including form of 
treatment (traditional/herbal/western), family history of disease, smoking and alcohol consumption 
status, early deaths in family and personal history of disease, were administered by trained 
fieldworkers. Three BP measurements, using an Omron BP monitor with an appropriately sized cuff, 
were taken at 2-minute intervals after the participant was seated for 5 minutes. The BP measurement 
used in the analysis was the average of the second and third BP measurement.  
Anthropometric measurements were obtained by three trained staff members, of which two were 
nurses. Weight to the nearest 0.5kg was determined using a calibrated digital scale with participants 
barefoot and wearing light clothing. Height to the nearest 0.1cm was measured with a stadiometer. 
Waist and hip circumference to the nearest 0.1cm was measured using a flexible, non-elastic tape 
measure. The smallest circumference between the lower sternum and the umbilicus during 
exhalation while standing was taken as the waist measurement; and the measurement of the 
maximum posterior perturbance of the buttocks was taken as the hip measurement (Alberti et al., 
2006).  
Blood samples were drawn for glucose and lipid estimations following a 10-hour overnight fast. An 
oral glucose tolerance test was then administered, and blood samples were again drawn 2 hours 
later (WHO, 1999).  
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2.3 Definitions used for the diagnosis of diseases in this study 
Cardiovascular disease can occur secondary to other diseases. Having one of these diseases places 
an individual at higher risk of CVD, and each consecutive disease increases the risk of CVD. The 
disease components that increase the risk of CVD, and used in this study, are type 2 diabetes 
mellitus, obesity, hypertension, dyslipidaemia and MetS.  
The definitions of each risk phenotype used in this study to diagnose disease, reported elsewhere 
(Peer et al., 2012), are as follow:  Diabetes was defined using the 1998 WHO criteria of fasting 
glucose >7mmol/l or glucose tolerance >11mmol/l; use of hypoglycaemic medication or diagnosis 
by a doctor or nurse (Table 2.1). Hypertension was defined as an average blood pressure (BP) 
measurement ≥140/90mmHg or the use of antihypertensive agents (Table 2.1). Obesity was defined 
by body mass index (BMI) ≥30kg/m2; waist circumference (WC) ≥94cm for males, ≥80cm for females 
and waist-to-hip ratio >1.0 for males and >0.85 for females (Table 2.1). Dyslipidaemia was defined 
as total cholesterol >5mmol/l; triglycerides >1.5mmol/l, HDL-C <1.2mmol/l; LDL-C >3.0mmol/l and 
HDL-C/total cholesterol <20% (Table 2.1).  
According to WHO (1999) and the IDF’s Joint Interim Statemenst (JIS) (Alberti et al., 2009), 
metabolic syndrome (MetS) is defined as a collection of risk factors of CVD that occur together more 
often than by chance alone. To be diagnosed with MetS, using the JIS criteria, 3 out of the 5 
abnormal findings are required: WC: ≥94cm for males and ≥80cm for females; Triglycerides: 
>1.7mmol/l; HDL-C: <1mmol/l for males and <1.3mmol/l for females; BP: ≥130/85mmHg; and 
Fasting glucose: ≥5.6mmol/l (Table 2.1). 
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Table 2.1 Definitions of risk phenotypes used for the diagnosis of disease in this study (Peer et al., 
2012). 
Diabetes 
Fasting glucose  >7mmol/l 
Glucose tolerance  >11mmol/l 
Obesity 
Body mass index 
Overweight: 25-29,99 kg/m2 
Obese: >30kg/m2 
Waist circumference 
Males: >94cm 
Females: >80cm 
Waist-to-hip ratio 
Males: >1.0 
Females: >0.85 
Hypertension 
Blood pressure >140/90mmHg 
Dyslipidaemia 
Total cholesterol >5mmol/l 
Triglycerides 
Males: <1mmol/l 
Females: <1.3mmol/l 
HDL-C <1.2mmol/l 
LDL-C >3.0mmol/l 
HDL-C/total cholesterol <20% 
Metabolic syndrome 
Waist circumference 
Males: >94cm 
Females: >80cm 
Triglycerides >1.7mmol/l 
HDL-C 
Males: <1mmol/l 
Females: <1.3mmol/l 
Blood pressure >130/85mmHg 
Fasting glucose  >5.6mmol/l 
2.4 DNA extraction   
Whole blood was collected from 1 116 participants in ethylene diamine triacetic acid (EDTA) blood 
collection tubes and separated into individual components (plasma, buffy coat and red blood cells) 
by gradient centrifugation. The buffy coat, containing white blood cells and platelets, was stored at -
80°C for deoxyribonucleic acid (DNA) extraction. In order to obtain a high quantity and quality of 
DNA, the DNA extraction protocol was optimised. This was necessary because the samples were 
stored for many years (~10 years) and underwent many freeze-thaw cycles. There was also a 
definite period of time, over a long weekend in summer, where the freezers were off due to an electric 
outage with no back-up to maintain the temperature of the samples. These are all factors that 
contribute to the degradation of DNA and lead to a low quantity and quality of DNA. 
Deoxyribonucleic acid (DNA) was extracted using the Gentra Puregene blood kit (Qiagen, Hilden, 
Germany) following the manufacturer’s instructions. Briefly, 1.5ml red blood cell (RBC) lysis solution 
was added to 500 μl buffy coat, and this was incubated for 10 minutes (min) at room temperature 
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(RT). Samples were then centrifuged for 5 min at 2 000 x g and the supernatant was subsequently 
discarded. The pellet was resuspended in the residual liquid by vortex-mixing and 3 ml lysis solution 
was added to the re-suspended pellet. After adding 15 μl RNase A to the re-suspended pellet, and 
mixing by inversion, samples were incubated for 10 min at 37 °C and then for 3 min on ice. Following 
the addition of 1 ml protein precipitation solution, samples were centrifuged for 5 min at 2 000 x g. In 
a clean 15 ml centrifuge tube, 3 ml isopropanol was added along with the supernatant from the 
centrifugation step after the addition of protein precipitation solution and mixed by inversion. Samples 
were then centrifuged at 2 000 x g for 3 min, the supernatant discarded, and the pellet drained. The 
pellet was then washed with 3 ml 70% ethanol (EtOh) and centrifuged for 1 min at 2 000 x g. The 
pellet was then allowed to air dry at RT. The samples were then rehydrated with 150 μl DNA 
hydration solution and incubated at 65 °C for one hour followed by an overnight incubation at RT 
with shaking. DNA quality was assessed using the NanoDrop 2000c spectrophotometer (Thermo 
Scientific, Delaware, USA) using the NanoDrop 2000/2000c software (version 1.5). Values between 
1.8-2.0 nm for the 260/280 ratio and 2.0-2.2 nm for the 260/230 ratio were deemed suitable.  
2.4.1 Optimization of the DNA extraction protocol 
After attempting the DNA extraction following the manufacturer’s instructions and obtaining a low 
DNA yield and poor 260/280 ratios, the extraction was attempted using twice the amount of buffy 
coat (500 μl) as specified by the manufacturer’s instructions. The extraction of another batch of 
samples was attempted using twice the volume of reagents (3 ml RBC lysis solution, 6 ml cell lysis 
solution, 30 μl RNase A, 2 ml protein precipitation solution, 6ml isopropanol, 6ml 70% EtOH) to 
determine if increasing the amount of buffy coat required more reagents, but did not change the 
volume of DNA hydration solution (150 μl) and compared the results to when following the 
manufacturer’s instructions. A low DNA yield was still obtained, and the DNA extraction was then 
attempted using 500 μl buffy coat and half the stipulated volume of reagents (750 μl RBC lysis 
solution, 1.5 ml cell lysis solution, 7.5 μl RNase A, 500 μl protein precipitation solution, 1.5 ml 
isopropanol, 1.5 ml 70% ethanol and 100 μl DNA hydration solution), optimising the extraction 
protocol.  
The optimised protocol thus used 500 μl of buffy coat with 750 μl RBC lysis solution, 1.5 ml cell lysis 
solution, 7.5 μl RNase A, 500 μl protein precipitation solution, 1.5 ml isopropanol, 1.5 ml 70% ethanol 
and 100 μl DNA hydration solution. Following optimization of the protocol, DNA was extracted using 
half the amounts of reagent as described above and DNA quality was assessed using the NanoDrop 
2000c spectrophotometer (Thermo Scientific, Delaware, USA) using the NanoDrop 2000/2000c 
software (version 1.5). Values between 1.8-2.0 for the 260/280 ratio and 2.0-2.2 for the 260/230 ratio 
were deemed suitable for DNA purity.  
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2.4.2 DNA dilution 
DNA samples with a concentration greater than 100 ng/μl were diluted to 50 ng/μl in dH2O for 
downstream analyses. DNA quality of the dilutions was assessed using the Nanodrop 2000c 
spectrophotometer (Thermo Scientific, Delaware, USA) using the Nanodrop 2000/2000c software 
(version 1.5). Values between 1.8-2.0 for the 260/280 ratio and 2.0-2.2 for the 260/230 ratio were 
deemed suitable.  
2.4.3 Gel electrophoresis 
All DNA samples were electrophoresed on an agarose gel to assess DNA quality. Prior to gel 
electrophoresis, ~5 μl DNA samples were mixed with cresol and together with a 50 bp Kapa 
Universal DNA Ladder (Kapa Biosystems, Western Cape, South Africa) were electrophoresed on a 
1% agarose gel (Addendum A) at 160 V, for approximately 1 hour in 1x sodium borate (SB) buffer 
(Addendum A). DNA visualization was aided by ethidium bromide (EtBr) using the G box (Syngene, 
Maryland, USA) with GeneSnap Syngene software (version 7.12.06). 
2.5 PCR genotyping of ACE  
The ACE insertion/deletion (I/D) polymorphism (rs4646994) was amplified using the primers used 
by Youssof et al. (2009) (Table 2.2) (Integrated DNA technologies, Iowa, USA). The region of interest 
was amplified using the polymerase chain reaction (PCR) in a final volume of 25 μl (1 x dyed Kapa 
Taq Ready Mix PCR Kit, 10 μM of each primer and 50 ng/μl genomic DNA). The PCR was performed 
in a 2720 Thermal Cycler PCR machine (Applied Biosystems, California). The optimised conditions 
of the PCR were an initial denaturation step, 35 cycles of denaturation, annealing and extension, 
followed by a final extension and cooling (Table 2.2). Optimization of the annealing step was required 
as non-specific binding was observed. 
Table 2.2 Primer sequence and PCR cycling conditions used for the genotyping of the ACE 
rs4646994 I/D polymorphism (Youssof et al., 2009). 
ACE primers 
 Primer sequence Tm (°C) GC content (%) 
Forward primer  5' - CTG GAG ACC ACT CCC ATC CTT TCT - 3' 60.0 54.2 
Reverse primer 5; - GAT GTG GCC ATC ACA TTC GTC AGA T - 3' 59.2 48.0 
PCR cycling conditions 
Step Temp (°C) Time (min) Cycles 
Initial 
denaturation 
95 5 
 
Denaturation 95 1 
35 Annealing 60 1 
Extension 72 2 
Final extension 72 10 
 
Hold 4 ꝏ 
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2.5.1 Gel electrophoresis of ACE 
All PCR products and a 50 bp Kapa Universal DNA Ladder (Kapa Biosystems, Western Cape, 
South Africa) were electrophoresed on a 1% agarose gel (Addendum A) at 160V for approximately 
1 hour in 1 x sodium borate (SB) buffer (Addendum A). PCR product visualization was aided by 
ethidium bromide (EtBr) using the G box (Syngene, Maryland, USA) with GeneSnap Syngene 
software (version 7.12.06). 
2.6 KASP genotyping 
Samples with a concentration ≥20 ng/μl were diluted to 5-20 ng/μl for genotyping by Kompetitive 
Allele-Specific PCR (KASP) genotyping at LGC Genomics (Hertfordshire, United Kingdom). The 
DNA sequences (Table 2.3) flanking the SNPs of interest were sent to LGC Genomics and the 
primers were designed in-house.  
Table 2.3 DNA sequences flanking the SNPs of interest for KASP genotyping. 
Gene SNP SNP sequence 
ACE I/D CCCATCCTTTCTCCCATTTCTCTAGACCTGCTGCCTATACAGTCACTTTT[TT
TTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCCAGGCTGGAGTGCAG/-
]TTTTATGTGGTTTCGCCAATTTTATTCCAG CTCTGAAATTCTCTGAGCTC 
AGT rs699 TGACAGGTTCATGCAGGCTGTGACAGGATGGAAGACTGGCTGCTCCCTGA
C/TGGGAGCCAGTGTGGACAGCACCCTGGCTTTCAACACCTACGTCCACTT 
AT1R rs5186 AAGAAGGAGCAAGAGAACATTCCTCTGCAGCACTTCACTACCAAATGAGCA/
CTTAGCTACTTTTCAGAATTGAAGGAGAAAATGCATTATGTGGACTGAACC 
MC4R rs1782313 CTTTAATGACTACAACATTATAGAAGTTTAAAGCAGGAGAGATTGTATCCC/T
GATGGAAATGACAAGAAAAGCTTCAGGGGGAAGGTGACATTTAAGTTGG 
rs12970134 CAGACATTTTTTCGTTAATAATTCATCCTTTCGTACTCATTAATCCTTACA/GT
ATATCTTACATAATTTCAGTGTTTCTGGGTTGCCTATTCTGTTCTATGC 
rs2229616 GCAGCTCTAAATGCACAGTCCAGAGTCATCCTTACCTGCCTTCTGCCACCA/
GCCGACCCCAGGCTATATTTTGAGTAGGATGGGACCTGAGAAGGCTTGCC 
FTO rs17817499 CCACTACTTTACAAATATTACTCAATAAATATCAGTTTAATTAAGTTGGGA/TT
TTTTCTTATTATTTTAGTAACTTTGGATTCTAAATGTGCTTCTGGGTAT 
TCF7L2 rs7903146 ACCTAGCACAGCTGTTATTTACTGAACAATTAGAGAGCTAAGCACTTTTTAG
ATAC/TTATATAATTTAATTGCCGTATGAGGCACCCTTAGTTTTCAGACGAGA 
TNFα rs1800629 CAGAGAAGGGAAGCAGTTTGAGAAAAAAAATGGGAATCCAAAGTACAAGAA/
GGGGGCCCTGTTACAGTGGCCAGGATAGAGGGAATGTCTCTTCCAGAA 
DNA sequences in red represent the base change of the SNP. rs180692 and rs4646994 was excluded from the analysis 
as reproducible results were not obtained. ACE – Angiotensin-converting enzyme; AGT – Angiotensinogen; AT1R – Angiotensin II 
type I receptor; MC4R – Melanocortin 4 receptor; FTO – fat-mass and obesity associated; TCF7L2 – Transcription factor 7-like 2; TNFα 
– Tumour necrosis factor-alpha. 
KASP is a homogenous, fluorescence-based assay which enables the bi-allelic discrimination of 
known DNA sequence variants by making use of allele-specific fluorescence labelled primers. The 
KASP assay mix contains two allele-specific forward primers and one common reverse primer. Each 
allele-specific primer contains either a FAM dye labelled tail sequence, or a HEX dye labelled tail 
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sequence, which corresponds to a universal fluorescence resonance energy transfer (FRET) 
cassette. During the PCR amplification, the relevant allele-specific primer binds the template DNA 
and elongates adding the dye labelled tail sequence to the newly synthesized strand. As the 
compliment of this dye labelled tail sequence is generated, the FRET cassette is then able to bind 
to the DNA, enabling the fluorescence emission. One fluorescent signal indicates homozygosity for 
a specific SNP while heterozygosity generates a mixed fluorescence signal (Figure 2.1).  
 
Figure 2.1 KASP genotyping is based on the competitive binding of allele-specific primers and 
FRET to discriminate between known SNPs (He et al., 2014). 
2.7 Statistical analysis 
Various definitions are used for the diagnosis of disease as there is no “gold standard” for diagnosis, 
and as such, this study looked at the most common definitions used.  
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Data analysis was performed using R statistical software (v3.5.1). Demographic and clinical 
characteristics were summarised as mean and standard deviation if approximately normally 
distributed, and as medians and interquartile ranges (IQRs) if unevenly distributed. Genotype counts 
(%) and Hardy-Weinberg equilibrium (HWE) p-values were summarised separately for each of the 
CVD risk phenotypes (Type 2 diabetes mellitus, obesity, hypertension, dyslipidaemia and metabolic 
syndrome) under investigation (Table 2.1).  
General linear modelling (GLM) was used to express the risk phenotype as a function of genotype, 
under the log-additive allelic model, adjusting for possible confounders. For association testing, the 
confounders were age and gender, and these were included in the GLM. Alleles were coded as the 
number of minor alleles (0, 1, 2) and each haplotype was similarly coded as number present. 
Haplotypes were only inferred in the blocks constructed using the solid spine of linkage 
disequilibrium (LD) method, implemented in Haploview software (v4.2) and were investigated under 
log-additive models only.  
We used multiplicative (log-additive) genetic inheritance as an initial “screening” mechanism to 
identify signals that were worth pursuing in other genetic models (namely the dominant and recessive 
inheritance models). This is because the multiplicative model uses chromosomes (alleles) as the 
unit of analysis, and thus increases the power for detecting significant association that may be 
missed in other genetic modelling. Here, genotypes were coded as 3 categories (2 degrees of 
freedom). 
Linear regression analysis was used to express the risk phenotype as a function of its measurements 
to determine continuous risk, adjusting for the possible confounding effects of gender and age. 
Alleles were coded as the number of minor alleles (0, 1, 2). 
All modelling was done separately for the various CVD risk phenotypes described. When significant 
effects were detected using a multiplicative (log-additive) model, (<0.05), further investigation in 
other genetic models was performed. A trend towards significance (p=0.05-0.075) was used in the 
initial screening (log-additive model) of association. 
Effects corresponding to p-values below 0.05 were described as significant, except for the HWE 
tests, where 0.01 was the critical p-value. All analyses were done using R and functions from R 
packages, SNPassoc and haplo.stats. 
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Results  
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3. Results 
3.1 Protocol optimization 
3.1.1 DNA extraction protocol 
Following the manufacturer’s protocol for the extraction of DNA using the Gentra Puregene blood 
kit, low yields and quality of DNA was obtained. The extraction was then attempted using the 
double the amount of buffy coat and reagents, but low yields and quality was still obtained. 
The protocol was thus optimised using double the amount of buffy coat (500 μl) with half the 
amount of reagents stipulated (750 μl RBC lysis solution, 1.5 ml cell lysis solution, 7.5 μl RNase A, 
500 μl protein precipitation solution, 1.5 ml isopropanol, 1.5 ml 70% ethanol and 100 μl DNA 
hydration solution). DNA quantity and quality were assessed using the NanoDrop 2000 
spectrophotometer.  Although not degraded (Figure 3.1), many of the DNA samples were not pure 
as they did not meet the values of 1.8-2.0 for the 260/280 ratio or 2.0-2.2 for the 260/263 ratio 
indicating protein and RNA contamination.  
 
Figure 3.1 DNA quality was assessed using agerose gel electrophoresis to determine if sample 
degradation had occurred. 
3.1.2 PCR amplification protocol 
The ACE rs4646994 I/D polymorphism was PCR amplified using the protocol and primers used by 
Youssof et al. (2009) (Table 2.2). The PCR amplification was first attempted with an annealing 
temperature of 58°C, but non-specific binding was observed (Figure 3.2 A). The annealing 
temperature was thus increased to 60°C, overcoming the non-specific binding (Figure 3.2 B), and 
this temperature was used throughout.  
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A.  B.  
Figure 3.2 Optimization of the PCR protocol annealing temperature to overcome the observed 
non-specific binding. (A) annealing at 58°C with non-specific binding observed (lanes 4010, 5182 
and the positive control); (B) annealing at 60°C where the non-specific binding has been overcome 
(lane 4010_dil1). 
3.2 Genotyping cohort 
Five hundred and eighty-five DNA samples were available for KASP genotyping (n=194 (33.2%) 
male; n=391 (66.8%) female). The median age was 43 years (IQR: 23 years – 53 years) (Figure 
3.3). 
 
Figure 3.3 Median age (IQR) of males and females in the KASP-genotyped cohort.  
3.3 Sample characteristics 
3.3.1  CVD risk phenotypes according to age 
Older individuals were found to exhibit significantly more risk phenotypes associated with CVD than 
younger individuals (Table 3.1). This was true for all diseases, except for the presence of 
dyslipidaemia which was not statistically different between younger and older individuals.  
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Table 3.1 The association of age with risk phenotypes. 
Disease definition <25 25-34 35-44 45-54 55-64 >65 p-value 
Overall T2DM 0 7 31 16 11 0 3.038x10-10 
T2DM by fasting 
glucose 
0 6 27 13 8 0 
6.432x10-12 
T2DM by glucose 
tolerance 
0 5 25 11 8 0 
5.646x10-7 
Overall obesity 1 108 196 60 31 1 1.709x10-6 
Obesity by BMI 1 77 145 37 21 1 0.00077 
Obesity by waist 
circumference 
1 107 193 57 29 2 
8.665x10-5 
Obesity by waist-to-
hip ratio 
0 44 106 36 17 1 
1.157x10-7 
Hypertension 0 6 55 32 12 1 2.224x10-15 
Overall dyslipidaemia 3 176 227 80 35 3 0.508 
Dyslipidaemia by total 
cholesterol 
1 29 73 40 16 1 
2.927x10-10 
Dyslipidaemia by 
triglycerides 
0 15 44 15 13 0 
2.470x10-7 
Dyslipidaemia by 
HDL-C 
2 144 174 52 20 2 
0.0019 
Dyslipidaemia by 
LDL-C 
1 75 125 57 22 2 
2.698x10-7 
Dyslipidaemia by 
HDL-C/total 
cholesterol 
0 47 55 24 8 0 
0.038 
Metabolic syndrome 0 14 91 33 15 0 <2.2x10-16 
3.3.2 CVD risk phenotypes according to gender  
Females were found to be more obese than males, with higher BMI (p<2.2x10-16), WC (p=2.2x10-16) 
and waist-to-hip ratio (p=9.11x10-6) (Table 3.2). The overall prevalence of obesity was 68.72%, with 
23.71% of all males and 91.05% of all females classified as being obese (p<2.2x10-16) according to 
BMI, WC and/or waist-to-hip ratio (Figure 3.4 and Table 3.3). The prevalence of obesity in males 
and females by BMI, WC and waist-to-hip ratio, respectively, was 10.82% and 66.75% (p<2.2x10-
16); 20.62% and 89.26% (p<2.2x10-16); and 8.25% and 48.08% (p<2.2x10-16) (Table 3.3).  
The overall prevalence of T2DM was 11.79% (n=69), with 8.25% male (n=16) and 13.55% female 
(n=53) (p=0.082) according to fasting glucose (>7 mmol/l) and glucose tolerance (<11 mmol/l) values 
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(Figure 3.4 and Table 3.3). The prevalence of T2DM by fasting glucose and 2h glucose tolerance 
respectively was 6.19% in males (n=12) and 9.72% in females (n=38) (p=0.331), and 4.12% in males 
(n=8) and 10.23% in females (n=40) (p=0.015), respectively (Table 3.3). In total, 49.28% (n=34) of 
the participants (25% of males (n=4) and 56.60% of females (n=30)) with T2DM by fasting glucose 
(<7 mmol/l) and/or glucose tolerance (<11 mmol/l) were on insulin treatment. Fasting glucose levels 
and glucose tolerance were similar in males and females (p=0.651 and p=0.053, respectively) (Table 
3.2). 
Table 3.2 The median and IQRs of CVD risk factors by gender in the total sample genotyped 
(n=585).  
 Males (n=194) Females (n=391) Total (n=585) p-value 
Anthropometry 
BMI 22.17  
(19.92-38.58) 
33.04 (27.92-
38.58) 
29.52 
(23.21-35.57) 
<2.20X10-16 
Waist 
circumference 
80.5  
(74.63-91.5) 
97.65  
(88.13-108.23) 
92.5  
(80.93-105.0) 
<2.20X10-16 
Waist-to-hip ratio 0.87 (0.83-0.94) 0.85 (0.8-0.9) 0.86 (0.81-0.91) 9.108X10-6 
Blood pressure 
Systolic 127 (115-140) 118 (107-132) 121 (110-136) 1.722x10-6 
Diastolic 80 (73-90) 80 (72-89) 80 (72-89) 0.651 
Glucose 
Fasting glucose 4.9 (4.5-5.3) 4.8 (4.3-5.4) 4.9 (4.4-5.4) 0.651 
Glucose tolerance 5.9 (4.6-7.3) 6.0 (4.9-7.85) 5.9 (4.8-7.5) 0.053 
Lipid profile 
Total cholesterol 4.28 (3.52-5.02) 4.37 (3.69-5.12) 4.34 (3.64-5.04) 0.214 
Triglycerides 0.96 (0.71-1.3) 0.98 (0.72-1.29) 0.97 (0.71-1.29) 0.930 
HDL-C 1.45 (0.93-1.41) 1.04 (0.87-1.27) 1.06 (0.89-1.32) 0.0018 
LDL-C 2.81 (2.2-3.43) 3.06 (2.47-3.74) 2.97 (2.38-3.66) 0.0011 
HDL-C/Total 
cholesterol ratio 
26.89 
(21.98-34.99) 
24.26 
(19.98-29.14) 
25.1  
(20.69-30.42) 
1.208X10-5 
BMI – Body mass index; HDL-C – High-density lipoprotein cholesterol; LDL-C – Low-density lipoprotein cholesterol. 
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Figure 3.4 Prevalence of CVD risk phenotypes according to gender in the KASP-genotyped 
cohort.                                                                    
Percentage refers to number of affected individuals per total sample (n=585), per total number of males (n=194) and per 
total number of females (n=391) in the KASP genotyped samples.   
Diabetes: fasting glucose >7mmol/l, glucose tolerance >11mmol/l; Hypertension: BP ≥140/90mmHg; Dyslipidaemia: total 
cholesterol >5mmol/l, triglycerides >1.5mmol/l, HDL-C <1.2mmol/l, LDL-C >3.0mmol/l, HDL-C/total cholesterol ratio <20%; 
Obesity: BMI ≥30kg/m2, waist circumference males ≥94cm, females ≥80cm, waist-to-hip ratio males >1, females >0.85.  
Systolic BP was higher in males (p=1.72x10-6), but diastolic BP was similar in males and females 
(p=0.651) (Table 3.2). The overall prevalence of hypertension was 18.29% (n=107), with 22.17% of 
those being male (n=43) and 16.37% female (n=64) (0.111) (Figure 3.4 and Table 3.3). Of those 
with raised BP, 13.95% of males (n=6) and 46.88% of females (n=30) were on antihypertensive 
medication.   
Total cholesterol and triglyceride levels (p=0.214 and p= 0.930, respectively) were similar in males 
and females (Table 3.2). HDL-C, LDL-C and HDL-C/total cholesterol levels were found to be higher 
in males than females (p=0.0018, p=0.0011, and p=1.21x10-5, respectively) (Table 3.2). The overall 
prevalence of dyslipidaemia was 86.84% (n=508), with 80.93% of all males (n=157) and 89.77% of 
all females (n=351) having lipid abnormalities (p=0.0044) (Figure 3.4 and Table 3.3). The prevalence 
of dyslipidaemia by raised TC (>5 mmol/l) was 24.74% (n=48) in males and 27.62% (n=108) in 
females (p=0.487) (Table 3.3). The prevalence of raised triglycerides (>1.5 mmol/l) was 17.53% 
(n=34) in males and 14.32% (n=56) in females (p=0.395) (Table 3.3). The prevalence of decreased 
HDL-C levels (<1.2 mmol/l) in males was 59.28% (n=115) and 68.29% (n=267) in females (p=0.028) 
(Table 3.3). The prevalence of raised LDL-C levels (<3 mmol/l) was 41.75% (n=81) in males and 
51.15% (n=200) in females (p=0.027) (Table 3.3). The prevalence of decreased HDL-C/total 
cholesterol (<20%) was 14.95% (n=29) in males and 24.81% (n=97) in females (0.0076) (Table 3.3). 
Overall, the majority of females were obese, type 2 diabetic and had abnormal lipid profiles. All 
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medians and IQRs of CVD risk factors (Table 3.2) is graphically represented in Addendum B (Figure 
B1-12). 
Table 3.3 Counts and percentage of affected males and females for the measures of CVD risk 
factors (n=585). 
 
Males (n=194) 
n (%) 
Females (n=391) 
n (%) 
Total sample 
(n=585) 
n (%) 
p-value 
Obesity 
Obese 46 (23.71) 356 (91.05) 402 (68.72) <2.20x10-16 
BMI 21 (10.82) 261 (66.75) 282 (48.21) <2.20x10-16 
Waist 
circumference 
40 (20.62) 349 (89.26) 
389 (66.5) 
<2.20x10-16 
Waist-to-Hip ratio 16 (8.25) 188 (48.08) 204 (34.87) <2.20x10-16 
Type 2 diabetes mellitus 
Diabetic 16 (8.25) 53 (13.55) 69 (11.79) 0.082 
Fasting glucose 12 (6.19) 38 (9.72) 50 (8.55) 0.331 
Glucose tolerance 8 (4.12) 40 (10.23) 48 (8.21) 0.015 
Hypertension 
Blood pressure 43 (22.17) 64 (16.37) 107 (18.29) 0.111 
Dyslipidaemia 
Dyslipidaemic 157 (80.93) 351 (89.77) 508 (86.84) 0.0044 
Total cholesterol 48 (24.74) 108 (27.62) 156 (26.67)  0.487 
Triglycerides 34 (17.53) 56 (14.32) 90 (15.38) 0.395 
HDL-C 115 (59.28) 267 (68.29) 382 (65.3) 0.028 
LDL-C 81 (41.74) 200 (51.15) 281 (48.03) 0.028 
HDL-C/Total 
cholesterol ratio 
29 (14.95) 97 (24.81) 126 (21.54) 0.0076 
BMI – Body mass index; HDL-C – High-density lipoprotein cholesterol; LDL-C – Low-density lipoprotein cholesterol.                          
Percentage refers to number of affected individuals per total sample (n=585), per total number of males (n=194) and per 
total number of females (n=391) in the KASP genotyped samples.          
Diabetes: fasting glucose >7mmol/l, glucose tolerance >11mmol/l; Dyslipidaemia: total cholesterol >5mmol/l, triglycerides 
>1.5mmol/l, HDL-C <1.2mmol/l, LDL-C >3mmol/l, HDL-C/total cholesterol ratio <20%; ; Hypertension: BP ≥140/90mmHg; 
Obesity: BMI ≥30kg/m2, waist circumference males ≥94cm, females ≥80cm, waist-to-hip ratio males >1, females >0.85. 
One hundred and fifty-four were diagnosed as having MetS by the JIS criteria (Alberti et al., 2009). 
The overall prevalence of MetS was 26.32% (n=154), with 14.95% of males (n=29) and 31.71% of 
females (n=125) being diagnosed (p=1.698x10-5) (Figure 3.5 and Table 3.4).  
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Figure 3.5 Prevalence of MetS, as defined by the JIS, by number of components in affected males 
and females.                                                                                                                                                                     
MetS calculated per total sample (n=585), number of componets calculated per number of affected individuals in total 
(n=154), number of affected males (n=29) and affected females (n=125)                              
Blood pressure (BP): ≥130/85mmHg; Fasting glucose: ≥5.6mmol/l; High-density lipoprotein cholesterol (HDL-C): males 
<1.0mmol/l, females <1.3mmol/l; Triglycerides: >1.7mmol/l; Waist circumference (WC): males >94cm, females >80cm. 
The prevalence of raised BP (82.76% (n=24) males vs. 63.20% (n=79) females, p=0.0891) and 
triglyceride levels (65.52% (n=19) males vs. 25.60% (n=32) females, p= 4.79x10-5) was highest 
among affected males than affected females (Figure 3.6 and Table 3.4). The prevalence of increased 
fasting glucose (62.40% (n=78) females vs. 55.17% (n=16) males, p=0.5152), WC (100.00% (n=125) 
females vs. 72.41% (n=21) males, p=1.767x10-7) and HDL-C levels (91.20% (n=114) females vs. 
68.97% (n=20) males, p=0.0027) was higher in affected females than in affected males (Figure 3.6 
and Table 3.4). 
Table 3.4 Counts and percentage of affected males and females for the measures of MetS in the 
KASP genotyped samples. 
 Males Females Total sample p-value 
MetS 29 (14.95) 125 (31.71) 154 (26.32) 1.698x10-5 
Waist 
circumference 
21 (72.41) 125 (100.00) 146 (94.81) 1.767x10-7 
Fasting glucose 16 (55.17) 78 (62.40) 94 (61.04) 0.5152 
Blood pressure 24 (82.76) 79 (63.20) 103 (66.88) 0.0891 
Triglycerides 19 (65.52) 32 (25.60) 51 (33.12) 4.79x10-5 
HDL-C 20 (68.97) 114 (91.20) 134 (87.01) 0.0027 
BP: ≥130/85mmHg; Fasting glucose: ≥5.6mmol/l; HDL-C: males <1mmol/l, females <1.3mmol/l; MetS: Diagnosis by JIS 
criteria; Triglycerides: >1.7mmol/l; Waist circumference: males ≥94cm, females ≥80cm. 
Overall, an obese WC (males ≥94 cm; females ≥80 cm) (94.81%, n=146) was the component most 
prevalent among individuals with MetS, with all affected females meeting this criterion. However, in 
affected males, BP (≥130/85 mmHg) (82.76%, n=24) was the most prevalent component (Figure 3.6 
0
5
10
15
20
25
30
35
MetS 3/5 4/5 5/5
Pr
ev
al
en
ce
 (%
) o
f M
et
S 
(d
ef
in
ed
 b
y 
th
e 
JI
S 
cr
ite
ria
)
Number of MetS components (defined by the JIS criteria) for diagnosis
Men
Women
Total
Stellenbosch University  https://scholar.sun.ac.za
71 
 
and Table 3.4). Decreased HDL-C (males <1 mmol/l; females <1.3 mmol/l) was the second most 
common criterion met by all individuals with MetS (87.01%, n=134) and by affected females (91.20%, 
n=114), while in affected males the second most common criterion met was an obese WC (72.43%, 
n=21) (Figure 3.6 and Table 3.4). Raised triglycerides (>1.7 mmol/l) was the least common among 
all affected individuals (33.12%, n=51) and affected females (25.60%, n=32), while in affected males 
fasting glucose (≥5.6 mmol/l) was the least common criterion met (55.17%, n=16) (Figure 3.6 and 
Table 3.4). 
 
 
Figure 3.6 Prevalence of MetS components by gender among affected individuals.                                        
Blood pressure (BP): ≥130/85mmHg; Fasting glucose: ≥5.6mmol/l; High-density lipoprotein cholesterol (HDL-C): males 
<1.0mmol/l, females <1.3mmol/l; Triglycerides: >1.7mmol/l; Waist circumference (WC): males >94cm, females >80cm. 
3.4 Genotype distributions 
3.4.1 PCR genotyping  
Three hundred and thirty-four samples were genotyped for the ACE I/D variation using PCR 
amplification (Figure 3.7). One hundred and fifty-six (156) (46.71%) were homozygous for the D 
allele (DD genotype) (represented by lanes 1089 and 1097 at 190bp in Figure 3.7), 31 (9.28%) were 
homozygous for the I allele (II genotype) (represented by lanes 1094 and 1100 at 490bp in Figure 
3.5) and 147 (44.01%) were heterozygous (ID genotype) (represented by lanes 1088, 1090, 1092, 
1101, 1102 and 1105 in Figure 3.7). 
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Figure 3.7 A representative image of the gel electrophoresis following PCR amplification of the 
ACE rs4646994 I/D polymorphism.  
3.4.2 KASP genotyping 
3.4.2.1 Hardy-Weinberg equilibrium 
All SNPs were in Hardy-Weinberg equilibrium for cases and controls (p>0.05), except rs17817499 
and it was thus excluded from further analysis. 
3.4.2.2 Genotype frequencies 
The following genes were genotyped using the KASP method:  
Fat-mass and obesity associated (FTO) gene 
Transcription factor 7-like 2 (TCF7L2) 
Melanocortin 4 receptor (MC4R) 
Angiotensinogen (AGT) 
Angiotensin II type I receptor (AT1R).  
Genotype frequencies of each SNP can be found in the table below (Table 3.5). The genotype 
distributions are also graphically represented in Addendum C (Figure C1-7). 
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Table 3.5 Genotype distributions of samples genotyped using KASP technology. 
TCF7L2 
rs7903146 
T/C 260 
(45.90%) 
C/C 243 
(42.19%) 
T/T 64 (11.30%) 
MC4R 
rs229616 
G/G 326 
(56.79%) 
G/A 209 
(36.41%) 
A/A 39 (6.79%) 
rs17782313 
T/T 304 
(52.69%) 
T/C 232 
(40.21%) 
C/C 41 (7.11%) 
rs1297034 
G/G 463 
(80.94%) 
G/A 102 
(17.83%) 
A/A 7 (1.22%) 
AGT 
rs699 
C/C  496 
(86.26%) 
C/T 76 (13.22%) 
T/T 3 (0.52%) 
AT1R 
rs5186 
A/A 562 
(99.47%) 
C/A 3 (0.3%) 
C/C 0 
AGT – Angiotensinogen; AT1R – Angiotensin II type I receptor; FTO – Fat-mass and obesity associated; MC4R – 
Melanocortin 4 receptor; TCF7L2 – Transcription factor 7-like 2. 
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3.4.3 Genotype distributions by disease under a log-additive model 
An additive model was used to determine if any of the SNPs were associated with any of the CVD 
risk variables in this study. 
3.4.3.1 Type 2 diabetes mellitus 
No SNPs were associated with overall T2DM diagnosis by fasting glucose (>7 mmol/l) and/or 
glucose tolerance (>11 mmol/l) under an additive model adjusted for gender and age (Table 3.6).  
Table 3.6 Genotype distributions and frequencies of all SNPs in controls and T2DM cases by 
fasting glucose and/or glucose tolerance under a log-additive inheritance model, adjusted for 
gender and age. 
Gene SNP Genotype Controls Cases OR 95% CI p-value 
ACE rs4646994 
D/D 136 (45.6) 20 (55.6) 
0.87 
0.49-
1.54 
0.633 I/D 135 (45.3) 12 (33.3) 
I/I 27 (9.1) 4 (11.1) 
TCF7L2 rs7903146 
T/T 209 (41.7) 34 (51.5) 
0.69 
0.45-
1.07 
0.092 T/C 232 (46.3) 28 (42.4) 
C/C 60 (12.0) 4 (6.1) 
MC4R 
rs229616 
G/G 282 (55.7) 44 (64.7) 
0.80 
0.51-
1.26 
0.331 G/A 189 (37.4) 20 (29.4) 
A/A 35 (6.9) 4 (5.9) 
rs17782313 
T/T 273 (53.7) 31 (44.9) 
1.29 
0.85-
1.95 
0.238 T/C 200 (39.4) 32 (46.4) 
C/C 35 (6.9) 6 (8.7) 
rs1297034 
G/G 407 (80.9) 56 (81.2) 
0.92 
0.50-
1.72 
0.8 G/A 89 (17.7) 13 (18.8) 
A/A 7 (1.4) 0 
AGT rs699 
C/C 437 (86.0) 59 (88.1) 
0.81 
0.38-
1.73 
0.577 C/T 68 (13.4) 8 (11.9) 
T/T 3 (0.6) 0 
AT1R rs5186 
A/A 496 (99.4) 66 (100.0) 
- - - C/A 3 (0.6) 0 
C/C 0 0 
T2DM diagnosis by fasting glucose (>7mmol/l) and/or glucose tolerance (>11 mmol/l).                                                                             
ACE – Angiotensin-converting enzyme; AGT – Angiotensinogen; AT1R – Angiotensin II type I receptor; MC4R – 
Melanocortin 4 receptor; TCF7L2 – Transcription factor 7-like 2. 
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High-risk and diabetic individuals were first separated and then combined as cases for genetic 
analysis to determine if any SNP is involved in disease predisposition and/or on disease diagnosis. 
Under a log-additive genetic model, adjusted for gender and age, rs17782313 (C/C genotype) of 
MC4R was significantly associated with T2DM (assessed using fasting glucose levels) when 
controls, high-risk (5.6-7 mmol/l) and diabetic (>7 mmol/l) individuals were investigated (p=0.043) 
(Table 3.7). 
Table 3.7 Genotype distributions and frequencies of all SNPs in controls, high-risk and T2DM 
cases by fasting glucose levels under a log-additive inheritance model, adjusted for gender and 
age. 
Gene SNP Genotype Controls High-risk Cases Diff 95% CI p-value 
ACE rs4646994 
D/D 119 (44.4) 24 (63.2) 13 (46.4) 
-0.023 -0.121-0.075 0.649 I/D 124 (46.3) 31 (31.6) 11 (39.1) 
I/I 25 (9.3) 2 (5.6) 4 (14.3) 
TCF7L2 rs7903146 
T/T 191 (42.9) 25 (35.7) 27 (56.2) 
-0.036 -0.11-0.037 0.335 T/C 203 (45.6) 38 (54.3) 18 (37.5) 
C/C 51 (11.5) 7 (10.0) 3 (6.2) 
MC4R 
rs229616 
G/G 249 (55.3) 42 (60.0) 32 (65.3) 
-0.197 -0.099-0.058 0.61 G/A 173 (38.4) 21 (30.0) 13 (26.5) 
A/A 26 (6.2) 7 (10.0) 4 (8.2) 
rs17782313 
T/T 250 (55.3) 30 (42.9) 23 (46.0) 
0.081 0.003-0.16 0.043 T/C 175 (38.7) 33 (47.1) 22 (44.0) 
C/C 27 (6.0) 7 (10.0) 5 (10.0) 
rs1297034 
G/G 357 (79.9) 61 (87.1) 42 (84.0) -0.089 -0.203-0.025 0.126 G/A 83 (18.6) 9 (12.9) 8 (16) 
A/A 7 (1.6) 0 0 
AGT rs699 
C/C 388 (85.8) 61 (88.4) 42 (85.7) -0.029 -0.162-0.103 0.666 C/T 61 (13.5) 8 (11.6) 7 (14.3) 
T/T 3 (0.7) 0 0 
AT1R rs5186 
A/A 441 (99.5) 68 (98.6) 
48 
(100.0) -0.057 -0.729-0.614 - C/A 2 (0.5) 1 (1.4) 0 
C/C 0 0 0 
The difference instead of an OR is reported as the analysis was performed with quantitative 
variables (3 categories) and not dichotomous variables.                                                                                                           
T2DM diagnosis by fasting glucose (>7mmol/l; High-risk: 5.6-7 mmol/l).                                                                                                      
ACE – Angiotensin-converting enzyme; AGT – Angiotensinogen; AT1R – Angiotensin II type I receptor; MC4R – 
Melanocortin 4 receptor; TCF7L2 – Transcription factor 7-like 2 
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Under a log-additive inheritance model, adjusted for gender and age, rs17782313 (CC genotype) 
of MC4R was significantly associated with T2DM by fasting glucose when high-risk (5.6-7 mmol/l) 
and diabetic (>7 mmol/l) individuals were combined to represent cases (OR=1.48, 95%CI=1.06-
2.06, p=0.022) (Table 3.8). The rs1297034 SNP of MC4R was also nominally associated with 
T2DM by fasting glucose when high-risk (5.6-7 mmol/l) and diabetic (>7 mmol/l) individuals were 
combined (OR=0.62, 95%CI=0.35-1.07, p=0.072) (Table 3.8). 
Table 3.8 Genotype distributions and frequencies of all SNPs in controls and T2DM cases by 
fasting glucose levels when high-risk and diabetic and individuals are combined (cases) under a 
log-additive inheritance model, adjusted for gender and age.  
Gene SNP Genotype Controls Cases OR 95% CI p-value 
ACE rs4646994 
D/D 119 (44.4) 37 (56.1) 
0.78 
0.50-
1.22 
0.269 I/D 124 (46.3) 23 (34.9) 
I/I 25 (9.3) 6 (9.1) 
 
TCF7L2 
rs7903146 
T/T 191 (42.9) 52 (44.1) 
0.95 
0.68-
1.32 
0.766 T/C 203 (45.6) 56 (47.5) 
C/C 51 (11.5) 10 (8.5) 
MC4R 
rs229616 
G/G 249 (55.3) 74 (62.2) 
0.96 0.68-1.5 0.8 G/A 173 (38.4) 34 (28.6) 
A/A 28 (6.2) 11 (9.2) 
rs17782313 
T/T 250 (55.3) 53 (44.2) 
1.48 
1.06-
2.06 
0.022 T/C 175 (38.7) 55 (45.8) 
C/C 27 (6.0) 12 (10.0) 
rs1297034 
G/G 357 (79.9) 103 (85.8) 
0.62 
0.35-
1.07 
0.072 G/A 83 (18.6) 17 (14.2) 
A/A 7 (1.6) 0 
AGT rs699 
C/C 388 (858.8) 103 (87.3) 
0.82 
0.45-
1.49 
0.505 C/T 61 (13.5) 15 (12.7) 
T/T 3 (0.7) 0 
AT1R rs5186 
A/A 441 (99.5) 116 (99.1) 
1.48 
0.13-
16.59 
- C/A 2 (0.5) 1 (0.9) 
C/C 0 0 
T2DM diagnosis by fasting glucose (>5.6 mmol/l).                                                                                                     
ACE – Angiotensin-converting enzyme; AGT – Angiotensinogen; AT1R – Angiotensin II type I receptor; MC4R – 
Melanocortin 4 receptor; TCF7L2 – Transcription factor 7-like 2 
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No SNPs were associated when T2DM was diagnosed according to glucose tolerance under a log-
additive inheritance model, adjusted for gender and age (Table 3.9). 
Table 3.9 Genotype distributions and frequencies of all SNPs in controls and T2DM cases by 
impaired glucose tolerance under a log-additive inheritance model, adjusted for gender and age. 
Gene SNP Genotype Controls Cases OR 95% CI p-value 
ACE rs4646994 
D/D 437 (86.0) 42 (89.4) 
0.89 
0.49-
1.62 
0.695 I/D 68 (13.4) 5 (10.6) 
I/I 3 (0.6) 0 
TCF7L2 rs7903146 
T/T 211 (42.0) 19 (42.2) 
0.91 
0.55-
1.50 
0.712 T/C 235 (46.8) 23 (51.1) 
C/C 56 (11.2) 3 (6.7) 
MC4R 
rs229616 
G/G 279 (55.1) 32 (68.1) 
0.67 
0.39-
1.18 
0.154 G/A 193 (38.1) 13 (27.7) 
A/A 34 (6.7) 2 (4.3) 
rs17782313 
T/T 270 (53.0) 21 (43.8) 
1.26 
0.77-
2.04 
0.358 T/C 204 (40.1) 23 (47.9) 
C/C 35 (6.9) 4 (8.3) 
rs1297034 
G/G 408 (81.0) 40 (83.3) 
0.80 
0.38-
1.71 
0.554 G/A 89 (17.7) 8 (16.7) 
A/A 7 (1.4) 0 
AGT rs699 
C/C 437 (86.2) 42 (89.4) 
0.76 
0.30-
1.92 
0.5451 C/T 67 (13.2) 5 (10.6) 
T/T 3 (0.6) 0 
AT1R rs5186 
A/A 497 (99.4) 45 (100.0) 
- - - C/A 3 (0.6) 0 
C/C 0 0 
T2DM diagnosis by glucose tolerance (>11 mmol/l).                                                                                                
ACE – Angiotensin-converting enzyme; AGT – Angiotensinogen; AT1R – Angiotensin II type I receptor; MC4R – 
Melanocortin 4 receptor; TCF7L2 – Transcription factor 7-like 2 
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3.4.3.2 Obesity 
Under a log-additive genetic model, adjusted for gender and age, rs4646994 (D/D genotype) of 
ACE was significantly associated with overall obesity diagnosis by BMI (≥30kg/m2), WC (males 
>94cm, females >80cm) and/or waist-to-hip ratio (males >1, females >0.85) (OR=0.55, 
95%CI=0.32-0.96, p=0.034) (Table 3.10). 
Table 3.10 Genotype distributions and frequencies of all SNPs in controls and obese cases by 
BMI, waist circumference and/or waist-to-hip ratio under a log-additive inheritance model, adjusted 
for gender and age. 
Gene SNP Genotype Controls Cases OR 95% CI p-value 
ACE rs4646994 
D/D 39 (43.3) 117 (48.0) 
0.55 
0.32-
0.96 
0.034 I/D 41 (45.6) 106 (43.4) 
I/I 10 (11.1) 21 (8.6) 
TCF7L2 rs7903146 
T/T 75 (42.1) 168 (43.2) 
0.99 
0.68-
1.44 
0.958 T/C 81 (45.5) 179 (46.0) 
C/C 22 (12.5) 42 (10.8) 
MC4R 
rs229616 
G/G 99 (55.0) 227 (57.6) 
0.72 
0.48-
1.07 
0.107 G/A 64 (35.6) 145 (36.8) 
A/A 17 (9.4) 22 (5.6) 
rs17782313 
T/T 98 (54.4) 206 (51.9) 
0.97 
0.65-
1.45 
0.893 T/C 67 (37.2) 165 (41.6) 
C/C 15 (8.3) 26 (6.5) 
rs1297034 
G/G 147 (81.7) 316 (80.6) 
0.87 
0.49-
1.55 
0.642 G/A 32 (17.8) 70 (17.9) 
A/A 1 (0.6) 6 (1.5) 
AGT rs699 
C/C 149 (83.7) 347 (87.4) 
0.88 
0.44-
1.72 
0.701 C/T 27 (15.2) 49 (12.3) 
T/T 2 (1.1) 1 (0.3) 
AT1R rs5186 
A/A 175 (100.0) 387 (99.2) 
- - - C/A 0 3 (0.8) 
C/C 0 0 
Overall obesity diagnosis by BMI (≥30kg/m2), waist circumference (males ≥94cm; females ≥80cm) 
and/or waist-to-hip ratio (males >1, females >0.85).                                                                                                                              
ACE – Angiotensin-converting enzyme; AGT – Angiotensinogen; AT1R – Angiotensin II type I receptor; MC4R – 
Melanocortin 4 receptor; TCF7L2 – Transcription factor 7-like 2 
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Overweight and obese individuals were first separated and then combined as cases for genetic 
analysis to determine if any SNP is involved in disease predisposition and/or on disease diagnosis. 
No association with obesity by BMI when overweight (25-29.99kg/m2) and obese (≥30kg/m2) 
individuals were separated was observed under a log-additive model of inheritance adjusted for 
gender and age (Table 3.11).  
Table 3.11 Genotype distributions and frequencies in controls, overweight and obese cases by 
BMI under a log-additive inheritance model, adjusted for gender and age. 
Gene SNP Genotype Controls Overweight Cases Diff 95% CI 
p-
value 
ACE rs4646994 
D/D 42 (43.3) 31 (47.7) 83 (47.7) -
0.095 
-0.207-
0.017 0.097 I/D 45 (46.4) 24 (38.1) 78 (44.8) 
I/I 10 (10.3) 8 (12.7) 13 (7.5) 
TCF7L2 rs7903146 
T/T 80 (45.1) 49 (45.4) 112 (40.4) 
0.057 -0.031-0.144 0.205 T/C 78 (42.9) 49 (45.4) 
133 
(48.0) 
C/C 22 (12.1) 10 (9.3) 32 (11.6) 
MC4R 
rs229616 
G/G 100 (54.1) 67 (59.8) 159 (57.4) 
-0.06 -0.154-0.033 0.204 G/A 67 (36.2) 42 (37.5) 100 (36.1) 
A/A 18 (9.7) 3 (2.7) 18 (6.5) 
rs17782313 
T/T 108 (58.1) 50 (45.0) 146 (52.1) 
0.006 -0.087-0.098 0.907 T/C 62 (33.3) 53 (47.7) 117 (41.8) 
C/C 16 (8.6) 8 (7.2) 17 (6.1) 
rs1297034 
G/G 151 (82.1) 88 (80.0) 224 (80.6) 
0.001 -0.134-0.136 0.989 G/A 33 (17.9) 19 (17.3) 50 (18.0) 
A/A 0 3 (2.7) 4 (1.4) 
AGT rs699 
C/C 154 (84.2) 102 (91.1) 240 (85.7) 
0.034 -0.124-0.193 0.67 C/T 27 (14.8) 10 (8.9) 39 (13.9) 
T/T 2 (1.1) 0 1 (0.4) 
AT1R rs5186 
A/A 182 (100.0) 108 (100.0) 
272 
(98.9) 0.792 -0.013-1.597 - C/A 0 0 3 (1.1) 
C/C 0 0 0 
Obesity diagnosis by BMI (≥30kg/m2; high-risk: 25-29.99kg/m2).  
The difference instead of an OR is reported as the analysis was performed with quantitative 
variables (3 categories) and not dichotomous variables.                                                                                                                                                    
ACE – Angiotensin-converting enzyme; AGT – Angiotensinogen; AT1R – Angiotensin II type I receptor; MC4R – 
Melanocortin 4 receptor; TCF7L2 – Transcription factor 7-like 2 
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No association with obesity by BMI when overweight (25-29.99kg/m2) and obese (≥30kg/m2) 
individuals were combined as cases was observed under a log-additive genetic model adjusted for 
gender and age (Table 3.12). However, a nominal association for rs229616 (G/G genotype) of 
MC4R was observed (OR=0.72, 95%CI=0.51-1.01, p=0.059) (Table 3.12). 
Table 3.12 Genotype distributions and frequencies of all SNPs in controls and obese cases by BMI 
when overweight and obese individuals are combined (cases) under a log-additive inheritance 
model, adjusted for gender and age. 
Gene SNP Genotype Controls Cases OR 95% CI p-value 
ACE rs4646994 
D/D 42 (43.3) 114 (48.3) 
0.69 
0.44-
1.10 
0.12 I/D 45 (46.4) 102 (43.2) 
I/I 10 (10.3) 21 (8.9) 
TCF7L2 rs7903146 
T/T 82 (45.1) 161 (41.8) 
1.15 
0.83-
1.59 
0.402 T/C 78 (42.9) 182 (47.3) 
C/C 22 (12.1) 42 (10.9) 
MC4R 
rs229616 
G/G 100 (54.1) 226 (58.1) 
0.72 
0.51-
1.01 
0.059 G/A 67 (36.2) 142 (36.5) 
A/A 18 (9.7) 21 (5.4) 
rs17782313 
T/T 108 (58.1) 196 (50.1) 
1.17 
0.83-
1.64 
0.368 T/C 62 (33.3) 170 (43.5) 
C/C 16 (8.6) 25 (6.4) 
rs1297034 
G/G 151 (82.1) 312 (80.4) 
1.09 
0.65-
1.81 
0.744 G/A 33 (17.9) 69 (17.8) 
A/A 0 7 (1.8) 
AGT rs699 
C/C 154 (84.2) 342 (87.2) 
0.86 
0.48-
1.52 
0.599 C/T 27 (14.8) 49 (12.5) 
T/T 2 (1.1) 1 (0.3) 
AT1R rs5186 
A/A 182 (100.0) 380 (99.2) 
- - - C/A 0 3 (0.8) 
C/C 0 0 
Obesity diagnosis by BMI when high-risk (≥25kg/m2) and obese (≥30kg/m2) individuals are 
combined.                                                                                                                         ACE – 
Angiotensin-converting enzyme; AGT – Angiotensinogen; AT1R – Angiotensin II type I receptor; MC4R – Melanocortin 4 
receptor; TCF7L2 – Transcription factor 7-like 2 
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Under a log-additive genetic model adjusted for gender and age, rs4646994 (DD genotype) of ACE 
was significantly associated with obesity by WC (males ≥94cm, females ≥80cm) (OR=0.58, 
95%CI=0.34-0.99, p=0.044) (Table 3.13). 
Table 3.13 Genotype distributions and frequencies of all SNPs in controls and obese cases by 
waist circumference under a log-additive inheritance model, adjusted for gender and age. 
Gene SNP Genotype Controls Cases OR 95% CI p-value 
ACE rs4646994 
D/D 40 (43.0) 116 (48.1) 
0.58 
0.34-
0.99 
0.044 I/D 43 (46.2) 104 (43.2) 
I/I 10 (10.8) 21 (8.7) 
TCF7L2 rs7903146 
T/T 79 (41.8) 164 (43.4) 
0.92 
0.64-
1.33 
0.661 T/C 86 (45.5) 174 (46.0) 
C/C 24 (12.7) 40 (10.6) 
MC4R 
rs229616 
G/G 106 (55.5) 220 (57.4) 
0.75 
0.51-
1.10 
0.139 G/A 67 (35.1) 142 (37.1) 
A/A 18 (9.4) 21 (5.5) 
rs17782313 
T/T 105 (54.7) 199 (51.7) 
1.02 
0.69-
1.51 
0.904 T/C 72 (37.5) 160 (41.6) 
C/C 15 (7.8) 26 (6.8) 
rs1297034 
G/G 158 (82.3) 305 (80.3) 
1.00 
0.56-
1.76 
0.986 G/A 33 (17.2) 69 (18.2) 
A/A 1 (0.5) 6 (1.6) 
AGT rs699 
C/C 157 (83.1) 38 (87.8) 
0.77 
0.40-
1.48 
0.434 C/T 30 (15.9) 46 (11.9) 
T/T 2 (1.1) 1 (0.3) 
AT1R rs5186 
A/A 186 (100.0) 376 (99.2) 
- - - C/A 0 3 (0.8) 
C/C 0 0 
Obesity diagnosis by waist circumference (males ≥94cm; females ≥80cm).                                                          
ACE – Angiotensin-converting enzyme; AGT – Angiotensinogen; AT1R – Angiotensin II type I receptor; FTO – Fat-mass 
and obesity associated gene; MC4R – Melanocortin 4 receptor; TCF7L2 – Transcription factor 7-like 2 
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No SNPs were associated with obesity by waist-to-hip ratios (males >1, females >0.85) under a 
log-additive genetic model adjusted for gender and age (Table 3.14). 
Table 3.14 Genotype distributions and frequencies of all SNPs in controls and obese cases by 
waist-to-hip ratio under a log-additive inheritance model, adjusted for gender and age. 
Gene SNP Genotype Controls Cases OR 95% CI p-value 
ACE rs4646994 
D/D 97 (44.9) 59 (50.0) 
0.77 
0.53-
1.13 
0.174 I/D 96 (44.4) 51 (43.2) 
I/I 23 (10.7) 8 (6.8) 
TCF7L2 rs7903146 
T/T 153 (41.5) 90 (45.5) 
0.86 
0.64-
1.15 
0.314 T/C 171 (46.3) 89 (44.9) 
C/C 45 (12.2) 19 (9.6) 
MC4R 
rs229616 
G/G 210 (56.0) 116 (58.3) 
0.99 
0.73-
1.36 
0.957 G/A 141 (37.6) 68 (34.2) 
A/A 24 (6.4) 15 (7.5) 
rs17782313 
T/T 203 (54.1) 101 (50.0) 
1.06 
0.78-
1.45 
0.698 T/C 145 (38.7) 87 (43.1) 
C/C 27 (7.2) 14 (6.9) 
rs1297034 
G/G 302 (81.4) 161 (80.1) 
1.08 
0.70-
1.66 
0.731 G/A 66 (17.8) 36 (17.9) 
A/A 3 (0.8) 4 (2.0) 
AGT rs699 
C/C 326 (87.2) 169 (84.5) 
1.52 
0.88-
2.60 
0.134 C/T 46 (12.3) 30 (15.0) 
T/T 2 (0.5) 1 (0.5) 
AT1R rs5186 
A/A 366 (99.7) 196 (99.0) 
4.48 
0.25-
81.62 
 C/A 1 (0.3) 2 (1.0) 
C/C 0 0 
Obesity diagnosis by waist-to-hip circumference (males >1; females >0.85).                                                      
ACE – Angiotensin-converting enzyme; AGT – Angiotensinogen; AT1R – Angiotensin II type I receptor; MC4R – 
Melanocortin 4 receptor; TCF7L2 – Transcription factor 7-like 2 
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3.4.3.3 Hypertension 
No SNPs were associated with BP (≥140/90 mmHg) under a log-additive genetic model adjusted 
for gender and age (Table 3.15).  
Table 3.15 Genotype distributions and frequencies of all SNPs in controls and hypertensive cases 
by blood pressure under a log-additive inheritance model, adjusted for gender and age. 
Gene SNP Genotype Controls Cases OR 95% CI p-value 
ACE rs4646994 
D/D 129 (47.3) 27 (44.3) 
1.51 
0.96-
2.39 
0.073 I/D 123 (45.1) 24 (39.3) 
I/I 21 (7.7) 10 (16.4) 
TCF7L2 rs7903146 
T/T 198 (43.0) 45 (42.5) 
0.94 
0.67-
1.33 
0.74 T/C 206 (44.7) 54 (50.9) 
C/C 57 (12.4) 7 (6.6) 
MC4R 
rs229616 
G/G 262 (56.0) 64 (60.4) 
0.98 
0.68-
1.41 
0.903 G/A 175 (37.4) 34 (32.1) 
A/A 31 (6.6) 8 (7.5) 
rs17782313 
T/T 252 (53.5) 52 (49.1) 
1.18 
0.82-
1.68 
0.372 T/C 187 (39.7) 45 (42.5) 
C/C 32 (6.8) 9 (8.5) 
rs1297034 
G/G 376 (80.9) 87 (81.3) 
1.06 
0.63-
1.79 
0.815 G/A 84 (18.1) 18 (16.8) 
A/A 5 (1.1) 2 (1.9) 
AGT rs699 
C/C 410 (87.2) 86 (81.9) 
1.47 
0.83-
2.60 
0.196 C/T 58 (12.3) 18 (17.1) 
T/T 2 (0.4) 1 (1.0) 
AT1R rs5186 
A/A 458 (99.6) 104 (99.0) 
1.72 
0.15-
19.3 
- C/A 2 (0.4) 1 (1.0) 
C/C 0 0 
Hypertension diagnosis by blood pressure (≥140/90 mmHg).                                                                                 
ACE – Angiotensin-converting enzyme; AGT – Angiotensinogen; AT1R – Angiotensin II type I receptor; MC4R – 
Melanocortin 4 receptor; TCF7L2 – Transcription factor 7-like 2 
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3.4.3.4 Dyslipidaemia 
No SNPs were associated with overall dyslipidaemia diagnosis by total cholesterol (>5 mmol/l), 
triglycerides (>1.5 mmol/l), HDL-C (<1.2 mmol/l), LDL-C (>3 mmol/l) and/or HDL-C/total cholesterol 
(<20%) under a log-additive genetic model adjusted for gender and age (Table 3.16). 
Table 3.16 Genotype distributions and frequencies of all SNPs in controls and dyslipidaemia cases 
total cholesterol, triglycerides, HDL-C, LDL-C and/or HDL-C/total cholesterol measurements under 
a log-additive inheritance model, adjusted for gender and age. 
Gene SNP Genotype Controls Cases OR 95% CI p-value 
ACE rs4646994 
D/D 25 (54.4) 131 (45.5) 
1.34 
0.80-
2.22 
0.257 I/D 18 (39.1) 129 (49.8) 
I/I 3 (6.5) 28 (9.7) 
TCF7L2 rs7903146 
T/T 32 (43.2) 211 (42.8) 
0.95 
0.66-
1.37 
0.779 T/C 31 (41.9) 229 (46.5) 
C/C 11 (14.9) 53 (10.8) 
MC4R 
rs229616 
G/G 44 (59.5) 282 (56.4) 
1.02 
0.69-
1.51 
0.912 G/A 24 (32.4) 185 (37.0) 
A/A 6 (8.1) 33 (6.6) 
rs17782313 
T/T 39 (52.7) 265 (52.7) 
0.85 
0.58-
1.24 
0.389 T/C 26 (35.1) 206 (41.0) 
C/C 9 (12.2) 32 (6.4) 
rs1297034 
G/G 62 (83.8) 401 (80.5) 
1.17 
0.64-
2.15 
0.603 G/A 11 (14.9) 91 (18.3) 
A/A 1 (1.4) 6 (1.2) 
AGT rs699 
C/C 62 (84.9) 434 (86.5) 
0.92 
0.48-
1.74 
0.789 C/T 11 (15.1) 65 (12.9) 
T/T 0 3 (0.6) 
AT1R rs5186 
C/C 74 (100.0) 488 (99.4) 
- - - C/A 0 3 (0.6) 
A/A 0 0 
Overall dyslipidaemia diagnosis by total cholesterol (>5 mmol/l), triglycerides (>1.5 mmol/l), HDL-C 
(<1.2 mmol/l), LDL-C (>3 mmol/l) and/or HDL-C/total cholesterol (<20%).                                                                                     
ACE – Angiotensin-converting enzyme; AGT – Angiotensinogen; AT1R – Angiotensin II type I receptor; MC4R – 
Melanocortin 4 receptor; TCF7L2 – Transcription factor 7-like 2.  
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No SNPs were associated with dyslipidaemia by TC (>5 mmol/l) under a log-additive genetic 
model adjusted for gender and age (Table 3.17). 
Table 3.17 Genotype distributions and frequencies of all SNPs in controls and dyslipidaemia cases 
by levels of total cholesterol under a log-additive inheritance model, adjusted for gender and age. 
Gene SNP Genotype Controls Cases OR 95% CI p-value 
ACE rs4646994 
D/D 111 (47.4) 45 (45.0) 
1.30 
0.88-
1.92 
0.184 I/D 104 (44.4) 43 (43.0) 
I/I 19 (8.1) 12 (12.0) 
TCF7L2 rs7903146 
T/T 170 (41.2) 72 (47.4) 
0.98 
0.73-
1.32 
0.908 T/C 201 (48.7) 59 (38.8) 
C/C 42 (10.2) 21 (13.8) 
MC4R 
rs229616 
G/G 241 (57.4) 83 (54.6) 
1.16 
0.85-
1.57 
0.352 G/A 151 (36.0) 58 (38.2) 
A/A 28 (6.7) 11 (7.2) 
rs17782313 
T/T 222 (52.6) 81 (52.9) 
0.95 
0.70-
1.30 
0.757 T/C 170 (40.3) 62 (40.5) 
C/C 30 (7.1) 10 (6.5) 
rs1297034 
G/G 336 (80.6) 126 (82.4) 
0.86 
0.54-
1.36 
0.516 G/A 75 (18.0) 26 (17.0) 
A/A 6 (1.4) 1 (0.7) 
AGT rs699 
C/C 365 (87.1) 130 (84.4) 
1.24 
0.74-
2.06 
0.417 C/T 52 (12.4) 23 (14.9) 
T/T 2 (0.5) 1 (0.6) 
AT1R rs5186 
A/A 410 (99.5) 150 (99.3) 
1.07 
0.1-
11.96 
- C/A 2 (0.5) 1 (0.7) 
C/C 0 0 
Dyslipidaemia diagnosis by total cholesterol (>5 mmol/l).                                                                                        
ACE – Angiotensin-converting enzyme; AGT – Angiotensinogen; AT1R – Angiotensin II type I receptor; MC4R – 
Melanocortin 4 receptor; TCF7L2 – Transcription factor 7-like 2 
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No SNPs were associated with dyslipidaemia by triglycerides (>1.5 mmol/l) under a log-additive 
genetic model adjusted for gender and age (Table 3.18). 
Table 3.18 Genotype distributions and frequencies of all SNPs in controls and dyslipidaemia cases 
by levels of triglycerides under a log-additive inheritance model, adjusted for gender and age. 
Gene SNP Genotype Controls Cases OR 95% CI p-value 
ACE rs4646994 
D/D 126 (45.0) 30 (55.6) 
0.76 
0.47-
1.24 
0.271 I/D 127 (45.4) 20 (37.0) 
I/I 27 (9.6) 4 (7.4) 
TCF7L2 rs7903146 
T/T 203 (42.4) 39 (45.3) 
0.86 
0.60-
1.25 
0.432 T/C 219 (45.7) 41 (47.7) 
C/C 57 (11.9) 6 (7.0) 
MC4R 
rs229616 
G/G 269 (55.7) 55 (61.8) 
0.92 
0.63-
1.35 
0.676 G/A 182 (37.7) 27 (30.3) 
A/A 32 (6.6) 7 (7.9) 
rs17782313 
T/T 253 (52.2) 50 (55.6) 
0.92 
0.63-
1.35 
0.679 T/C 199 (41.0) 33 (36.7) 
C/C 33 (6.8) 7 (7.8) 
rs1297034 
G/G 388 (80.5) 74 (84.1) 
0.75 
0.41-
1.35 
0.32 G/A 87 (18.0) 14 (15.9) 
A/A 7 (1.5) 0 
AGT rs699 
C/C 421 (86.8) 74 (84.1) 
1.11 
0.60-
2.05 
0.739 C/T 61 (12.6) 14 (15.9) 
T/T 3 (0.6) 0 
AT1R rs5186 
A/A 474 (99.8) 86 (97.7) 
9.04 
0.81-
101 
- C/A 1 (0.2) 2 (2.3) 
C/C 0 0 
Dyslipidaemia diagnosis by triglycerides (>1.5 mmol/l).                                                                                           
ACE – Angiotensin-converting enzyme; AGT – Angiotensinogen; AT1R – Angiotensin II type I receptor; MC4R – 
Melanocortin 4 receptor; TCF7L2 – Transcription factor 7-like 2 
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No SNPs were associated with dyslipidaemia by HDL-C (<1.2 mmol/l) under a log-additive genetic 
model adjusted for gender and age (Table 3.19).  
Table 3.19 Genotype distributions and frequencies of all SNPs in controls and dyslipidaemia cases 
by levels of HDL-C under a log-additive inheritance model, adjusted for gender and age. 
Gene SNP Genotype Controls Cases OR 95% CI p-value 
ACE rs4646994 
D/D 55 (45.1) 101 (47.6) 
0.93 
0.65-
1.32 
0.68 I/D 57 (46.7) 90 (42.5) 
I/I 10 (8.2) 21 (9.9) 
TCF7L2 rs7903146 
T/T 82 (42.1) 160 (43.2) 
0.87 
0.66-
1.13 
0.285 T/C 86 (44.1) 174 (47.0) 
C/C 27 (13.8) 36 (9.7) 
MC4R 
rs229616 
G/G 104 (53.6) 220 (58.2) 
0.85 
0.64-
1.13 
0.262 G/A 76 (39.2) 133 (35.2) 
A/A 14 (7.2) 25 (6.6) 
rs17782313 
T/T 107 (54.0) 196 (52.0) 
1.03 
0.78-
1.37 
0.819 T/C 76 (38.4) 156 (41.4) 
C/C 15 (7.6) 25 (6.6) 
rs1297034 
G/G 161 (82.6) 301 (80.3) 
1.14 
0.75-
1.72 
0.547 G/A 32 (16.4) 69 (18.4) 
A/A 2 (1.0) 5 (1.3) 
AGT rs699 
C/C 162 (83.5) 333 (87.9) 
0.76 
0.47-
1.21 
0.244 C/T 31 (16.0) 44 (11.6) 
T/T 1 (0.5) 2 (0.5) 
AT1R rs5186 
A/A 195 (100.0) 365 (99.5) 
- - - C/A 0 3 (0.8) 
C/C 0 0 
Dyslipidaemia diagnosis by HDL-C (<1.2 mmol/l).                                                                                                       
ACE – Angiotensin-converting enzyme; AGT – Angiotensinogen; AT1R – Angiotensin II type I receptor; MC4R – 
Melanocortin 4 receptor; TCF7L2 – Transcription factor 7-like 2 
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No SNPs were associated with dyslipidaemia by LDL-C (>3 mmol/l) under a log-additive genetic 
model adjusted for gender and age (Table 3.20).  
Table 3.20 Genotype distributions and frequencies of all SNPs in controls and dyslipidaemia cases 
by levels of LDL-C under a log-additive inheritance model, adjusted for gender and age. 
Gene SNP Genotype Controls Cases OR 95% CI p-value 
ACE rs4646994 
D/D 76 (48.4) 80 (45.2) 
1.32 
0.93-
1.87 
0.116 I/D 71 (45.2) 76 (42.9) 
I/I 10 (3.4) 21 (11.9) 
TCF7L2 rs7903146 
T/T 119 (41.5) 120 (44.0) 
0.99 
0.77-
1.28 
0.0967 T/C 137 (47.7) 121 (44.3) 
C/C 31 (10.8) 32 (11.7) 
MC4R 
rs229616 
G/G 168 (57.5) 152 (55.3) 
1.09 
0.83-
1.44 
0.516 G/A 104 (35.6) 104 (37.8) 
A/A 20 (6.8) 19 (6.9) 
rs17782313 
T/T 154 (52.6) 146 (52.7) 
0.99 
0.75-
1.30 
0.932 T/C 119 (40.6) 111 (40.1) 
C/C 20 (6.8) 20 (7.2) 
rs1297034 
G/G 240 (82.5) 218 (79.6) 
1.14 
0.77-
1.69 
0.514 G/A 47 (16.2) 53 (19.3) 
A/A 4 (1.4) 3 (1.1) 
AGT rs699 
C/C 250 (85.6) 241 (87.3) 
0.92 
0.57-
1.47 
0.715 C/T 41 (14.0) 33 (12.0) 
T/T 1 (0.3) 2 (0.7) 
AT1R rs5186 
A/A 284 (99.3) 271 (99.6) 
0.41 
0.04-
4.63 
- C/A 2 (0.7) 1 (0.4) 
C/C 0 0 
Dyslipidaemia by LDL-C (>3 mmol/l).                                                                                                                            
ACE – Angiotensin-converting enzyme; AGT – Angiotensinogen; AT1R – Angiotensin II type I receptor; MC4R – 
Melanocortin 4 receptor; TCF7L2 – Transcription factor 7-like 2 
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Under an additive model adjusted for gender and age, rs229616 (GG genotype) of MC4R was 
significantly associated with dyslipidaemia by HDL-C/total cholesterol (<20%) (OR=1.39, 
95%CI=1.01-1.90, p=0.043) (Table 3.2) under a log-additive genetic model adjusted for gender 
and age. 
Table 3.21 Genotype distributions and frequencies of all SNPs in controls and dyslipidaemia cases 
by HDL-C-to-total cholesterol ratios under a log-additive inheritance model, adjusted for gender 
and age. 
Gene SNP Genotype Controls Cases OR 95% CI p-value 
ACE rs4646994 
D/D 120 (46.5) 36 (47.4) 
1.02 
0.68-
1.53 
0.917 I/D 115 (44.6) 32 (42.1) 
I/I 23 (8.9) 8 (10.5) 
TCF7L2 rs7903146 
T/T 183 (41.3) 59 (48.4) 
0.82 
0.60-
1.13 
0.226 T/C 209 (47.2) 51 (41.8) 
C/C 51 (11.5) 12 (9.8) 
MC4R 
rs229616 
G/G 261 (58.3) 63 (50.8) 
1.39 
1.01-
1.90 
0.043 G/A 161 (35.9) 48 (38.7) 
A/A 26 (5.8) 13 (10.5) 
rs17782313 
T/T 236 (52.2) 67 (54.5) 
0.89 
0.64-
1.23 
0.47 T/C 183 (40.5) 49 (39.8) 
C/C 33 (7.3) 7 (5.7) 
rs1297034 
G/G 362 (81.0) 100 (81.3) 
0.99 
0.62-
1.57 
0.955 G/A 80 (17.9) 21 (17.1) 
A/A 5 (1.1) 2 (1.6) 
AGT rs699 
C/C 382 (85.3) 113 (90.4) 
0.63 
0.33-
1.18 
0.131 C/T 63 (14.1) 12 (9.6) 
T/T 3 (0.7) 0 
AT1R rs5186 
A/A 438 (99.5) 122 (99.2) 
1.64 
0.14-
18.67 
- C/A 2 (0.5) 1 (0.8) 
C/C 0 0 
Dyslipidaemia diagnosis by HDL-C/total cholesterol (<20%).                                                                                    
ACE – Angiotensin-converting enzyme; AGT – Angiotensinogen; AT1R – Angiotensin II type I receptor; MC4R – 
Melanocortin 4 receptor; TCF7L2 – Transcription factor 7-like 2 
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3.4.3.5 Metabolic syndrome 
No SNPs were associated with MetS, as defined by the JIS criteria (waist circumference: males 
≥94cm, females ≥80cm; triglycerides: >1.7 mmol/l; HDL-C: males <1 mmol/l, females <0.85 mmol/l; 
blood pressure: ≥130/85 mmHg; fasting glucose: ≥5.6 mmol/l), under a log-additive genetic model 
adjusted for gender and age (Table 3.22). 
Table 3.22 Genotype distributions and frequencies of all SNPs in controls and metabolic syndrome 
cases by the JIS criteria under a log-additive inheritance model, adjusted for gender and age. 
Gene SNP Genotype Controls Cases OR 95% CI p-value 
ACE rs4646994 
D/D 106 (44.4) 50 (52.6) 
0.87 
0.58-
1.31 
0.506 I/D 111 (46.4) 36 (37.9) 
I/I 22 (9.2) 9 (9.5) 
TCF7L2 rs7903146 
T/T 177 (42.4) 66 (44.0) 
0.88 
0.64-
1.20 
0.408 T/C 187 (44.8) 73 (48.7) 
C/C 53 (12.7) 11 (7.3) 
MC4R 
rs229616 
G/G 231 (54.7) 95 (62.5) 
0.83 
0.60-
1.16 
0.274 G/A 162 (38.4) 47 (30.9) 
A/A 29 (6.9) 10 (6.6) 
rs17782313 
T/T 230 (54.2) 74 (48.4) 
1.14 
0.83-
1.57 
0.435 T/C 164 (38.7) 68 (44.4) 
C/C 30 (7.1) 11 (7.) 
rs1297034 
G/G 340 (81.0) 123 (80.9) 
0.99 
0.63-
1.56 
0.96 G/A 75 (17.9) 27 (17.8) 
A/A 5 (1.2) 2 (1.3) 
AGT rs699 
C/C 365 (86.3) 131 (86.2) 
0.98 
0.57-
1.71 
0.952 C/T 55 (13.0) 21 (13.8) 
T/T 3 (0.7) 0 
AT1R rs5186 
A/A 413 (99.5) 149 (99.3) 
1.02 
0.08-
12.19 
- C/A 2 (0.5) 1 (0.7) 
C/C 0 0 
Metabolic syndrome diagnosis by the JIS criteria (waist circumference: males ≥94cm, females 
≥80cm; triglycerides: >1.7 mmol/l; HDL-C: males <1 mmol/l, females <1.3 mmol/l; blood pressure: 
≥130/85 mmHg; fasting glucose: >5.6 mmol/l).                                                                                                                                        
ACE – Angiotensin-converting enzyme; AGT – Angiotensinogen; AT1R – Angiotensin II type I receptor; MC4R – 
Melanocortin 4 receptor; TCF7L2 – Transcription factor 7-like 2 
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3.4.4 Post-hoc investigation of significant findings 
SNPs that were significantly and nominally associated with disease under a log-additive genetic 
model were further investigated under dominant and recessive genetic models. These include the 
significant associations of rs17782313 with T2DM by fasting glucose when high-risk and diabetic 
individuals were separated (p=0.043) and combined as cases (p=0.022); rs4646994 with overall 
obesity (p=0.034) and obesity by WC (p=0.044); and rs229616 with dyslipidaemia by HDL-C/total 
cholesterol (p=0.043). As well as the nominal associations of rs1297034 with T2DM when high-risk 
and diabetic individuals are combined as cases (p=0.072) and rs229616 with obesity by BMI when 
overweight and obese individuals are combined as cases (p=0.059). 
3.4.4.1 rs4646994 of ACE is associated with obesity and WC under a dominant 
model 
3.4.4.1.1 Angiotensin-converting enzyme (ACE) 
Under a dominant model adjusted for gender and age, rs4646994 (D/D genotype) was significantly 
associated with obesity by BMI (≥30kg/m2), WC (males ≥94cm, females ≥80cm) and/or waist-to-hip 
ratio (males >1, females >0.85), while the I/D and I/I genotypes were protective (OR=0.46, 
95%CI=0.21-1.01, P=0.047) (Table 3.23). This SNP was also associated with obesity by WC (males 
≥94cm, females ≥80cm) (OR=0.48, 95%CI=0.23-1.00, p=0.044) (Table 3.23).  
The nominal associations with obesity by BMI when overweight (25-29.9kg/m2) and obese 
(≥30kg/m2) individuals were separated (Table 3.11) and BP (≥140/90 mmHg) (Table 3.15) observed 
under a log-additive inheritance model adjusted for gender and age was not observed under a 
dominant model of inheritance adjusted for gender and age (Table 3.23). 
3.4.4.1.2 Transcription factor 7-like 2 (TCF7L2) 
The nominal association of rs7903146 (T/C and T/T genotypes) with T2DM by fasting glucose (>7 
mmol/l) and/or glucose tolerance (>1 mmol/l) observed under an additive model adjusted for gender 
and age (Table 3.6) was not observed under a dominant model adjusted for gender and age (Table 
3.23). 
3.4.4.1.3 Melanocortin 4 receptor (MC4R) 
Under a dominant model adjusted for gender and age, rs17782313 (T/C and C/C genotypes) was 
nominally associated with T2DM by fasting glucose when high-risk (5.6-7 mmol/l) and diabetic (>7 
mmol/l) individuals when they were combined as cases, while the T/T genotype was protective 
(OR=1.51, 95%CI=0.99-2.13, p=0.054) (Table 3.23). 
The nominal associations observed between rs229616 (GA and AA genotypes) and dyslipidaemia 
by HDL-C/total cholesterol or between rs1297034 (GA and AA genotypes) and T2DM by fasting 
glucose when high-risk (5.6-7 mmol/l) and diabetic (>7 mmol/l) individuals combined under log-
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additive inheritance models, adjusted for gender and age (Table 3.21 and Table 3.8, respectively), 
was not observed under a dominant model adjusted for gender and age (Table 3.23). 
Table 3.23 SNPs associated with CVD risk phenotypes under a dominant inheritance model, 
adjusted for gender and age. 
Gene SNP 
Associated 
genotype 
Disease 
variable 
Adjusted 
OR 95% CI p-value 
ACE rs4646994 
D/D Ob 0.46 0.21-1.01 0.047 
D/D ob_wc 0.48 0.23-1.00 0.044 
I/I Bp 1.29 0.71-2.33 0.407 
TCF7L2 rs7903146 C/C Db 1.00 0.51-1.95 0.995 
MC4R 
rs17782313 C/C or T/C db_2h_hr 1.51 0.99-2.31 0.054 
rs229616 G/G dl_hdlctc 1.38 0.92-2.06 0.121 
rs1297034 A/A db_2h_hr 0.64 0.36-1.14 0.117 
Gene SNP 
Associated 
genotype 
Disease 
variable 
Adjusted 
Diff 95% CI p-value 
ACE rs4646994 D/D ob_bmi -0.10097 
-0.2463-
0.04437 
0.1743 
MC4R rs17782313 T/T db_2h 0.08352 
-0.0141-
0.1812 
0.09422 
95%CI – 95% Confidence interval; BMI – Body mass index; bp – Blood pressure; db_2h – Diabetes by fasting glucose 
when high-risk and diabetic individuals are separated; db_2h_hr – Diabetes by fasting glucose when high-risk and diabetic 
individuals combined; Diff – Difference; dl_hdlctc – Dyslipidaemia by HDL-C/TC; dl_ldlc – Dyslipidaemia by LDL-C; HDL-
C – High-density lipoprotein cholesterol; HDL-C/TC – HDL-C to total cholesterol ratio; IGT – Impaired glucose tolerance; 
LDL-C – Low-density lipoprotein cholesterol; ob – obesity by any definition; ob_bmi – Obesity by BMI when overweight 
and obese individuals are separated; db_wc – Obesity by waist circumference; OR – Odds ratio; SNP – Single nucleotide 
polymorphism; TC – Total cholesterol. 
3.4.4.2 rs4646994 of ACE is associated with BP and LDL-C under a 
recessive model 
3.4.4.2.1 Angiotensin-converting enzyme (ACE) 
Under a recessive model adjusted for gender and age, rs4646994 (I/I genotype) was significantly 
associated with hypertension by BP (≥140/90 mmHg) while the I/D and D/D genotypes were 
protective (OR=3.25, 95%CI=1.32-7.99, p=0.014) (Table 3.24). It was also significantly associated 
with dyslipidaemia by LDL-C (>3 mmol/l) (OR=2.31, 95%CI=1.02-5.23, p=0.038) (Table 3.24). 
The significant associations observed under a log-additive inheritance model, adjusted for gender 
and age, with obesity by BMI (≥30kg/m2), WC (males ≥94cm, females ≥80cm) and/or waist-to-hip 
ratio (males >1, females >0.85) (Table 3.10) and obesity by WC (males ≥94cm, females ≥80cm) 
(Table 3.13); and the nominal association with obesity by BMI when overweight (25-29.9kg/m2) and 
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obese (≥30kg/m2) individuals were separated (Table 3.11) was not observed under a recessive 
model adjusted for gender and age (Table 3.24). 
3.4.4.2.2 Transcription factor 7-like 2 (TCF7L2) 
Under a recessive model adjusted for gender and age, rs7903146 (T/T genotype) was nominally 
associated with dyslipidaemia by total cholesterol (>5 mmol/l), while the T/C and C/C genotypes 
were protective (OR=1.72, 95%CI=0.96-3.08, p=0.075) (Table3.24). 
The nominal association observed with T2DM by fasting glucose (>7 mmol/l) and/or glucose 
tolerance (>11 mmol/l) observed under a log-additive inheriatnce model, adjusted for gender and 
age (Table 3.6), was not observed under a recessive inheritace model adjusted for gender and age 
(Table 3.24). 
3.4.4.2.3 Melanocortin 4 receptor (MC4R) 
Under a recessive inheritance model, adjusted for gender and age, rs1297034 was nominally 
associated with T2DM by fasting glucose when high-risk (5.6-7 mmol/l) and diabetic (>7 mmol/l) 
individuals were combined (p=0.075); however, no conclusion can be drawn regarding the 
associated genotype as the OR was 0, which could be an artefact of the cohort, as there was no 
cases with the A/A genotype (Table 3.24). 
The rs17782313 (C/C genotype) was nominally associated with T2DM by fasting glucose when high-
risk (5.6-7 mmol/l) and diabetic (<7 mmol/l) individuals were combined as cases, while the T/C and 
T/T genotypes were protective (OR=2.02, 95%CI=0.96-4.26, p=0.075) (Table 3.24). 
The rs229616 (A/A genotype) was nominally associated with dyslipidaemia by HDL-C/total 
cholesterol (<20%), while the T/A and T/T genotypes were protective (OR=2.03, 95%CI=1.00-4.13, 
p=0.059) (Table 3.24). 
3.4.4.2.4 Angiotensinogen (AGT) 
Under a recessive inheritance ,model adjusted for gender and age, rs699 was nominally associated 
with MetS as defined by the JIS criteria (WC: males ≥94cm, females ≥80cm, triglycerides: >1.7 
mmol/l; HDL-C: males <1 mmol/, females <1.3 mmol/l; BP: ≥130/85 mmHg; fasting glucose: >5.6 
mmol/l) (p=0.076) however, no conclusion can be drawn regarding the associated genotype as the 
OR was 0, which could be an artefact of the cohort, as there was no cases with the T/T genotype 
(Table 3.24). 
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Table 3.24 SNPs associated with CVD risk phenotypes under a recessive inheritance model, 
adjusted for gender and age. 
Gene SNP 
Associated 
genotype 
Disease 
variable 
Adjusted 
OR 95% CI p-value 
ACE rs4646994 
I/I Bp 3.25 1.32-7.99 0.014 
I/I dl_ldlc 2.31 1.02-5.23 0.038 
D/D Ob 0.47 0.16-1.38 0.179 
D/D ob_wc 0.55 0.19-1.56 0.268 
TCF7L2 rs7903146 
T/T dl_tc 1.72 0.93-3.08 0.075 
C/C Db 0.59 0.20-1.73 0.306 
MC4R 
rs1297034 - db_2h_hr 0 0 0.075 
rs17782313 T/T db_2h_hr 2.02 0.96-4.26 0.075 
rs229616 A/A dl_hdlctc 2.03 1.00-4.13 0.059 
AGT rs699 - Ms 0 0 0.075 
Gene SNP 
Associated 
genotype 
Disease 
variable 
Adjusted 
Diff 95% CI p-value 
ACE rs4646994 D/D ob_bmi -0.17360 
-0.4233-
0.07613 
0.174 
MC4R rs17782313 T/T db_2h 0.16583 
-0.02756-
0.3592 
0.093 
95%CI – 95% Confidence interval; BMI – Body mass index; bp – Blood pressure; db – Diabetes by any definition; db_2h 
– Diabetes by fasting glucose when high-risk and diabetic individuals are separated; db_2h_hr – Diabetes by fasting 
glucose when high-risk and diabetic individuals combined; Diff – Difference; dl_hdlctc – Dyslipidaemia by HDL-C/TC; 
dl_ldlc – Dyslipidaemia by LDL-C; HDL-C – High-density lipoprotein cholesterol; HDL-C/TC – HDL-C to total cholesterol 
ratio; IGT – Impaired glucose tolerance; LDL-C – Low-density lipoprotein cholesterol; ms – Metabolic syndrome by JIS 
criteria; ob – obesity by any definition; ob_bmi – Obesity by BMI when overweight and obese individuals are separated; 
ob_wc – Obesity by waist circumference; OR – Odds ratio; SNP – Single nucleotide polymorphism; TC – Total cholesterol. 
3.4.4.3 Investigating the continuous measurements of glucose and blood 
pressure 
As the risk of T2DM and hypertension is continuous and the cut-offs for diagnosis are constantly 
changing (Matsha et al., 2013), linear regression analysis was performed to determine the 
association of each SNP with continuous measurements of glucose and blood pressure adjusted 
for gender and age as covariates (Table 3.25). Individuals on glucose management or blood 
pressure lowering medication were excluded from this analysis as although they are diseased, 
treatment will lower their measurements and classify them as “healthy” affecting the association 
outcome.  
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Table 3.25 The association of each SNP to the variation in disease diagnosis measures. 
Disease 
measure  
AGT 
rs699 
MC4R 
rs229616 
MC4R 
rs1297034 
MC4R 
rs17782313 
TCF7L2 
rs7903146 
AT1R 
rs5186 
Glucose measurements 
Fasting glucose 
R²=0,059 
p=0,239 
R²=0,052 
p=0,723 
R²0,05 
p=0,862 
R²=0,051 
p=0,255 
R²=0,054 
p=0,923 
R²=0,051 
p=0,8646 
Glucose 
tolerance 
R²=0,101 
p=0,160 
R²=0,098 
p=0,9933 
R²=0,10 
p=0,1983 
R²=0,099 
p=0,319 
R²=0,103 
p=0,8703 
R²=0,103 
p=0,4534 
Blood pressure measurements 
Systolic BP 
R²=0,193 
p=0,798 
R²=0,199 
p=0,0987 
R²=0,195 
p=0,681 
R²=0,198 
p=0,303 
R²=0,194 
p=0,61 
R²=0,196 
p=0,676 
Diastolic BP 
R²=0,042 
p=0,063 
R²=0,039 
p=0,146 
R²=0,037 
p=0,337 
R²=0,035 
p=0,649 
R²=0,038 
p=0,229 
R²=0,035 
p=0,845 
AGT – Angiotensin; AT1R – Angiotensin II type I receptor; MC4R – Melanocortin 4 receptor; R2 – Multiple R-squared; 
TCF7L2 – Transcription factor 7-like 2 
No SNPs in any of the genes were associated with continual risk of T2DM or hypertension. However, 
a nominal association was observed between AGT rs699 and diastolic BP measurements, 
associated with a 4.2% increased risk of hypertension (R2=0.042). R2 explains the percentage of 
data variability around the mean.    
3.5 Haplotype analysis of MC4R 
Haplotype analysis of the MC4R SNPs was not performed, as the SNPs were not in LD (Table 
3.26). 
Table 3.26 Linkage disequilibrium analysis of the MC4R SNPs rs17782313, rs229616 and 
rs1297034.  
L1 L2 D’ R2 
rs17782313 rs1297034 0.106 0 
rs17782313 rs229616 0.017 0 
rs1297034 rs229616 0.025 0 
D2 and r2 values obtained using the “solid spine of LD” setting in Haploview v4.2.  
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4. Discussion 
To our knowledge, the present study represents one of the first to investigate candidate genes 
involved in risk phenotypes associated with CVD in isiXhosa-speaking SA Black individuals. Many 
genetic studies  (both candidate and GWAS-based) have previously been performed in European 
populations and have identified candidate genes involved in risk phenotypes associated with CVD, 
however very few genetic investigations have been done on African populations, where the risk 
phenotypes associated with CVD have been found to be highly prevalent and continue to increase 
(IDF, 2013; Shisana et al., 2013; Sengwayo et al., 2013; Schutte et al., 2008). However, the results 
in this study differed to that of a study conducted in SA Blacks of Zulu descent (Pirie et al., 2010). In 
the Pirie et al. (2010) study, an association was observed between rs7903146 of TCF7L2 and T2DM, 
which was not observed in the present study of isiXhosa-speaking Black individuals. The present 
study also did not investigate the same genes as chosen by Pirie et al. (2010). This difference 
highlights the need to study SA Black individuals with different ethnicities, as the allele frequencies 
may differ between them. Individuals of different ethnicities also follow different ways of life, and 
thus, as has been shown previously (Ouedemi et al., 2009), their environment, diet and lifestyles 
may also predispose them to disease.  
Candidate genes in the present study were selected based on a thorough review of the literature, as 
discussed in the introduction, and we have replicated the associations of SNPs present in ACE 
(rs4646994) (Zitouni et al., 2018; Aung et al., 2017; Motawi et al., 2016; Amrani et al., 2015; Mao & 
Huang, 2015; Kooffreh et al., 2013a; Shaker et al., 2009; Kramer et al., 2005; Rotimi et al., 1997) 
and MC4R (Cauchi et al., 2012) (rs17782313) and risk phenotypes associated with CVD in various 
ethnic African populations. The sections below provide detailed discussion on these findings.  
4.1 Angiotensin-converting enzyme (ACE) 
The D/D genotype of ACE rs4646994 was found to be associated with overall obesity (BMI 
(≥30kg/m2), waist circumference (males≥94cm, females ≥80cm) and/or waist-to-hip ratio (males >1, 
females >0.85)) (p=0.047, OR=0.46) and WC (p=0.044, OR=0.48) under a dominant model of 
inheritance, after correcting for gender and age (Table 3.23). Here, it was found that individuals who 
carried at least one I allele were at significantly reduced risk of obesity, compared to individuals 
homozygous for the D-allele. This is in accordance with what was seen in a sample of Ethiopian 
females with a mean age of 48.8 years, where rs4646994 (D/D genotype) was associated with 
obesity overall as measured by BMI, WC and waist-to-hip ratios in the presence of IR (Motawi et al., 
2016) and with increased risk of obesity in a meta-analysis of African studies, that included 3 371 
cases and 4 490 controls (Mao & Huang, 2015).  
Under a recessive model of inheritance, rs4646994 (I/I genotype) was significantly associated with 
BP after adjustment for gender and age (p=0.014) (Table 3.24). Individuals with the I/I genotype 
were at significantly higher  risk of having increased BP, compared to those who carried at least one 
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D-allele (p=0.014, OR=3.25). This contradicts a previous finding in 388 hypertensive Tunisians, 
where no association of the rs4646994 D-allele with BP was observed (Kabadou et al., 2013). 
Although this difference could be as a result of a difference in the frequency of the I/I genotype 
(10.1% (n=39) in Kabadou et al. (2013) study vs. 16.4% (n=10) in the present study), it appears to 
be instead as a result of varying genetic architecture  between the populations – the I-allele may be 
in linkage disequilibrium (LD) with a causal variant that affects BP in our South Afrcan population, 
but this causal variant may not be in LD with the causal variant in the Tunisian population.  
rs4646994 was not associated with T2DM in the present study, contrary to findings of association of 
rs4646994 D/D genotype in Tunisians (Berhouma et al., 2012; Mehri et al., 2010a; Mehri et al., 
2010b; Baroudi et al., 2009) and rs4646994 I/I genotype in Egyptians (Settin et al., 2015) being 
associated with T2DM. This could be due to varying genetic architecture in different populations and 
geographical locations.  
After adjustment for gender and age, rs4646994 (I/I genotype) was significantly associated with 
dyslipidaemia by increased LDL-C levels (p=0.038) under a recessive model of inheritance (Table 
3.24), Here, individuals homozygous for the I-allele were found to possess increased risk for 
increased LDL-C levels, compared to those individuals who possessed at least one D-allele 
(OR=2.31). This is an association not previously reported in Black individuals as the association of 
the ACE gene with dyslipidaemia has not been studied in the African Black population. 
The angiotensin converting enzyme (ACE) is important for the RAAS, involved in BP control (Figure 
1.2), and has previously been associated with T2DM (Settin et al., 2015; Berhouma et al., 2012; 
Mehri et al., 2010a; Mehri et al., 2010b; Baroudi et al., 2009), hypertension (Motawi et al., 2016; Mao 
& Huang, 2015; Kramer et al., 2005) and obesity (Kabadou et al., 2013; Baroudi et al., 2004; Zhu et 
al., 2001) in different populations. The angiotensin-converting enzyme is required for the cleavage 
of Ang I to Ang II for the optimal functioning of the RAAS to control BP. The D allele has been found 
to affect the activity of ACE, reducing the functioning of the RAAS in BP control (Gard, 2010). 
Interestingly, in the present study, both the I and D alleles conferred increased risk for various CVD 
risk phenotypes. The I/I genotype was significantly associated with raised BP and raised LDL-C 
associated with dyslipidaemia, while the D/D genotype was associated with overall obesity and an 
obese WC. LDL-C is associated with cholesterol deposits in arteries which may result in restricted 
blood flow, which in turn results in a rise in BP. Blood pressure is also proportional to pulse rate 
which is affected by the deposits in arteries. Thus, the association of the I/I genotype of rs4646994 
with both BP and LDL-C suggests that these two risk phenotypes are in fact related. Although one 
would expect obesity to be associated with BP and dyslipidaemia, they are not necessarily causal 
factors, so while expecting the same genotypes to be responsible for the observed phenotypes, 
many factors such as dietary composition and physical exercise, which affects both fat stores as well 
as cholesterol deposits, and in turn BP, were  not taken into account and may be why in the present 
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study the D/D genotype is associated with obesity. These observations suggest a cross-phenotype 
association and increased risk of CVD associated with this SNP.  
4.2 Angiotensinogen (AGT) 
Angiotensinogen (AGT) is involved in regulating the BP and fluid and salt balance (Figure 1.2). 
Previous studies have found the T allele of the rs699 SNP to be associated with BMI in Tunisian 
pregnant females (Zitouni et al., 2018)  and the T/T genotype associated with hypertension (pre-
eclampsia) in Tunisian and SA Black Zulu-speaking pregnant females (Zitouni et al., 2018; Aung et 
al., 2017), but not with hypertension in non-pregnant Algerians (Amrani et al., 2015) and Nigerians 
(Rotimi et al., 1997). No association of the AGT rs699 variant with disease was observed in this 
study, potentially due to the fact that the study population for the present study were not pregnant, 
and rs699 appears to only have an effect in pregnancy-specific (pre-eclampsia) hypertension and 
thus rs699’s harmful affects are context-dependent. 
4.3 Angiotensin II type I receptor (AT1R) 
The angiotensin II type I receptor (AT1R) is responsible for vasoconstriction through AngII and 
cardiac and vessel hypertrophy. A computational analysis ranked rs5186, an A to C substitution in 
the 3’ untranslated region, as the most plausible genotype to be associated with hypertension in 
Xhosa and Zulu-speaking SA Black individuals (Tiffin et al., 2010), but as seen in Nigerians and 
Cameroonians, no association with hypertension was found in the present study (Table 3.15). 
Previous studies have also associated this SNP with CAD in Egyptians (Abd El-Aziz et al., 2012; 
Motawi et al., 2011; Shaker et al., 2009) and Tunisians (Abboud et al., 2010), but as CAD was not 
looked at as a phenotype in the present study, no conclusion can be made regarding the association 
of rs5186 with CAD in this population. However, no association was observed between rs5186 and 
any of the CVD risk phenotypes investigated in the current study. Although selection of candidate 
SNPs was made based on literature, the absence of association in the present study suggests that 
rs5186 may indeed not be associated with hypertension as suggested by a computational analysis 
(Tiffin et al., 2010), potentially related to the ethnic differences within Black individuals and the 
variability between computational and biological tests.   
4.4 Melanocortin 4 receptor (MC4R) 
The melanocortin 4 receptor (MC4R) is involved in regulating energy homeostasis and food intake 
(Logan et al., 2016). In Moroccans, the C/C genotype of the rs17782313 SNP of MC4R was 
associated with T2DM under a log-additive model of inheritance (Cauchi et al., 2012). In the same 
study, under a dominant model of inheritance in Moroccans and Tunisians (T/C and C/C genotype), 
and a recessive model of inheritance in Moroccans (T/T genotype), rs17782313 was nominally 
associated with increased T2DM risk (Cauchi et al., 2012). In line with these resuts, we found that 
the rs17782313 T/C and C/C genotypes were nominally associated with increased T2DM risk under 
a dominant model of inheritance, when high-risk (fasting glucose 5.6-7.0 mmol/l) and diabetic (fasting 
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glucose >7mmol/l) individuals were combined as cases, after adjustment for gender and age 
(p=0.054) (Table 3.26). High-risk and diabetic individuals were first separated and then combined as 
cases for genetic analysis to determine if any SNP is involved in disease predisposition and/or on 
disease diagnosis. Those individuals who carried at least one C-allele were found to be at 
significantly increased risk (OR=1.51) of developing T2DM, according to fasting glucose and glucose 
tolerance, compared to T/T homozygotes.  
In SA Black individuals from Soweto, the rs17782313 SNP (C/C genotype) was found to be 
associated with BMI and a 2.5% increased risk of BMI (Lombard et al., 2012). However, in this study, 
no association between rs17782313 and BMI or obesity was observed. These contradictory results 
could potentially be because the study by Lombard et al. (2012) investigated the predisposition to 
obesity in early life in adolescents, whereas the population in the current study are mostly between 
the ages of 25-44 years. Possibly indicating an age specific association between rs17782313 and 
obesity. The nominal association of increased risk observed between rs17782313 (T/C and C/C 
genotypes) and T2DM in our population may, however, indicate a possible connection to BMI, not 
observed in the present study, as T2DM is modulated by obesity and the accompanying IR (Ouedemi 
et al., 2009), an underlying cause of T2DM. rs17782313 is located downstream near the MC4R 
gene, and although its function is unknown, its proximity to MC4R suggests that it may play a role in 
food intake and energy homeostasis. rs17782313 has also been found to be in LD with rs17700144, 
rs4450508 and rs12970134 in Europeans and East Asians, previously found to be associated with 
obesity (Xi et al., 2012). However, it should be noted that rs17700144 and rs4450508 were not 
investigated in the present study, so the LD with rs17782313 is not know in our sample. 
The melanocortin 4 receptor is involved in energy homeostasis and food intake, and given that 
T2DM, in addition to genetic predisposition, is a disease of lifestyle, MC4R represents a valuable 
genetic target to investigate for treatment of T2DM. However, the absence of association with obesity 
observed in the present study, contrary to what was seen in Black individuals from Soweto (Lombard 
et al., 2012), may suggest a more profound environmental effect in the isiXhosa-speaking Black 
population from Cape Town.   
Although rs17782313 of MC4R was associated with T2DM diagnosis by fasting glucose, no SNPs 
were associated with T2DM diagnosis by glucose tolerance in the present study, or others. One 
would expect that rs17782313 would also be associated with glucose tolerance, as both fasting 
glucose and glucose tolerance represent the same end-point disease, T2DM. This may however be 
attributable to the fact that these are in themselves separate phenotypes that we are able to measure 
in order to evaluate the physiological mechanisms of glucose utility and the affect these phenotypes 
have on disease progression may thus differ (Karakas et al., 2010) or that rs17782313 may be 
associated only with specific T2DM endophenotypes (in this case, fasting glucose levels).  
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The G allele of MC4R rs229616 has previously been found to be highly prevalent in obese SA Black 
individuals compared to normal weight SA Black individuals and obese SA Caucasian individuals 
(Logan et al., 2016).  Caucasian. However, in the current study, a nominal association (p=0.059) 
was however observed between rs229616 (G/G genotype) and obesity by BMI when overweight and 
obese individuals were combined as cases under a log-additive model of inheritance. This difference 
in association could be due to the difference in sample size of the study populations used in both 
studies, as a larger sample sze would increase the power to detect an association. No SNPs were 
associated with obesity diagnosis by waist-to-hip ratio under any of the models of inheritance. This 
could potentially be due to the inefficiency of the waist-to-hip ratio cut-points to diagnose obesity in 
the Black population of SA (Motala et al., 2011).  
After adjustment for gender and age, rs229616 (GG genotype) was associated with increased HDL-
C/TC ratios under a log-additive inheritance model (p=0.043) (Table 3.21), and suggestive evidence 
was observed after adjustment for gender and age under a recessive model (p=0.059) (Table 3.24). 
Individuals who carried at least one A-allele were at increased risk of increased HDL-C/TC 
(OR=2.03), compared to G/G homozygotes. 
Although rs229616 has not yet been found to be functional, based on the association with HDL-C/TC 
in the present study, and its location within the MC4R gene, it could be involved in metabolism and 
energy imbalance, affecting the levels of HDL-C and TC. The present study demonstrates that 
rs229616 may be involved in dyslipidaemia, but since dyslipidaemia is understudied in Africa, no 
definite conclusions can be drawn until further studies are undertaken. No studies have previously 
reported this association between rs229616 and dyslipidaemia and HDL-C/TC as a measure thereof 
in African or SA populations. The difference in genetics observed in the present study with regards 
to the various measures of diagnosing dyslipidaemia may be attributable to the fact that these are in 
themselves separate physiological parameters of lipid profile, and may therefore play different rolesin 
the mechanisms underlyin dyslipidaemia (Bitzur et al., 2009); highlighting an inconsistency that will 
need to be further investigated. There may also be underlying genetic causes not investigated in the 
present study. 
No significant association was observed between rs1297034 and any CVD risk phenotpye in this 
study, but suggestive evidence was observed for T2DM by fasting glucose when high-risk and 
diabetic individuals were combined as “cases”, after adjustment for gender and age under log-
additive (p=0.072) (Table 3.8) and recessive (p=0.075) (Table 3.24) models of inheritance. However, 
no conclusion can be drawn with regards to the associated genotype as the OR could not be 
calculated and was 0, as there were no cases with the A/A genotype. Although haplotype analysis 
was not performed in the present study due to the selected SNPs not being in LD, the rs1297034 
SNP may be in LD with other causal variants, not investigated in the present study, that may be 
implicated in disease.     
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Overall, the present study demonstrates that the MC4R gene may be involved in T2DM in the 
isiXhosa-speaking Black population of Cape Town, as seen in Moroccans and Tunisians. The MC4R 
gene regulates energy homeostasis and food intake, contributing to obesity. However, in the present 
study, MC4R was not significantly associated with obesity and we were thus unable to replicate the 
findings of Lombard et al. (2012) which reported an association with increased BMI in Black 
individuals from Soweto. This difference in association could be due to the difference in sample size 
of the study populations used in both studies, , as a larger sample sze would increase the power to 
detect an association. 
4.5 Transcription factor 7-like 2 (TCF7L2) 
Transcription factor 7-like 2 (TCF7L2) is involved in the downregulation of adipogenesis via the Wnt 
signalling pathway and is the most replicated gene for T2DM (Nguimmo-Metsadjio et al., 2017). The 
T/T genotype of TCF7L2 rs7903146 has been found to be associated with T2DM in Lebanese 
(Mtiraoui et al., 2012), Tunisian (Berhouma et al., 2014; Turki et al., 2014; Cauchi et al., 2012; 
Mtiraoui et al., 2012a; Bouhaha et al., 2010a), Sudanese (Ibrahim et al., 2016) and Moroccan 
(Cauchi et al., 2012) populations. However, as observed in SA Coloured individuals (Madubedube 
et al., 2015), rs7903146 was not associated with T2DM in this study. It may be that in populations 
where significant associations have been observed, rs7903146 was in LD with a causal variant, 
whereas in the isiXhosa-speaking Black population of SA, rs7903146 is not in LD with a causal 
variant. Moreover, no association was observed between rs7903146 and obesity in this study, in line 
with results from Cameroonians (Nguimmo-Metsadjio et al., 2017).  
4.6 Limitations 
The present study was conducted with some limitations, which are important to acknowledge and 
discuss. First, the samples for this study were collected during working hours, which could explain 
the over-representation of females during sampling, and may be biased to unemployed individuals 
who are usually less active than employed individuals, as individuals living in these communities are 
usually labourers (Peer et al., 2014). In addition, the number of samples collected in Langa was 
much more than for any other area as this area was sampled for a secondary study (Peer et al., 
2012).  
Second, CVD is a multifactorial disease, with numerous genes contributing to its aetiology. This 
complexity is further amplified by gene-gene and gene-environment interactions. Therefore, it would 
be pertinent to investigate these genetic variants using larger sample sizes (imparting increased 
power), in which epistatic and gene-environment interactions can be investigated. 
Third, based on home language reporting, all participants in the present study were assumed to be 
of isiXhosa ethnicity. However, as this is done by means of self-report, it is only a proxy for ethnicity. 
We also did not take into account the genetic make-up of the isiXhosa population and assumed that 
it is homogenous (Shim et al., 2014; Magazi et al., 2008), as we did not employ any population 
Stellenbosch University  https://scholar.sun.ac.za
103 
 
stratification methodologies, such as genomic control (Devlin & Roeder, 1999), structured analysis 
(Pritchard et al., 2000), mixed models (Yu et al., 2006) and principal component analysis (Price et 
al., 2006), in the present study. 
Fourth, the DNA quality of the samples have been compromised as the samples for this study were 
collected 10 years ago and have undergone multiple freeze-thaw cycles (Shao et al., 2012). Of the 
1 116 samples available for this study, DNA from 963 samples was extracted. Of the 963 samples, 
only 585 were eligible for KASP genotyping of the selected SNPs. However, two SNPs, rs1800629 
in TNFα and rs4646994 in ACE, were not genotyped as the results could not be validated on an in-
house system. The rs4646994 SNP was genotyped by PCR, but only 344 samples were completed, 
and, despite numerous attempts to optimise the genotyping procedure, negative control 
contamination, and possibly sample contamination, persisted throughout the genotyping of this 
variant. Results pertaining to this variant should thus be interpreted with caution, and require 
replication using a larger sample size.  
Fifth, multiple testing was not corrected for, and if it had been, none of the significant associations 
would have been retianed. In total, six genes were investigated under three inheritance models, but 
multiple testing correction was not performed due to the exploratory nature of the present study.   
Increasing the sample size would increase the level of confidence and the power to detect 
differences, while decreasing the margin of error, and effect size. 
Sixth, validation of both genotyping methods, PCR and KASP genotyping, was not done. To show 
reliability of these genotyping methods, samples could be sent for Sanger sequencing and blindly 
compared to the results obtained for PCR and KASP genotyping.  
Finally, besides the SNPs in MC4R, only one SNP in the other genes were investigated, and thus 
the investigation of haplotypes could not be performed. Therefore, investigating multiple SNPs in 
one gene may help to detect SNPs that may otherwise not have enough penetrance within a given 
population, as many complex diseases are as a result of the combined effect of multiple variants 
and/or genes and this joint effect may be helpful for investigating causal genes and/or variants.  
4.7 Future studies 
Replicating the significant associations observed between ACE rs4646994 and overall obesity, WC, 
BP and LDL-C, and the nominal association between MC4R rs17782313 is crucial to understand the 
genetic risk factors that predispose SA Black individuals to CVD and diseases associated therewith, 
given that these risk phenotypes are common in Black population of SA, but the underlying genetics 
remains under-studied in this Black population. The results can be further validated by extending the 
sampling to predominantly Black communities in other provinces within South Africa, as 
environmental and dietary effects may further predispose an individual to disease (Tekola-Ayele et 
al., 2013). The effect of disease coexistence could also be analysed, as studies have shown that 
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T2DM is modulated by obesity, which are both modulated by IR and often times are end-points of 
complex physiological processes that involve gene-environment interactions.  
Knowledge of family history of disease and identifying shared genes between members of affected 
families could also add valuable insights into genes potentially predisposing an individual to 
increased risk of disease or genes that are the underlying cause of disease.  
In addition, the present study investigated only a handful of the many genes that have been 
associated with CVD risk phenotypes in Africa and invesitgating other genes will further help to 
understand the pathophysiology of the studied disease in Africa. Investigating more SNPs in each 
gene would allow for haplotype analysis which may further elucidate genes associated with disease 
as single SNPs may have small effect sizes that could potentially aggregate in a haplotype to cause 
disease. Haplotype analysis has also been shown to explain more of the observed phenotypic 
variance when compared to a single SNP that has previously been found to be the best candidate 
(Barendse, 2011).  
4.8 Conclusion 
Non-communicable diseases are a major public health problem in SA. Insulin resistance, 
inflammation and oxidative stress are linking factors among various NCDs (Lontchi-Yimagou et al., 
2013; Motala et al., 2011; Gallagher et al., 2010; Boura-Halfon & Zick, 2009; Eckel et al., 2005; 
Grundy et al., 2005; Hu et al., 2004; Smith & LeRoith, 2004; Stephens et al., 1997; Hotamisligil et 
al., 1994; Reaven, 1988). The prevalence of CVD in the Black population of SA is low (Mensah et 
al., 2015; Mayosi et al., 2009; Sliwa et al., 2008), but that of NCDs such T2DM, obesity, hypertension 
and dyslipidaemia, risk factors for CVD, is high (Nojilana et al., 2016; Abd El-Aziz et al., 2012; Mayosi 
et al., 2009; Tibawarza et al., 2009; Alberts et al., 2005; Akinboboye et al., 2003). This could partly 
be as a result of westernisation and the economic and social transitions SA is undergoing, in addition 
to underlying genetic causes. To date only about 10.0-20.0% of the heritable risk of CVD and the 
associated disease risk factors have been explained. Heritability estimates of 35.0-57.0% for CVD, 
26.0-77.0% for measures of diabetes, 50.0-89.0% for measures of obesity, 30.0-60.0% for 
hypertension and 8.0-72.0% for measures of dyslipidaemia have been reported.  
In the present study we investigated  the role of the transcription factor 7-like 2 (TCF7L2), 
melanocortin 4 receptor (MC4R), angiotensinogen (AGT), angiotensin II type I receptor (AT1R), 
angiotensin converting enzyme (ACE), fat-mass and obesity associated (FTO) and tumour necrosis 
factor-alpha (TNFα) genes in the development of CVD, T2DM, obesity, hypertension and 
dyslipidaemia in the SA Black population, as few genetic studies of CVD risk has been conducted in 
SA.  
In summary, two SNPs (rs4646994 and rs17782313) in two genes (ACE and MC4R, respectively) 
were associated with risk phenotypes associated with CVD. These risk phenotypes include T2DM 
and fasting glucose and IGT as measures thereof; obesity and BMI, WC and waist-to-hip ratios as 
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measures thereof; and dyslipidaemia and TC, triglycerides, HDL-C, LDL-C and HDL-C/TC as 
measures thereof. Two SNPs in MC4R (rs1297034 and rs229616) were also nominally associated 
with T2DM and HDL-C/TC, respectively. Some of these genes have not previously been associated 
with these diseases in SA and/or SSA and cross-phenotype associations were observed, providing 
valuable insight to understand the role genetic risk factors have on predisposing an individual to 
disease and the contribution of one disease to the risk of another disease. However, no genes were 
associated with the measurements of glucose and/or blood pressure. 
Overall, genetic associations with CVD risk phenotypes were replicated in the isiXhosa-speaking SA 
Black population and novel asssociations were reported. The results of the present study indicate 
that the rs4646994 SNP in ACE and rs17782313 in MC4R need to be further studied in this 
population to validate these findings, as they could essentially be the predisposing genetic factors 
for disease, offering novel targets for treatment and prevention. However, further studies in this 
population is required to identify genes associated with CVD risk phenotypes, especially T2DM and 
hypertension.  
The prevalence of CVD risk factors is high in this population of isiXhosa-speaking SA Black 
individuals (Peer et al., 2014b; Peer et al., 2012), and very few studies to determine the genetic 
predisposition of these individuals to these diseases have been conducted. The results of this study 
suggest that this is an important population to study as there appears to be a genetic predisposition 
to CVD risk phenotypes in this population and genetic differences due to ethnicity need to be taken 
into account. The results of the present study lay the groundwork to understand the 
pathways/mechanisms leading to the development of these risk phenotypes in this population. The 
genes investigated and associated with CVD risk phenotypes in this study represent potential targets 
for treatment and preventative strategies as well as enabling the early identification of at-risk 
individuals.  
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Addendum A: Agarose gel electrophoresis 
A.1. 1x Sodium borate (SB) buffer 
Dissolve 1.907g di-sodium tetraborate decahydrate in 1l distilled water. 
 A.2. 1% Agarose gel 
Add 0.5g agarose powder in 50ml SB buffer. 
Microwave on high until the agarose powder is dissolved. 
Allow agarose to cool slightly and add 2μl ethidium bromide. 
Pour agarose mixture into a gel mould and insert well comb. 
Allow agarose gel to set. 
 A.3. Gel electrophoresis 
Insert the set gel into a gel dock filled with SB buffer and remove the comb.  
Add 1μl 50bp Kapa Universal DNA Ladder (Kapa Biosystems, Western Cape, South Africa) to the 
first well of the gel. 
Add 10μl of the sample to the consecutive wells. 
Electrophorese at 160V for 1 hour. 
Visualise using the G box (Syngene, Maryland, USA) with GeneSnap Syngene software (version 
7.12.06). 
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Addendum B: Medians and IQR of CVD risk factors 
           
    
 
 
 
 
 
Figure B1 Median and IQR for BMI as a CVD risk factor by gender     
     
 
 
 
 
 
 
Figure B2 Median and IQR for WC as a CVD risk factor by gender  
     
 
 
 
 
 
 
Figure B3 Median and IQR for waist-to-hip ratio as a CVD risk factor by gender  
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Figure B4 Median and IQR for fasting glucose as a CVD risk factor by gender  
            
     
 
 
 
 
 
 
Figure B5 Median and IQR for impaired glucose tolerance as a CVD risk factor by gender  
           
   
Figure B6 Median and IQR for systolic BP as a CVD risk factor by gender  
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Figure B7 Median and IQR for diastolic BP as a CVD risk factor by gender  
           
      
Figure B8 Median and IQR for total cholesterol as a CVD risk factor by gender  
      
 
 
 
 
 
 
 
Figure B9 Median and IQR for triglycerides as a CVD risk factor by gender   
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Figure B10 Median and IQR for HDL-C as a CVD risk factor by gender  
            
      
Figure B11 Median and IQR for LDL-C as a CVD risk factor by gender 
            
      
Figure B12 Median and IQR for HDL-C/TC as a CVD risk factor by gender
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Addendum C: KASP genotype distributions 
 
Figure C1 Genotype distribution of  FTO rs17817499  Points circled in red: TT (87.52%); green: TA (6.32%): 
blue: AA (1.20%); black: no template control (NTC); not circled: no genotype results (4.96%). 
 
Figure C2 Genotype distribution of TCF7L2 rs7903146 Points circled in red: TC (44.07%); green: CC 
(41.71%); blue: TT (10.43%); black: NTC; not circled: no genotype results (3.59%). 
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Figure C3 Genotype distribution of MC4R rs229616 Points circled in red: GG (55.21%); green: GA (35.56%); 
blue: AA (6.67%); black: NTC; not circled: no genotype results (2.56%). 
 
Figure C4 Genotype distribution of MC4R rs17782313 Points circled in red: TT (51.79%); green: TC 
(39.49%); blue: CC (6.67%); black: NTC; not circled: no genotype results (2.05%). 
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Figure C5 Genotype distribution of MC4R rs1297034 Points circled in red: GG (78.80%); green: GA 
(17.09%); blue: AA (1.20%); black: NTC; not circled: no genotype results (2.91%). 
 
Figure C6 Genotype distribution of AGT rs699 Points circled in red: CC (83.93%); green: CT (13.16%); blue: 
TT (0.51%); black: NTC; not circled: no genotype results (2.39%).  
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Figure C7 Genotype distribution of AT1R rs5186. Points circled in red: AA (95.39%); green: CA (0.51%); 
blue: CC (0%); black: NTC; not circled: no genotype results (5.64%).  
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